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Preface 
 
I clearly remember my first encounter with the Major Histocompatibility Complex (MHC) class I 
protein. It was during the final year of my bachelor’s degree program in biochemistry and I was 
attending a course in Protein Science. My group decided to work with the MHC molecule 
because it was obvious that here was a protein with a striking functionality. What I did not 
know was how it was related to immunology. In fact I did not know anything about immunology 
at that time. Choosing the MHC molecule as our model in protein science turned out to be the 
spark from which my passion for immunology burn strongly today. 
After the course I was hooked on MHC, and decided to contact Professor Søren Buus, whom I 
would later find was one of the world leading experts in this field. This was how I really got the 
appetite for immunology and fortunately, Prof. Søren Buus agreed to let me into his Laboratory 
of Experimental Immunology at the University of Copenhagen to do my bachelor’s, and later 
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my Master’s degrees in Biochemistry. For reasons that I do not know, Søren had just recently 
put his interest into porcine MHC molecules, and hence he had his student (me) produce, 
characterize and analyze Swine Leukocyte Antigen (SLA) proteins; The porcine MHC class I 
molecules. Those three years of working with SLA introduced me to different areas of protein 
science, biochemistry and not least immunology. Surrounded by extremely skilled and 
professional people I was taught not only how to navigate in a laboratory but also how to 
design, set up and adjust techniques to fit different experimental approaches on the way in 
trying to solve scientific questions and problems that I have encountered, and hopefully will 
continue to encounter throughout my career.  
 
Graduating from the University of Copenhagen I found myself being a “still-wet-behind-the-
ears” but fairly well trained post Master’s scientist with a granted fellowship to go and work for 
the United States Department of Homeland Security (DHS) and Department of Agriculture 
(USDA). Through Prof. Søren Buus I got connected with Dr. William T. Golde and Prof. Gregers 
Jungersen. These three scientists turned out to play a major role in my future research and 
education as my PhD thesis mentors. A scientific collaboration forged between the Technical 
University of Denmark (DTU), the University of Copenhagen (KU) and the USDA at Plum Island 
Animal Disease Center (PIADC) in New York, USA, where I moved to and lived for a year and a 
half to perform part of my thesis research. The rest of the research and work was carried out in 
Copenhagen, Denmark at KU and DTU. 
 
The research presented in this Ph.D. thesis was performed in the Section for Immunology and 
Vaccinology, National Veterinary Institute, Technical University of Denmark, Copenhagen, at 
the Institute of International Health, Immunology and Microbiology (ISIM), University of 
Copenhagen, Denmark and at the United States Department of Homeland Security, Plum Island 
Animal Disease Center, New York, USA in the period 2009 - 2012.  
The project was funded by the Danish Council for Independent Research, Technology and 
Production Sciences (274-09-0281) in collaboration with the Agricultural Research Service, 
USDA (CRIS #1940-32000-053-00D) and the United States National Institutes of Health (NIH) 
(HHSN266200400025C). 
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The thesis consists of eight chapters starting with an introduction to the field of immunology 
seeing the MHC class I molecule as the focal point, followed by chapter 2 which describes 
specific methodological approaches and other considerations. Chapters 3 – 6 are devoted to 
the four manuscripts which constitute the backbone of this thesis. These chapters also include 
respective results as well as general discussion. Chapter 7 discusses the SLA tetramer work 
related to paper IV and influenza tetramer staining experiments performed at DTU. The eighth 
and final chapter concerns general conclusions on the topic and thesis work as well as 
perspectives. 
 
This thesis includes four manuscripts (I – IV): 
•   Paper I Pedersen LE, Harndahl M, Rasmussen M, Lamberth K, Golde WT, Lund O, Nielsen 
M, Buus S. Porcine major histocompatibility complex (MHC) class I molecules and 
analysis of their peptide-binding specificities. Immunogenetics. 2011 
Dec;63(12):821-34. doi: 10.1007/s00251-011-0555-3.  
•   Paper II Pedersen LE, Harndahl M, Nielsen M, Patch JR, Jungersen G, Buus S, Golde WT. 
Identification of peptides from foot-and-mouth disease virus structural proteins 
bound by class I swine leukocyte antigen (SLA) alleles, SLA-1*0401 and SLA-
2*0401. Animal Genetics. 2012 Sep 18. doi: 10.1111/j.1365-2052.2012.02400.x. 
•   Paper III Pedersen LE, Rasmussen M, Harndahl M, Nielsen M, Buus S, Jungersen G. An 
analysis of affinity and stability in the identification of peptides bound by Swine 
Leukocyte Antigens (SLA) combining matrix- and NetMHCpan based peptide 
selection. Manuscript ready for submission to Immunogenetics. 
•   Paper IV Patch JR, Pedersen LE, Toka FN, Moraes M, Grubman MJ, Nielsen M, Jungersen G, 
Buus S, Golde W.T. Induction of foot-and-mouth disease virus-specific cytotoxic T 
cell killing by vaccination. Clinical and Vaccine Immunology: CVI. 2011 
Feb;18(2):280-8. 
 
Figure 1 illustrates the relation between the four manuscripts. 
 
  7 
 
 
Figure 1. Diagram illustrating how the manuscripts of this thesis are related. 
 
Acknowledgements 
 
I have learned that great things are rarely achieved alone. For the past three years I have 
crossed paths and thoughts with a lot of interesting people. My path has taken me from 
Copenhagen to New York, dropping by Baltimore, further educating myself in Minneapolis, 
learning about livestock viruses in Barcelona, presenting research in Tokyo, expanding my 
horizon in Edinburgh before returning to Copenhagen. All the people that I have met on this 
journey deserve a thank you for all the interesting discussions, for sharing of research ideas as 
well as results, for opening their doors, for listening to opinions and for contributing to my 
development and education as a scientist as well as a person. 
 
I would like to thank my mentor and main advisor Prof. Gregers Jungersen for welcoming me 
into his group at DTU, for making this project possible and for always being supportive and 
taking his time to reflect on and help with ongoing projects and scientific problems. 
My two co-advisors deserve special thanks as well;  
Prof. Søren Buus for teaching me that serious work often produce serious results and for 
reminding me that science is far from always easy, nor logic.  
Paper I
Expression of SLA-1*0401 and the
establishment of peptide affinity 
screening of porcine MHC class I 
comparing human and porcine β2m
Paper II
Determining the binding matrix for 
SLA-2*0401 and the identification of 
candidate T cell epitopes from FMDV for 
the SLA-1 and -2*0401 molecules
Paper III
Combining SLA matrix and NetMHCpan
predictions and high-throughput assays
to identify peptides bound by SLA-1, -2, 
and -3*0401 with high affinity and stability
Paper IV
Staining of FMDV specificCTLs and the 
identification of a T cell epitope
using SLA tetramers and correlating
with specifickilling
  8 
Dr. William Golde for letting me into his laboratory as well as into his family, for all the scientific 
discussions and exciting experimental setups made possible by him and for putting an honor in 
being my mentor. 
 
A big thank you goes to my science buddy and good friend Michael Rasmussen. Thank you for 
being critical upon my results and data analysis as well as for discussing interesting topics about 
anything under the sun. Our Friday afternoons at Mikkeller’s brew house has not only been fun 
but also inspiring. 
 
I thank all the people in the Section for Immunology and Vaccinology, National Veterinary 
Institute, DTU for their kind help in the laboratory as well as in regard to general issues and 
problems, for advice and lunch time conversations, and for making me feel as part of a social, 
diverse and very professional group of people, all connected by veterinary science. I owe Ulla 
Riber, Dorte Fink Vadekær and Panchale Olsen a special thanks for their help with flow 
cytometry, SLA typing and peptide affinity tests, respectively.  
 
I also thank the Buus group at the Institute of International Health, Immunology and 
Microbiology (ISIM), University of Copenhagen for always providing help and expertise when 
needed. Particularly, I thank Mikkel Harndahl for his help with our high-throughput peptide 
binding experiments as well as discussing the data output with me. The same goes for Morten 
Nielsen of the Center for Biological Sequence Analysis, DTU, without whose contributions and 
knowledge this thesis work would not have been what it is today. 
 
All the people who are, or have been, part of the Golde group at PIADC in New York, during the 
time that I have been working there deserve a warm thank you for always making me feel 
welcome and as a part of the team, and for helping me with the continuous porcine tetramer 
work that we have been performing on and off for the past three years. Special thanks goes to 
Jared Patch for numerous discussions on different scientific topics, for escorting me in the BSL-3 
facility before I got my Select Agent Clearance from FBI and for coming early and staying late on 
the island with me whenever it was needed. 
  9 
 
Last but not least, I would like to thank my friends and family. Without them none of this would 
ever have been possible. I would like to thank my friends for sharing my enthusiasm, frustration 
and laughs, and I would like to thank you, my mom and dad, for always believing in and 
supporting me, for telling me how good I am and for never letting me doubt how proud you are 
of me. A warm thank you goes to my sister Rikke as well, for always listening to what I have to 
say and for sharing ideas. Finally, I would like to thank my wife, my love, my life, Kristina for her 
limitless support and patience with me. You are always there when I need you the most.  
It has been three intense years, which have required some sacrifice but also given me a 
tremendous insight in the field of immunology as well as in myself. I am looking forward to 
seeing all of you again now that my thesis is written and published. 
 
Thank You 
 
Copenhagen, December 2012. 
Lasse Eggers Pedersen 
 
Summary 
 
The immune system has evolved in such a way that it is capable of specifically distinguishing 
between self and non-self structures. Combining this with the ability to memorize and strongly 
prepare for all pathogens that it has previously encountered, is essential for the proper and 
effective function of the immune system, and provides the cornerstone for vaccine design. In all 
vertebrate animals, CD8+ cytotoxic T lymphocytes (CTLs) survey the intracellular environment 
for signs of invasion by pathogenic organisms such as viruses and bacteria. CTLs survey major 
histocompatibility complex (MHC) class I molecules, which are highly polymorphic peptide 
receptors which select and present endogenously derived peptides to circulating CTLs. Peptides 
that are recognized by CTLs in the context of MHC are epitopes, and represent a small sample 
of the pathogen proteome, making it possible for the immune system to specifically identify 
and react upon non-self peptide fragments unique only to the foreign intruder. The 
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polymorphism of the MHC molecule effectively individualizes the immune response of each 
member of any given species. Moreover, responding T cells recognize antigen ligands, only in 
the context of peptide:MHC:β2m (pMHC) complex.  
 
The gene encoding the MHC is one of the most polymorphic regions of the genome known. 
Despite thousands of different human leukocyte antigen (HLA) variants identified, each 
member of a species only inherits and expresses a few of these MHC alleles. The “MHC 
fingerprint” of an individual can be identified by defining MHC alleles. This is classically called 
“tissue typing” and is done by analyzing the reactivity of peripheral blood cells with sera unique 
to MHC alleles. Such knowledge is paramount to analysis of the immune response regarding 
MHC restriction and CTL recognition of pathogen-specific proteins.  
Most of the polymorphism of MHC proteins is resident in the peptide binding groove. Hence, 
each MHC is unique in the way it binds peptides, and by inference it individualizes the entire T 
cell repertoire of the host. In this way, the diversity of MHC within a species makes immune 
escape almost impossible for any intruding pathogen.  
Characterization of the SLA class I and class II gene products and their peptide binding capacity 
defines the T cell epitopes of any given pathogen proteome.  
To date the analysis of MHC peptide interactions, strength (affinity) and stability of the 
peptide:MHC complex, has been extensively reported in mice and humans, whereas data for 
livestock animals such as the pig is rather limited. This thesis describes adapting and applying 
analytical approaches, originally developed for man and mice to understand porcine MHC class 
I peptide binding characteristics in relation to immune responses to vaccination or infection. 
Applying proven technologies to newly produced, recombinant swine leukocyte antigen (SLA) 
class I proteins yielded a body of data for peptide:SLA:β2m (pSLA) complex affinity and stability. 
Mapping the SLA proteins for their peptide binding requirements along with the identification 
of their cognate virally derived peptides, made it possible to explore the nature of the SLA 
proteins and the roles they play in establishing adaptive immunity. The development of SLA 
tetramers, enabled investigation of the specific CTL response elicited as a result of 
immunization against foot-and-mouth-disease virus (FMDV) and swine influenza A virus. These 
studies resulted in the identification of T cell epitopes from both viruses.  
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As SLA:peptide binding data accumulates in these and similar studies, it becomes possible for 
collaborators at Center for Biological Sequence Analysis (CBS), DTU, to further strengthen the 
NetMHCpan algorithm. This prediction tool now has the capacity for the selection of peptide 
candidates to be bound by human (HLA), bovine (bovine leukocyte antigen (BoLA)) and swine 
(SLA) MHC proteins.  
 
Expanding the knowledge of porcine MHC class I molecules, mapping their peptide binding 
matrices, and producing tetramers as well as improving today’s state-of-the-art method for SLA 
peptide prediction will modernize immunological science of livestock species. These 
approaches and results should lead to accelerated development of vaccines with increased 
efficacy due to optimal activation of cell-mediated immune responses with minimal adverse 
events. 
 
Resumé (Danish summary) 
 
Immunsystemet har udviklet sig på en sådan måde, at det er i stand til specifikt at skelne 
mellem selv og ikke-selv strukturer. Ved at kombinere dette med evnen til effektivt at huske og 
forberede sig imod samtlige patogener, som det tidligere er stødt på, er af afgørende betydning 
for et korrekt og effektivt fungerende immunsystem og er selve grundstenen i ethvert design af 
vacciner. I alle hvirveldyr overvåger kroppens CD8+ cytotoksiske T-lymfocytter (CTL'er) det 
intracellulære miljø i søgen efter tegn på invasion af udefrakommende patogene organismer 
såsom virus og bakterier. CTL'er overvåger major histocompatibilitets kompleks (MHC) klasse I 
molekyler, som er stærkt polymorfe peptid-receptorer, der udvælger og præsenterer endogent 
afledte peptider til cirkulerende CTL'er. Peptider, der genkendes af CTL'er i samspil med MHC 
molekylet, er såkaldte epitoper og repræsenterer et lille fragment af det patogene proteom, 
hvilket gør det muligt for immunsystemet specifikt at identificere og reagere imod fremmede 
peptid fragmenter, som er unikke for den invaderende patogen. MHC molekylets polymorfi er 
det, der individualiserer immunresponset for hvert enkelt individ i en given art. Endvidere 
genkender kroppens T-celler kun antigene peptid ligander, når de fremstår som del af det 
trimere peptid:MHC:β2m (pMHC) kompleks.  
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Genet der koder for MHC er kendt som en af de mest polymorfe regioner i genomet. Til trods 
for eksistensen af tusindvis af forskellige humane leukocyt antigen (HLA) varianter, arver og 
udtrykker hvert medlem af en art kun et par stykker af disse MHC alleler. Selve "MHC 
fingeraftrykket" udtrykt af et individ, kan identificeres ved at definere MHC alleler. Den unikke 
MHC allel kan fastslås ved en metode, traditionelt kendt som ”vævstypebestemmelse”, som 
foretages ved at analysere perifere blod cellers reaktivitet overfor vævstypnings-sera. En sådan 
viden er afgørende, for at kunne analysere et immunrespons i forhold til MHC restriktion og CTL 
genkendelse af patogen-specifikke proteiner.  
Størstedelen af MHC proteinets polymorfi er lokaliseret i den peptidbindende kløft. Derfor er 
hvert enkelt MHC molekyle unikt i måden det binder peptid-antigener på og som følge heraf 
individualiseres også hele individets T-celle repertoire via MHC. På denne måde er de enkelte 
MHC molekylers forskellighed indenfor en bestemt art medvirkende til, at det stort set er 
umuligt for indtrængende patogener, at undslippe immun systemets søgelys. 
Karakterisering af individuelle SLA klasse I- og klasse II gen produkter og deres unikke peptid 
bindende kriterier definerer T-celle epitoper fra ethvert givent patogen proteom. 
Til dato er analysen af MHC klasse I molekylets evne til at binde og præsentere peptider, både i 
form af bindingsstyrke (affinitet) og stabilitet af peptid:MHC komplekset, blevet omfattende 
beskrevet i både mus og mennesker. Sådanne data er stadig relativt begrænsede for landbrugs 
dyr såsom svin. Denne ph.d. afhandling beskriver hvorledes analytiske tilgange, der oprindeligt 
er udviklet til mennesker og mus, kan tilpasses og anvendes i grise, for at opnå en bedre 
forståelse af de porcine MHC klasse I molekylers peptid-bindings karakteristika i forbindelse 
med immun responser rejst imod vaccinering eller infektion. En sådan anvendelse af tidligere 
afprøvede analyse metoder sammen med nyligt producerede, rekombinante SLA klasse I 
proteiner, førte til en betydelig mængde data for peptid:SLA:β2m (pSLA) kompleksets affinitet 
og stabilitet. Kortlægning af SLA proteinernes bindingsmotiver samt identifikationen af 
matchende virale peptider, gjorde det muligt at undersøge beskaffenheden af de forskellige SLA 
proteiner samt de roller, de spiller i etableringen af adaptiv immunitet. Udviklingen af pSLA-
baserede tetramerer muliggjorde endvidere studier af specifikke CTL responser fremkaldt som 
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et resultat af immunisering mod mund- og klovesyge virus (MKS) og svine influenza A virus. 
Disse undersøgelser resulterede i identifikationen af T-celle epitoper fra begge virus. 
Med stadigt stigende mængder peptid bindings data for de forskellige SLA molekyler, opnået 
igennem disse samt andres studier, er det muligt for vores samarbejdspartnere på Center for 
Biologisk Sekvensanalyse (CBS), DTU, yderligere at styrke og forbedre den peptid forudsigende 
algoritme NetMHCpan. Denne forudsigelses algoritme er nu i stand til at udpege peptid 
kandidater til binding af både humane (HLA), kvæg (BoLA) og svine (SLA) MHC proteiner. 
 
Ved at udvide kendskabet til porcine MHC klasse I molekyler, kortlægge deres peptid bindings 
motiver og producere pSLA baserede tetramerer, samt forbedre nutidens aktuelle tekniske 
niveau indenfor metoder til at forudsige SLA peptid binding, kan vi modernisere immunologisk 
videnskabelige studier i landbrugs dyr. Disse fremgangsmåder og resultater må forventes at 
føre til en fremskyndet og forbedret udvikling af vacciner med forøget effektivitet, på grund af 
optimal aktivering af det cellemedierede immunrespons med tilhørende minimale bivirkninger. 
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1. Introduction 
 
1.1. THE IMMUNE SYSTEM 
In a world in which we are constantly exposed to pathogenic microbes and viruses it is 
astounding how rarely we actually get ill. The primary reason for this is the immune system, 
which consists of an array of different cells and mechanisms that form the body’s defense 
system. The ability of the immune system to successfully overcome incessant pathogenic 
invasions relies on its aptitude to sense and evaluate microbial threats leading to the control 
and/or elimination of the intruding pathogen with minimal collateral host tissue destruction 
and alteration of homeostasis (Goldszmid and Trinchieri 2012). Protection of the host against 
the different responses of its own immune system is achieved by various levels of tight 
regulation (Banchereau et al. 2012, Germain 2012, Murray and Smale 2012). The immune 
system of vertebrates is often divided into two main arms; the innate and the adaptive immune 
systems (Messaoudi et al. 2011). These systems rely on different immune cells generated in the 
bone marrow from a common precursor (Figure 2), which display various functions. It is a 
delicate balance between these two branches, and a coordinated action of their respective 
  17 
cells, which underlies the immunologic function and success on which the host overall health 
depends.  
 
 
Figure 2. Key cellular components of the adaptive and innate branches of the immune system. Dendritic cells (DC), 
natural killer cells (NK). The figure is adapted from (Messaoudi et al. 2011). 
 
Traditionally, the immune response has been characterized by the type of antibodies (Ab) 
produced and their ability to mediate a range of functions. Different antigens and differential 
regulation of B cell stimulation, proliferation and differentiation into plasma cells (Shapiro-
Shelef and Calame 2005) leads to the production of Abs of various immunoglobulin (Ig) 
isotypes. These different isotypes mediate effector functions such as neutralization, 
complement fixation and opsonization of pathogens. With notable exceptions, the humoral 
immune response is controlled by T lymphocytes that regulate B cell responses via the 
cytokines they produce. This includes the T helper (Th) subsets, Th1, Th2, Th17, Th21, and the 
CD4+/CD25+/Foxp3+ regulatory T cells (Treg). In addition to the effector function mediated by B 
cells, a principal T cell effector function is mediated by the CD8+ cytotoxic T lymphocyte (CTL) 
lineage.  These cells are critical in anti-viral responses as they detect and kill virus infected cells. 
A detailed overview of the different cells, cell stages and primary cytokines involved in the 
induction and regulation of the innate and adaptive immune responses is illustrated in Figure 3 
(Thakur et al. 2012).  
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Figure 3. Illustration of the different cells and cell stages involved in the induction and regulation of the innate and 
adaptive immune responses. The figure was published in July 2012 by (Thakur et al. 2012), the author of this thesis 
being co-author. For clarification, the primary focus of this thesis has been framed (dashed line square). 
 
1.1.1. Innate Immunity  
The innate immune response is the body’s first and primary line of defense against pathogenic 
intruders, and provides immediate responses to a given infection, but without the 
establishment of long lasting protection. The primary line of defense consists of mechanical 
barriers like the gut and skin which are difficult for pathogens to penetrate. 
The primary leukocytes mediating innate responses are the NK cells, mast cells, eosinophils and 
basophils, also including the phagocytic cells; macrophages, dendritic cells and neutrophils 
(Murphy et al. 2008). Two key functions of the innate immune system are the capacity to 
broadly recognize and respond to conserved microbial products that are distinctive for non-
eukaryotic cells, mediated by germline encoded pattern-recognition receptors (PRRs), and 
recruitment of adaptive immune cells to the site of infection by the induction and production of 
cytokines (Janeway, Jr. 1989, Medzhitov 2007). 
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1.1.2. Adaptive Immunity 
In contrast to the innate immune system, the adaptive immune system is not immediate, and it 
takes time for specialized cells to be stimulated and proliferate in response to an infection. 
Compared to the innate immunity that relies on germline-encoded receptors to detect the 
presence of pathogens, the adaptive immune system utilizes a highly diverse set of antigen 
receptors generated through somatic recombination of gene segments, thereby creating huge 
numbers of B cell receptors (BCR) and antibodies with different specificities (Baranov and 
Eppel' 1984, Tonegawa 1983). The antigen receptor on T cells, the T cell receptor (TCR), can be 
nearly as diverse with specificities exceeding 1015 (Davis and Bjorkman 1988, Messaoudi et al. 
2011, Schatz 2004, Tonegawa 1983). TCR diversity is dependent on inexact recombination of 
gene segments during T cell development (Robins et al. 2009). The difference in antigen 
recognition by BCRs and TCRs lies in the way B cells directly recognize antigens, whereas T cells 
recognize antigens (non-self) in association with MHC (self), hereby combining the two 
(Danilova 2012). Such MHC restriction is particularly important during the development and 
maturation of primary lymphocytes in the thymus where T cells are forced to walk the fine line 
of positive selection (Anderson and Takahama 2012, Bevan 1977, Kisielow et al. 1988). In the 
bone marrow, auto-reactive B cells on the other hand, are negatively selected leading to 
apoptosis (Gay et al. 1993, Hartley et al. 1993). B cell subsets are involved in the humoral 
immunity by producing antibodies while T cells are responsible for the cellular immunity and 
regulatory functions (Danilova 2012). TCR genomic rearrangements enable the adaptive 
immune response to produce receptors capable of covering the extremely diverse pathogenic 
pool by recognition of nearly any possible molecular structure. 
 
During T cell development, positive selection ensures that T cells, expressing TCRs with self 
MHC:peptide binding of a low level of affinity, receive sufficient signal to survive and further 
develop. At this point T cells expressing a TCR stimulated by self MHC:peptide complexes, i.e. 
auto-reactive, undergo negative selection resulting in induced apoptosis.  
Mature, naïve T cells leave the thymus and start to patrol the lymphatic system of the host in a 
constant search for pMHC complexes suitable for their specialized TCR. Upon encounter of a 
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pMHC complex presenting a foreign peptide antigen the T cell goes from being naïve to 
becoming activated, undergoing proliferation and eventually exiting the lymphatic system in 
high numbers. From there they migrate to the site of infection to clear the pathogenic invaders. 
Once the immediate infection has been cleared most of the activated effector cells will die off, 
whereas a minor subset of activated T cells will survive, and dependent on cytokine signals, 
such as interleukin (IL)-12 or interferon (IFN)-α at distinct stages of the response, become 
resting memory T cells (Mescher et al. 2006, Parish and Kaech 2009). These cells keep an 
elevated precursor frequency of the activated T cells, capable of functioning as fast responders 
to any subsequent similar infection. 
 
1.2. MHC CLASS I AND THE SWINE LEUKOCYTE ANTIGEN  
A large gene family exists in all vertebrates that encode the major histocompatibility complex 
(MHC) cell surface molecules. These proteins are sub divided into three classes of molecules, I, 
II and III. In humans, non-human primates and livestock animals, the focus is commonly set on 
the MHC class I and II proteins. Also encoded in this gene locus are several other proteins such 
as the transporter associated with antigen processing (TAP1 and TAP2), tapasin, MHC II DM and 
DR, which are involved in the processing and load of antigen into the MHC binding groove 
(Cresswell et al. 1999, Wijdeven et al. 2012).  
The MHC class I proteins are encoded by a highly polymorphic gene cluster in most jawed 
vertebrates (Ho et al. 2009c, Ujvari and Belov 2011). They are important protein determinants 
in immune responses to infectious diseases and vaccines, as well as to autoimmunity and in 
graft acceptance/rejection (Horton et al. 2004, Kelley et al. 2005, Singer et al. 1997). This region 
was originally discovered through genetic studies of transplant incompatibility and the related 
function of these proteins to create histocompatibility, or “self” identification through cell 
surface expression of these highly polymorphic proteins (Gorer et al. 1948). The MHC class I 
molecules are glycosylated, membrane-anchored proteins found on almost every nucleated cell 
in vertebrates.  
The MHC class I trimeric complex is made up of a heavy chain protein of approximately 43 kDa, 
simultaneously non-covalently bound to the stabilizing subunit protein light chain, β2m of 12 
kDa, and exogenous peptide (Cresswell et al. 1973, Grey et al. 1973). The heavy chain is made 
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up of three alpha domains, α1, α2 and α3 in addition to a membrane spanning domain and a 
small cytosolic C-terminal tail (Figure 4). Most of the sequence variation is found in the α1 and 
α2 domains which are responsible for the binding of exogenous peptides within the MHC class I 
peptide binding groove, whereas the α3 domain and β2m are far more conserved expressing 
homology to immune globulin domains (Bjorkman et al. 1987a, Bjorkman et al. 1987b, Orr et al. 
1979). The higher conservancy of the α3 domain is most likely due to its role in the interaction 
with the CTL surface expressed co-receptor CD8 (Salter et al. 1989).  
In pigs the MHC is termed swine leukocyte antigen (SLA). The existence of the SLA complex was 
clearly established more than 40 years ago (Vaiman et al. 1970, Viza et al. 1970), and it was 
later determined that the SLA region extends for 2.0 Mbp on chromosome 7 (Chardon et al. 
2000). Six different loci encode the classical (SLA-1, SLA-2, SLA-3) and non-classical (SLA-6, SLA-
7, SLA-8) SLA class I molecules (Ho et al. 2009b, Kusza et al. 2011). The SLA molecules are highly 
polymorphic and extensive comparisons of the classical SLA class I and human MHC class I 
genes (HLA-A, HLA-B, and HLA-C) have concluded, that there are more sequence homology 
amongst the SLA genes than between any of these SLA loci and any HLA class I gene (Smith et 
al. 2005). Furthermore, the overall genomic organization of the SLA class I region is quite 
different from that of the HLA class I region (Lunney et al. 2009). As a result, the SLA class I 
genes were assigned with numbers to avoid the implications that any loci were more 
homologous to the genes of the HLA system. The non-classical class I genes are categorized so 
because of their limited polymorphism and slight variations in the 3’ end specific of the 
cytoplasmic tail compared to the three classical genes (Chardon et al. 2001). All SLA allele 
sequences reported to date are publicly available at the Immune Polymorphism Database (IPD)-
MHC (http://www.ebi.ac.uk/ipd/mhc/sla/index.html). 
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Figure 4. Membrane bound SLA-1*0401 molecule illustrated with two different peptides bound (swine influenza A- 
(blue) and Ebola virus-derived (green)). The α1, α2, and α3 domains are displayed in grey, orange and pink, 
respectively, forming the heavy chain. The stabilizing subunit light chain, β2m, is shown in yellow. The membrane 
spanning domain and cytoplasmic C-terminal (COOH) tail is illustrated by the dotted line. The figure is modified 
from (Zhang et al. 2011). 
 
The diversity in peptide ligand binding of the SLA proteins has been shown to influence swine 
adaptive immune traits (Mallard et al. 1989a, Mallard et al. 1989b), vaccine responsiveness 
(Lumsden et al. 1993, Rothschild et al. 1984) and disease resistance (Lacey et al. 1989, Madden 
et al. 1990). Like the HLA molecules of humans, the SLA class I molecules of swine form a 
binding groove which can be divided into six pockets responsible for binding of the individual 
peptide antigen residues. These pockets are termed A, B, D, C, E and F and are responsible for 
the binding of peptide residues P1, P2, P3, P6, P7 and P9, respectively (Madden 1995, Zhang et 
al. 2011). The peptide specificity between different class I molecules is extremely diverse and is 
defined by structural requirements such as the presence of certain amino acids in specific 
positions of the peptide, especially at the peptide termini which account for most of the 
peptide-MHC interactions by hydrogen bonds between the peptide backbone and the MHC 
binding groove (Madden et al. 1992). These residues are often referred to as anchor positions 
and define the binding motif of each individual MHC class I molecule.  
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For most MHCs, the critical residues for peptide binding are the P2 and P9  (or C-terminus if the 
peptide is not a 9mer) of the peptide (Kubo et al. 1994). The side chains at P1, P4 and P5 of the 
peptide generally protrude toward the solvent and away from the peptide binding groove 
making them available for TCR recognition, whereas the P2, P3, P6 and P9 side chains face into 
the groove and stay shielded from the TCR. The A and F pocket structures are well conserved 
among many class I molecules. In comparison, those of the B through E pockets differ greatly 
between heavy chains with respect to size and chemical nature (Matsumura et al. 1992), 
sometimes leading to alternative peptide anchors in one of these pockets. 
Degradation of cytosolic proteins predominantly by the proteasome, generates peptides of 
both self and non-self origin depending on the status of the cell. Such peptides are actively 
transported into the lumen of the Endoplasmic Reticulum (ER) by the TAP1 and TAP2 and 
loaded onto the MHC class I in symphony with components of a multi molecular unit termed 
the peptide loading complex (PLC) (Dalchau et al. 2011, Elliott and Williams 2005). Once a 
peptide has been bound, the mature pMHC complex is being released from the PLC in the ER 
and into the Golgi Apparatus from where it is transported to the cell surface. At the surface 
pMHC complexes can be scanned by circulating CD8+ CTLs. In such a way, pSLA complexes 
constantly signal the cell’s current state of integrity to the immune system of the host. Upon 
recognition of foreign, non-self peptides, specific CTLs become activated to kill the infected or 
transformed cell (Bevan 1995, Doherty and Zinkernagel 1975, Harty et al. 2000), even though a 
given peptide:MHC complex is estimated to be present at the cell surface at 10 - 400 copies per 
cell (Hunt et al. 1992). 
The high number of SLA class I molecules and the level of polymorphism observed ensure the 
diversity between different alleles. The number of MHC loci varies among species. Humans and 
swine can express up to six different MHC class I molecules if they are heterozygous at all three 
class I loci. However, the presence of duplicated loci leading to copy number variance of some 
loci of classical SLA class I genes has been suggested to occur among SLA haplotypes (Ho et al. 
2009b, Ho et al. 2010b). Such duplication leads to encoding of more than two class I alleles of a 
gene in animals heterozygous for that particular locus (Ho et al. 2010b, Tanaka-Matsuda et al. 
2009). Altogether, such SLA heterozygosity increases immune-competence in that a greater 
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variety of antigens are likely to be presented leading to a more robust immune response (Penn 
et al. 2002). 
 
1.3. MONITORING CYTOTOXIC CD8+ T CELL FREQUENCY AND EFFECTOR FUNCTION –  
GOING FROM MICE AND MEN TO CATTLE AND PIG 
Section 1.3 of this thesis is modified from section 3.2 in a paper previously published in Vaccine (Thakur et 
al. 2012) with the thesis author as a coauthor including the responsibility for the writing of section 3.2. 
 
In recent years the scientific fields of immunology and biochemistry have seen great advances 
in the ability to detect and isolate antigen-specific CD8+ CTLs (Altman et al. 1996, Dunbar et al. 
1998, Romero et al. 1998). Successive modifications of methods like the recombinant MHC 
tetramer approach for staining of specific CTLs (Altman et al. 1996, Leisner et al. 2008), peptide 
affinity ELISA (Sylvester-Hvid et al. 2002), cytokine sensitive ELISpot assays (Hutchings et al. 
1989, Malyguine et al. 2007) and the use of chimeric molecules and transgenic animals (Choi et 
al. 2002), have all contributed to the increasing amount of data describing cytotoxic immune 
responses during infection and vaccination.  
A major function of immune-activated CTLs is the exocytosis of cytotoxic proteins such as pore 
forming proteins (perforins), serine proteases (granzymes), and cytokines such as IFN-γ, tumor 
necrosis factor (TNF)-α and interleukin (IL)-2 (Zuber et al. 2005). Such components, revealing 
the state of activation for individual CTLs, provide a relatively simple set of cytokines that can 
be used to monitor and define both CTL frequency and function in responses against infections 
that require T cells for protection (Seder et al. 2008). A potential drawback of using cytokines as 
a measure for cell activation and function is that the secretion of many cytokines such as IFN-γ 
is not necessarily indicative of CTL function, because they can be released by non-cytotoxic cells 
involved in the innate and adaptive immune responses (Figure 3). An assay measuring the 
secretion of molecules associated with lytic activity or the level of killing of specific target cells 
by CTLs provides a better approach for assessment of cytotoxic T cell function. Present and 
future approaches combining one such assay with highly specific MHC tetramer staining of CTLs 
and additional flow cytometry-based intracellular staining assays are state-of-the-art and could 
be applicable to models of almost any species of interest.  
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1.4. MHC CLASS I TETRAMERS  
MHC tetramers have been described for mouse (Lemke et al. 2011), human (Altman et al. 1996, 
Leisner et al. 2008) and bovine (Norimine et al. 2006). These complexes are four recombinant 
MHC molecules loaded with synthetic peptides that are bound (usually through the Biotin–
Streptavidin interaction) to a fluorescent tag (Figure 5). They have been well known for more 
than a decade (Altman et al. 1996), and being readily combined with functional assays they are 
becoming more important as a tool in monitoring immune responses and in the enumeration 
and characterization of T cells (Altman and Davis 2003, Wooldridge et al. 2009, Xu and Screaton 
2002). Although some interaction of T cells with MHC monomers and dimers can be detected, 
reproducible staining is best obtained with tetramers due to the higher avidity (Klenerman et 
al. 2002). Up to three of the four MHC monomers in a tetramer can be recognized and bound 
simultaneously by TCRs on the surface of the same antigen specific T cell thereby increasing the 
tetramer-CTL interaction. Furthermore, tetramers themselves might bind each other to form 
higher-order oligomers (Klenerman et al. 2002), which could further elevate the magnitude of 
staining depending on the corresponding level of structural hindrance resulting from random 
oligomerization. With the correct tetramers, antigen-specific CTLs can be directly enumerated 
ex vivo from peripheral blood samples although in cases of very low in vivo frequencies in vitro 
manipulations such as cell enrichment, cell expansion, and/or prolonged antigen stimulation 
may enhance the individual frequencies for more detailed analyses (Addo et al. 2003, Kiepiela 
et al. 2004, Leisner et al. 2008, Schmidt et al. 2009). However, such in vitro manipulations may 
hinder the accuracy of monitoring the natural existence and frequency of CTL responses elicited 
by infection or vaccination (Schmidt et al. 2009, thor Straten et al. 2000).  
One main disadvantage of tetramers is their single-specificity which is a problem when 
analyzing outbred animals and infections with certain viruses for which immunodominant 
peptides do not exist. In cases where a complex set of epitopes might be targeted by T cells, it 
would be necessary to perform analysis using several different class I tetramers produced with 
several different peptide epitope candidates to obtain multiple specificities. Furthermore, in 
the case of HLA and SLA, the limited number of recombinant MHC molecules available, and 
scarce details of their peptide binding preferences, restricts the usage of MHC tetramers 
(Saalmuller 2006). 
  26 
 
 
Figure 5. The basic construction of an MHC class I monomer and tetramer recognized by TCRs at the surface of an 
antigen-specific, CD8
+
 T cell. The fluorescently labeled streptavidin enables detection of CTLs that specifically bind 
the pMHC tetrameric complex with higher avidity as compared to the lower affinity of the monomer. Figure 
modified from (Klenerman et al. 2002). 
 
Despite the established importance of virus-specific, CTL-mediated killing of virus infected cells 
and the possibility to quantify induced CTLs by tetramer staining, the MHC heterogeneity of any 
outbred population, and the exclusive specificity of the MHC tetramer with the corresponding 
TCR, has so far made it difficult to use tetramer staining as an immunological correlate of 
protection by validation of specific CD8+ CTLs (Thakur et al. 2012). Tetramer stained CTLs are, 
however, important immune markers of the effects of vaccination as different vaccines or 
vaccine strategies can be directly evaluated for their induction of peptide antigen-specific CD8+ 
CTL subsets. In addition, adoptive transfer of human CTLs specifically purified by tetramer 
staining has been shown to induce protection against cytomegalovirus (Cobbold et al. 2005). 
Furthermore, tetramers should allow the investigation of different T cell recognition patterns 
with pMHC complexes for example by comparing peptides of different lengths. 
 
1.5. FOOT-AND-MOUTH-DISEASE AND SWINE INFLUENZA A VIRUS – OUTBREAK, 
TREATMENT AND CONTROL 
The focus of this PhD project has been set on two of the most contagious and costly viral 
infections that occasionally devastate the agricultural world, foot-and-mouth disease virus and 
swine influenza A virus.  
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1.5.1. Swine Influenza A Virus 
The swine influenza A virus strains are negative-sense, single-stranded RNA viruses of the 
family Orthomyxoviridae (Beigel and Bray 2008).  The most common influenza A virus strains 
circulating worldwide are the H1N1, H3N2, and H1N2 distinguished by their divergence in the 
two major glycoproteins hemagglutinin (HA) and neuraminidase (NA) (Brown et al. 1997, 
Campanini et al. 2010, Olsen 2002, Richt et al. 2003). HA and NA display a fine balance playing 
important roles in the influenza A replication cycle. HA mediates docking of the virions to their 
target cells through binding to sialic acid (which is covalently linked to the terminal galactose of 
an oligosaccharide, a glycoprotein or glycolipid). NA then functions by cleaving sialic acid from 
galactose to avoid virion docking on non-respiratory epithelial cells as well as to release newly 
formed virions from the surface of infected cells (Figure 6) (Beigel and Bray 2008, Jo et al. 2007, 
Olsen 2002, Richt et al. 2003).  
 
 
Figure 6. Replication of influenza A virus by initial docking of the virion to the surface of the target epithelial cell via 
HA-Sialic acid-galactose interactions (1), followed by endocytosis, HA cleavage, and fusion of the viral and 
endosomal membranes (2) which leads to the release and formation of ribonucleoprotein (RNP) particles into the 
cell cytoplasm and further migration to the nucleus (3). Transcription and genome replication takes place within 
the nucleus (4) resulting in translation of mRNA and the generation of nascent viral components such as HA and 
NA (5), and culminating in the virion assembly and release at the cell membrane (6 + 7). The figure is modified 
from (Beigel and Bray 2008). 
 
Swine may play an important role in influenza ecology because they express viral receptors that 
support infection with avian, swine and human influenza viruses, and by that act as mixing 
vessel for new influenza A virus re-assortments, which may have the potential to be 
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transmitted to other hosts, including humans (Kida et al. 1994, Kundin 1970, Torremorell et al. 
2012, Trebbien et al. 2011). Influenza A virus is mostly transmitted directly through pig-to-pig 
contact and via aerosols. Seasonal influenza outbreaks greatly affect the meat and agricultural 
industries every year due to illness, lowered meat production and in worst cases death within 
animal herds.  
The respiratory disease associated with influenza A virus has a global effect on swine as well as 
birds and humans (Webster et al. 1992) leading to seasonal high demands of Oseltamivir - also 
known as Tamiflu - which is the only currently available drug used in the prophylaxis of the 
disease (Saxena et al. 2012). To avoid the risk of resistance and because of the greatly increased 
price of the active compound of Tamiflu (shikimic acid), it is relevant to find alternative 
approaches for the prevention and treatment of swine influenza, making it extremely 
important to seek a better understanding of the immune response against influenza in swine, 
as well as of the different mechanisms of transmission within pigs and across species 
(Torremorell et al. 2012). Furthermore, in depth investigation and monitoring of porcine 
immune responses elicited by new vaccines and by natural disease would contribute to 
improved testing and development of future vaccines and vaccine delivery approaches.  
 
1.5.2. Foot-and-Mouth Disease Virus (FMDV) 
Foot-and-mouth disease virus is a member of the aphthovirus family of Picornaviridae. The 
genome consists of a positive stranded RNA molecule which encodes a single polyprotein that 
can be processed into four structural and nine non-structural proteins by virally encoded 
proteases, including 3CPro and LPro (Guzman et al. 2008, Racaniello V.R. 2006, Stanway et al. 
2005). The FMDV genome is surrounded by a densely packed icosahedral arrangement of 60 
protomers, each consisting of the four structural proteins VP1, VP2, VP3 and VP4 encoded in 
the P1 region (Figure 7) (Grubman and Baxt 2004, Rueckert and Wimmer 1984).  
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Figure 7. The FMDV virion (top) and the linear single-stranded RNA genome (bottom). The linear single-stranded 
RNA genome is composed of a single open reading frame (ORF) encoding a polyprotein. The genomic RNA has a 
linked viral protein (VPg) at its 5’ end. The long untranslated region (UTR) at the 5’ end contains an internal 
ribosome entry site (IRES). The P1 region encodes the structural proteins (VP1 – VP4), whereas The P2 and P3 
regions encode the nonstructural proteins associated with replication. The N-terminal leader protease (L
Pro
) is 
encoded in addition to the 3C protease (3C
Pro
). This figure is modified from the Swiss Institute of Bioinformatics 
(viralzone.expasy.org). 
 
FMD is a highly contagious disease of cloven-hoofed animals including livestock such as cattle, 
sheep, goats and swine. It is characterized by development of oral and pedal vesicles that result 
in high morbidity but mortality is low. However, infection in young animals may be lethal 
(Golde et al. 2005, Grubman and Baxt 2004, Pacheco et al. 2005). Devastating outbreaks such 
as the one experienced in the United Kingdom (UK) in 2001 resulted in the slaughter of over 4 
million animals and an estimated total loss to the UK economy of between US$ 12.3 and 13.8 
billion (Scudamore and Harris 2002, Thompson et al. 2002). 
 
Today, outbreaks that appear in previously FMD-free countries, such as in the UK, are 
controlled by inhibition of animal movement followed by slaughter of infected as well as in-
contact animals (stamping out) and completed by decontamination (Pacheco et al. 2005). Such 
methods are expensive in terms of lost agricultural production and export. In addition to this 
there is also a considerable expense in the killing and burning of millions of animals, which 
generally lead to public concern (Figure 8).  
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Along with the environmental problems raised by the need to eliminate these animals, such 
factors underline the needs for alternative and better ways of controlling and dealing with 
FMD. Although effective vaccines are currently available as chemically inactivated whole virus 
antigen in adjuvant (Doel 2003), the use of vaccination is most often a decision of last resort. 
The reason for this is that countries choosing to vaccinate animals (instead of stamping out) are 
subjects to a prolonged loss of export markets for livestock and livestock products due to a 
minimum of 6 months before regaining a status as FMD-free. Until recently this period was a 
full 12 months in accordance with the previous version of the International Animal Health Code 
of the Office International des Epizooties (OIE), which made the choice of vaccination further 
unfavorable (Golde et al. 2005). In comparison, at present a country can get classified as FMD-
free by documentation of an absence of disease for 3 consecutive months when clearing an 
outbreak by slaughter and decontamination. 
 
 
Figure 8. Over four millions animals infected by FMDV were culled and burned during the 2001 outbreak in the UK 
in an attempt to control and eradicate the virus. This picture was taken in North Cumbria, UK, one of the worst 
affected areas in the country. Foto: Murdo Mcleod (www.guardian.co.uk). 
 
Focusing more research on the control of FMDV and the development of further improved 
vaccines and effective outbreak response programs, could ultimately lead to a state where 
vaccination to prevent the disease, thereby saving millions of animals (and billions of US$), 
would not just be a goal but an achievement. 
 
Assays based on sensitive detection of antibodies against non-structural FMDV proteins, and 
hence capable of differentiating infected from vaccinated animals (DIVA), have been developed 
and are still being improved and redesigned for enhanced specificity and sensitivity (Brocchi et 
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al. 2006, Clavijo et al. 2004, Gao et al. 2012, Muller et al. 2010, Sorensen et al. 2005). 
Furthermore, the OIE recommends that FMDV vaccines are composed of inactivated and 
purified virus to remove non-structural viral proteins (Muller et al. 2010), thereby enabling 
assay specificity for detection of non-structural protein-specific antibodies unique only to 
infection and not to vaccination. One candidate for such a next-generation FMDV vaccine is the 
“empty capsid” platform comprised of a replication-defective human adenovirus 5 (Ad5) viral 
vector with the FMDV P1 capsid and 3CPro precursor inserted (Grubman et al. 2010). 
Compatible with present diagnostic tests, this vaccine strategy has DIVA capability as well as 
being effective in swine (Mayr et al. 1999, Mayr et al. 2001, Moraes et al. 2002) and cattle 
(Pacheco et al. 2005). A limitation is seen for the vaccine (as for killed-virus vaccines and natural 
infection in general) in that the neutralizing Abs raised against the vaccine strain of choice do 
not provide cross-serotype protection. Due to such a requirement for vaccine efficacy, the lack 
of cross-serotype protection limits the value of vaccination during outbreak or in disease 
eradication (Rodriguez and Grubman 2009). Improved DIVA assays and vaccines would facilitate 
the process of future vaccination programs to be preferred choices in the prevention, as well as 
control of FMD outbreaks. 
 
Previous work has demonstrated that vaccination of swine with wild type (3CPro intact) adeno-
vectored FMDV containing the strain A24 P1, 2A and strain A12 3C coding sequence (Ad5A24) 
resulted in the generation of protective anti-FMDV antibodies (Moraes et al. 2002). These 
experiments showed that swine vaccinated with a single dose of the Ad5A24 were completely 
protected against a following challenge with FMDV. In comparison, the two control groups, 
which were vaccinated with either a vesicular stomatitis virus G protein gene vectored by Ad5 
(Ad5VSV-G) or with PBS alone, both developed characteristic signs of foot-and-mouth disease 
(FMD). In addition, mutation of the 3CPro, specifically an amino acid change (C163S), resulted in 
inhibition of the processing of P1 into mature capsid proteins and a reduced production of anti-
FMDV antibodies (Grubman et al. 1995, Patch et al. 2011). These data illustrate that 3CPro is 
needed for successful structural capsid processing and virion assembly, which again is required 
for proper induction of an anti-FMDV antibody response. A simplified illustration of the viral 
FMDV replication cycle is shown in figure 9.  
 Figure 9. Illustration of the FMDV replication cycle. FMDV 
RNA into the cytosol (2) leading to viral takeover of the cells own replication machinery and
viral proteins (3), as well as viral RNA
Endoplasmic Reticulum (4). New viral RNA forms the
newly forming capsids (5). Once assembled the new
membrane, causing aggregation, and eventually 
particles capable of infecting healthy cells of the host
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1.6. SLA TISSUE TYPING 
Knowing which SLA alleles that are commonly occuring within a herd, a country or even on a 
global scale can be of great importance in regard to vaccine development and the 
establishment of immune protection in swine through broad coverage, highly specific, subunit 
based vaccination against viruses such as the previously mentioned swine influenza virus and 
FMDV. These technologies can also be applied to addressing other important viral diseases of 
swine such as porcine reproductive and respiratory syndrome virus (PRRSV), African swine 
fever virus (ASFV) and vesicular stomatitis virus (VSV). 
Because of the extensive polymorphic nature of SLA genes, it is necessary to have very accurate 
and sensitive typing methods to distinguish the different alleles (Ho et al. 2009c). Historically 
the most important means for determining SLA class I antigen specificities was serological 
typing using alloanti-sera (Kristensen 1988, Renard et al. 1988). This is compromised by the lack 
of typing sera with documented specificities, limiting SLA characterization. Since MHC 
molecules occasionally differ by sites inaccessible to antibody binding, and often share similar 
(outer) epitopes, SLA typing sera are limited in identifying specific expression patterns. A 
combination of sera is usually required to differentiate between animals, and most such typing 
reagents are directed against an entire haplotype rather than individual alleles, further 
complicating precise identification of particular SLA alleles. Hence the need for a more sensitive 
and highly specific typing system, enabling the examination of SLA class I allelic diversities in 
outbred populations, emerged.  
Today, such needs are met by the application of DNA-based typing methods using low- and 
high-resolution PCR sequence-specific primers (PCR-SSP). These allow high-throughput 
identification of individual SLA class I alleles, and overall SLA haplotype screening of pig herds 
and breeds of interest for class I (Essler et al. 2012, Ho et al. 2006, Ho et al. 2009c, Ho et al. 
2009a, Martens et al. 2003) and class II alleles (Ho et al. 2010a). The principle of allele-specific 
primer design is to identify primers where the 3’ end of one or both primers covers 
polymorphic sites unique to their allele, thereby enabling the identification of that exact allele 
using that particular pair of primers (Martens et al. 2003). To design site-specific primers, one 
must know the DNA sequences of the different SLA alleles present in the swine herd or 
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population being studied. This limits the sequence-based typing approach to alleles with known 
sequences. SLA allele sequences reported to date are publicly available at the IPD-MHC 
(http://www.ebi.ac.uk/ipd/mhc/sla/index.html). As of November 2012, there are 131 class I 
(SLA-1, SLA-2, SLA-3 (all classical class Ia), and SLA-6 (non-classical class Ib)) alleles officially 
designated (Table 1) with a total of 31 class I high-resolution haplotypes assigned at the allele 
level, which puts the SLA system among the most well characterized MHC systems in non-
primate species (Ho et al. 2012). 
 
 
Table 1. Statistics of the current SLA sequence database displaying the number of newly identified alleles since 
2005. The total number reported for each allele group is indicated in the lower graph. The table was modified and 
used with approval from the corresponding author (Ho et al. 2012). 
 
The relevance of SLA typing can be linked to the SLA peptide ligand binding and presentation 
(Lunney et al. 2009). An initial step in identifying virally derived T cell epitopes, that generate a 
protective T cell response against infection in pigs, is to identify which SLA alleles are expressed 
by the animals and which peptides they bind and present. Once candidate peptides or proteins 
have been identified, they may be used to specifically target, activate and/or monitor T cells 
mediating immunity through subunit based vaccination or synthetically designed pSLA 
2005
2009
Currently
Identified alleles
SLA class I 88
SLA class II 127
Previously
identified alleles
(2005)
Newly identified
alleles
Total
SLA class I 88 + 37 = 125
SLA class II 127 + 37 = 164
Previously
identified alleles
(2009)
Newly identified
alleles
Total
SLA class I 125 + 6 = 131
SLA class II 164 + 10 = 174
46 48
28
9
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multimers. Highly specific vaccines based on detailed information about SLA peptide binding 
and presentation could become useful in preventing the outbreaks of viruses such as swine 
influenza and FMDV, hereby limiting the almost inevitable financial losses and animal suffering, 
which are associated with such outbreaks. 
 
2. Methodological Setup and Considerations 
 
This chapter describes the methods and experimental approaches used throughout the PhD 
project, but not explicitly described in the respective manuscripts. General and detailed 
materials and methods sections for all methods and approaches of my PhD work can be found 
in the individual manuscripts presented in this thesis, Paper I – IV.  
 
2.1. PEPTIDE-SLA CLASS I AFFINITY MEASURES 
In the studies performed throughout this PhD project the affinities of hundreds of different 
peptides for binding by the three SLA class I molecules, SLA-1*0401, SLA-2*0401 and SLA-
3*0401 have been measured. The assay initially used for this was an enzyme-linked 
immunosorbent assay (ELISA) previously developed for HLA (Sylvester-Hvid et al. 2002) and 
through this project adapted to SLA (Paper I – III). The ELISA as such was first described in 1971 
and is based on specific Abs capturing antigen which is then detected by an enzyme conjugated 
detection Ab in symphony with a substrate to give a visible signal (Engvall and Perlmann 1971, 
Van Weemen and Schuurs 1971). Today the use of monoclonal Abs with various specificities is 
common practice in most laboratories allowing for an extremely broad range of antigen 
detection measures. The ELISA used in this project was based on the capture of biotinylated 
SLA molecules followed by the detection of human β2m using a monoclonal Ab (Figure 10A). 
This assay principle is based on data showing the affinity between β2m and the MHC heavy 
chain is enhanced in the presence of bound peptide ligand (Elliott et al. 1991). Hence β2m is 
only stably folded with SLA  class I when there is peptide binding. This results in no detection of 
peptide-empty SLA molecules in the assay. Due to the lack of a monoclonal Ab specific for 
porcine β2m we decided to build the assay with human β2m. This decision was based on the 
findings that both human and porcine β2m show equal capacity to support the folding of pMHC 
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class I complexes irrelevant of the heavy chain expressing an HLA or SLA α3 domain as 
presented in Paper I (Figure 4 + 5) of this thesis. The amount of peptide needed to fully saturate 
half of the SLA molecules made available will give the affinity constant (KD) of each peptide 
tested once correlated to a pre-folded HLA-A*02:01 standard curve based on non-linear curve 
regression (Figure 10B).  
 
 
Figure 10. Illustration of the SLA peptide affinity ELISA setup (A) and an example of curve-fitting to peptide 
dose/response titrations, and the corresponding pSLA complex formation (B). The ELISA plate is covered with 
streptavidin (orange) which bind the biotin (pink) linked to the SLA heavy chain molecule (green) with bound 
peptide (red) and the co-bound stabilizing subunit protein β2m (purple). β2m-specific primary Ab (yellow) captures 
correctly formed pSLA complex made visible by detection via an enzyme (glowing blue) conjugated detection Ab 
(grey). The peptide dose/response curve illustrates a peptide (MTAHITVPY) bound with extremely high affinity (KD, 
0.8 nM) as presented in Paper II of this thesis. 
 
2.2. HOMOGENOUS PEPTIDE AFFINITY AND pSLA COMPLEX STABILITY ASSAYS 
Luminescent oxygen channeling immunoassay (LOCI) is a technology which enables high 
throughput, homogenous screening of peptide-MHC class I interactions, among a wide range of 
other rapid, and quantitative determination possibilities. The technology itself was first 
described in the nineties (Ullman et al. 1994, Ullman et al. 1996), and the assay consists of two 
primary components, donor- and acceptor beads, the latter emitting a signal when brought into 
close proximity with excited donor beads (Figure 11). 
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Figure 11. The LOCI principle. Biotinylated pSLA (green) is bound to a streptavidin coated donor bead (blue) and 
captured by an anti SLA monoclonal Ab (PT85A, black) which is conjugated to an acceptor bead (orange). 
 
The donor beads contain a blue-green colored photosensitizing agent, phthalocyanine, which 
converts ambient oxygen into singlet oxygen upon illumination at 680 nm. The lifetime of 
singlet oxygen in water is very short (4 µs), hence it can only travel approximately 200 nm 
before returning to its ground state. This enables acceptor beads to become activated only 
when brought into close proximity of the donor bead, resulting in a chemiluminescent signal via 
the PT85A monoclonal Ab capture of correctly folded pSLA complex at the surface of the 
streptavidin conjugated donor beads (Figure 11). The resulting light emission from activated 
acceptor beads is at a higher energy than the light used for excitation, which result in very low 
background signals and a high signal-to-background ratio. In addition to this, the beads are 
bioactive and can easily be conjugated with Abs or other proteins (such as streptavidin). 
Furthermore, the homogenous nature of the LOCI assay leaves out the washing steps needed 
in-between steps for the ELISAs. Altogether, such assay qualities make the LOCI preferable to 
use in present and future peptide-SLA affinity analyses. To measure the assay signal an 
instrument like the EnVision® or EnSpire™ (Perkin Elmer Life Sciences) multilabel reader is 
needed. The LOCI technology was adapted to screen for peptide:SLA affinities having 
biotinylated heavy chain proteins and an SLA-specific Ab available and adjusted to the assay. 
LOCI based peptide affinity analysis is described and presented for the SLA-2*0401 and SLA-
3*0401 molecules in paper III.  
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In addition to the affinity, which is a measure for the likeliness of a given peptide to be bound 
by the MHC class I molecule, accompanying stability measures of pSLA complexes were 
included. The stability of pMHC has been proposed to be a better determinant of 
immunogenicity than the actual binding affinity (Busch and Pamer 1998, Harndahl et al. 2012, 
Mullbacher et al. 1999, van der Burg et al. 1996). To measure such stabilities we used a 
radiolabeled-based scintillation proximity assay (SPA). The first SPA emerged in the late 1970s 
(Hart and Greenwald 1979a, Hart and Greenwald 1979b) making the technology commercially 
available. By radio-labeling porcine β2m with the 
125I isotope we were able to develop a high 
throughput, homogenous assay for measuring pSLA complex stabilities. Such stability measures 
are based on the energy transfer between β-particles from the iodine isotope and the 
scintillation material imbedded in streptavidin coated FlashPlates which bind biotinylated 
peptide:SLA:125I-β2m complexes. Upon peptide binding by the SLA molecule, 
125I-labeled β2m 
will co-bind, which will bring the β2m close to the scintillation material in the plate, hereby 
activating it by the emitted electrons (β-particles). Activation of the plate then results in a 
positive signal read-out (Figure 12).  
 
 
Figure 12. Illustration of the SPA principle. All components are the same as described in Figure 10 with the 
exception of the β2m now being labeled with 
125
I (glowing pink) and the signal emitted from the activated 
scintillation material (glowing blue). 
 
The 125I isotope was chosen partly due to its short ranged electron emitters, hence only labeled 
125I-β2m brought in close proximity of the FlashPlate scintillation material by the streptavidin-
biotin interaction, will lead to signal in the reader. Electrons emitted from unbound 125I-β2m will 
be absorbed by the surroundings. The dissociation of 125I-β2m is used as a measure of the 
stability of the pSLA complex. Excess of un-labeled β2m is added to the sample when steady-
state of the complex folding reaction is reached, and just prior to sample measurement. This is 
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done to ensure that dissociated peptide:SLA:125I-β2m complex is only re-associated by support 
of un-labeled β2m, not leading to a false high stability by regeneration of measurable 
peptide:SLA:125I-β2m complexes. Samples are measured continuously in a TopCount NXT liquid 
scintillation counter for 24 hours at 37⁰C. The assay and the corresponding stability data 
achieved for SLA-1*0401, SLA-2*0401 and SLA-3*0401 is presented and discussed in detail in 
Paper III. 
 
2.3. DESIGNING NEGATIVE CONTROL PEPTIDES FOR THE PRODUCTION AND USE OF 
pSLA TETRAMERS 
Critical to interpreting tetramer binding data is the capacity to measure background signal. In 
order to address this, two peptides derived from the VP35 region of the Sudan Ebola virus and 
from the Vibrio Cholera bacteria, respectively were used as nonspecific controls. The binding 
prediction for the peptides with two SLA molecules, SLA-1*0401 and SLA-2*0401, and in vitro 
ELISA affinity tests, revealed both peptides as being strongly bound as presented in Paper II. 
The idea was to produce tetramers using these peptides as negative controls when staining 
PBMCs. It was based on the presumption that animals under study had never encountered 
either Ebola or Cholera, and therefore should not be expected to recognize such tetramers, 
leading to positive staining of their CTLs. This approach was most successful using the Ebola 
peptide, leading to relatively low false positive background staining. Using the Ebola peptide 
construct as the reference tetramer was effective, as presented in details in Paper IV. 
Considering the binding and overall conformation of pMHC complex, combining it with 
recognition by the TCR being based on the peptide and MHC protein, it follows that the smaller 
the AAs of the peptide, the less available would the peptide residues be for TCR identification. 
Following this logic, better control peptides for tetramer formation could be designed resulting 
in less false-positive tetramer staining. Synthetic 9mer peptides were designed based on three 
criteria; (i) satisfying the residue preferences inherent in the SLA-1*0401 binding matrix anchor 
positions P2 and P9, (ii) be comprised of as many alanines or glycines as possible, and (iii) be 
ranked as strong binders by the NetMHCpan algorithm. Following these criteria, five such 
peptides were synthesized and tested for affinity binding by SLA-1*0401. Three of the five 
peptides had high binding affinities of 19, 40 and 104 nM. The two peptides with the highest 
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affinities were included in the tetramer experiments to provide a “null” tetramer. From those 
studies we observed that the peptide ASYGAGAGY was consistent in exibiting low signal in the 
flow cytometry analysis of T cell staining. This peptide is currently our best option as a negative 
control in the tetramer experiments.  
 
2.4. VACCINATION TRIALS AGAINST FMDV USING A T CELL SPECIFIC VACCINE 
CONSTRUCT 
Performing the vaccination and boosting trials presented in Paper IV we compared two 
different vaccine constructs which differed in the functionality of the 3Cpro as described above. 
The reason for using a 3Cpro mutated version (C163S) of the original vaccine construct was in an 
attempt to specifically induce a CTL response. We hypothesized that a stronger CTL response 
would be induced by such an “FMDV-T activating” vaccine, as opposed to the FMDV-B 
activating construct displaying a functional 3Cpro protein. The hypothesis was based on 
previously published data showing that the mutated and inactivated protease lacks the ability 
to successfully cleave the FMDV P1 protein into the sub-proteins (VP1 – 4) which form the viral 
capsid, hereby enabling the virus to leave the cell. Instead, viral protein would stay captured 
inside the cells leading to proteasome degradation and elevated availability of various FMDV P1 
derived peptides for MHC class I load in the ER, and presentation at the cell surface. The work 
described in Paper IV presents the approaches made to test this hypothesis and the outcome of 
the experiments. 
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3. Paper I  
 
Porcine major histocompatibility complex (MHC) class I molecules and analysis of their 
peptide-binding specificities 
 
Pedersen LE, Harndahl M, Rasmussen M, Lamberth K, Golde WT, Lund O, Nielsen M, 
Buus S. 
 
Immunogenetics. 2011 Dec:63(12):821-34. doi: 10.1007/s00251-011-0555-3 
 
The work presented in this manuscript was focused on the production of the SLA-1*0401 
molecule and the porcine β2m stabilizing subunit protein. Generating chimeric human/swine 
MHC-molecules by systemically transferring domains of the frequently expressed SLA-1*0401 
onto a HLA-I molecule (HLA-A*11:01), enabled us to analyze the peptide-binding characteristics 
of these molecules and validate the effects of pMHC complex formation supported by either 
human or porcine β2m. 
In this study we demonstrated that the approaches developed for the “Human MHC Project” 
can be successfully applied to other species such as pigs. Furthermore, we here presented the 
complete PSCPL mapped binding motif for one of the most common SLA molecules worldwide, 
and showed that pMHC complex formation can be equally supported by human as well as 
porcine β2m, regardless of the α3 domain of the heavy chain being of human or porcine origin. 
In addition, we demonstrate the successful use of a pan-specific predictor of peptide:MHC class 
I binding, the NetMHCpan, in predicting the specificities of the SLA-1*0401 molecule. 
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Abstract In all vertebrate animals, CD8+ cytotoxic T
lymphocytes (CTLs) are controlled by major histocompat-
ibility complex class I (MHC-I) molecules. These are
highly polymorphic peptide receptors selecting and pre-
senting endogenously derived epitopes to circulating CTLs.
The polymorphism of the MHC effectively individualizes
the immune response of each member of the species. We
have recently developed efficient methods to generate
recombinant human MHC-I (also known as human leuko-
cyte antigen class I, HLA-I) molecules, accompanying
peptide-binding assays and predictors, and HLA tetramers
for specific CTL staining and manipulation. This has
enabled a complete mapping of all HLA-I specificities
(“the Human MHC Project”). Here, we demonstrate that
these approaches can be applied to other species. We
systematically transferred domains of the frequently
expressed swine MHC-I molecule, SLA-1*0401, onto a
HLA-I molecule (HLA-A*11:01), thereby generating re-
combinant human/swine chimeric MHC-I molecules as
well as the intact SLA-1*0401 molecule. Biochemical
peptide-binding assays and positional scanning combinato-
rial peptide libraries were used to analyze the peptide-
binding motifs of these molecules. A pan-specific predictor
of peptide–MHC-I binding, NetMHCpan, which was
originally developed to cover the binding specificities of
all known HLA-I molecules, was successfully used to
predict the specificities of the SLA-1*0401 molecule as
well as the porcine/human chimeric MHC-I molecules.
These data indicate that it is possible to extend the
biochemical and bioinformatics tools of the Human MHC
Project to other vertebrate species.
Keywords Recombinant MHC . Peptide specificity .
Binding predictions
Introduction
Major histocompatibility complex class I (MHC-I) mole-
cules are found in all vertebrate animals where they play a
crucial role in generating specific cellular immune
responses against viruses and other intracellular pathogens.
They are highly polymorphic proteins that bind 8–11 amino
acid long peptides derived from the intracellular protein
metabolism. The resulting heterotrimeric complexes—con-
sisting of the MHC-I heavy chain, the monomorphic light
chain, beta-2 microglobulin (β2m), and specifically bound
peptides—are translocated to the cell surface where they
displayed as target structures for peptide-specific, MHC-I-
restricted CTLs. If a peptide of foreign origin is detected,
the T cells may become activated and kill the infected target
cell.
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MHC-I is extremely polymorphic. In humans, more than
3,400 different human leukocyte antigen class I (HLA-I)
molecules have been registered (as of January 2011), and
this number is currently growing rapidly as more efficient
HLA typing techniques are employed worldwide. The
polymorphism of the MHC-I molecule is concentrated in
and around the peptide-binding groove, where it determines
the peptide-binding specificity. Due to this polymorphism,
it is highly unlikely that any two individuals will share the
same set of HLA-I molecules thereby presenting the same
peptides and generating T cell responses of the same
specificities—something, that otherwise would give micro-
organisms a strong evolutionary chance of escape. Rather,
this polymorphism can be seen as diversifying peptide
presentation thereby individualizing T cell responses and
reducing the risk that escape variants of microorganisms
might evolve.
In 1999, we proposed that all human MHC specificities
should be mapped (“the Human MHC Project”) as a
preamble for the application of MHC information and
technologies in humans (Buus 1999). Since then, we have
developed large-scale tools that are generally applicable
towards this goal: production, analysis, prediction and
validation of peptide–MHC interactions (Ferre et al. 2003;
Harndahl et al. 2009; Hoof et al. 2009; Larsen et al. 2005;
Lundegaard et al. 2008; Nielsen et al. 2003, 2007;
Ostergaard et al. 2001; Pedersen et al. 1995; Stranzl et al.
2010; Stryhn et al. 1996), and a “one-pot, read-and-mix”
HLA-I tetramer technology for specific T cell analysis
(Leisner et al. 2008). Here, we demonstrate that many of
these tools can be transferred to other vertebrate animals as
exemplified by an important livestock animal, the pig. We
have successfully generated a recombinant swine leukocyte
antigen I (SLA-I) protein, SLA-1*0401, one of the most
common SLA molecules of swine (Smith et al. 2005).
Using this protein, we have developed the accompanying
biochemical peptide-binding assays and demonstrated that
the immunoinformatics tools originally developed to cover
all HLA-I molecules, despite the evolutionary distance, can
be applied to SLA-I molecules. We suggest that the “human
MHC project” can be extended to cover other species of
interest.
Materials and methods
Peptides and peptide libraries
All peptides were purchased from Schafer-N, Denmark
(www.schafer-n.com). Briefly, they were synthesized by
standard 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry,
purified by reversed-phase high-performance liquid chro-
matography (to at least >80% purity, frequently 95–99%
purity), validated by mass spectrometry, and quantitated by
weight.
Positional scanning combinatorial peptide libraries
(PSCPL) peptides were synthesized using standard solid-
phase Fmoc chemistry on 2-chlorotrityl chloride resins.
Briefly, an equimolar mixture of 19 of the common Fmoc
amino acids (excluding cysteine) was prepared for each
synthesis and used for coupling in 8 positions, whereas a
single type of Fmoc amino acid (including cysteine) was
used in one position. This position was changed in each
synthesis starting with the N-terminus and ending with the
C-terminus. In one synthesis, the amino acid pool was used
in all nine positions. The library therefore consisted of 20×
9+1=181 individual peptide libraries:
& Twenty PSCPL sublibraries describing position 1: AX8,
CX8, DX8, …. YX8
& Twenty PSCPL sublibraries describing position 2:
XAX7, XCX7, XDX7, …. XYX7
& etc
& Twenty PSCPL sublibraries describing position 9: X8A,
X8C, X8D, …. X8Y
& A completely random peptide library: X9
X denotes the random incorporation of amino acids from
the mixture, whereas the single letter amino acid abbrevi-
ation is used to denote identity of the fixed amino acid.
The peptides in each synthesis were cleaved from the
resin in trifluoroacetic acid/1,2-ethanedithiol/triisopropylsi-
lane/water 95:2:1:3 v/v/v/v, precipitated in cold diethylether,
and extracted with water before desalting on C18 columns,
freeze drying, and weighting.
Recombinant constructs encoding chimeric
and SLA-1*0401 molecules
A synthetic gene encoding a transmembrane-truncated
fragment encompassing residues 1 to 275 of human HLA-
A*11:01 alpha chain followed by a FXa–BSP–HAT tag
(FXa = factor Xa cleavage site comprised of the amino acid
sequence IEGR, BSP = biotinylation signal peptide, HAT =
histidine affinity tag for purification purposes; see Online
Resource 1) had previously been generated and inserted
into the pET28 expression plasmid (Novagen) (Ferre et al.
2003). Synthetic genes encoding the corresponding frag-
ments of the SLA-1*0401 alpha chain (α1α2) and α3,
respectively, (Sullivan et al. 1997) were purchased from
GenScript. To exchange domains and generate chimeric
human/swine MHC-I gene constructs, a type II restriction
endonuclease-based cloning strategy (SeamLess® Strate-
gene; Cat#214400, Revision#021003a), with modifications,
was used. All primers were purchased HPLC-purified from
Eurofins MWG Operon (Ebersberg, Germany), and all PCR
amplifications were performed in a DNA Engine Dyad
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PCR instrument (MJ Research, MN, USA). All constructs
were validated by DNA sequencing. The following MHC-I
heavy chain constructs were made HHH, HHP, HPP, PHP,
and PPP, where the first, second, and third letter indicates
domains α1 (positions 1–90), α2 (positions 91–181), and α3
(positions 182–275), respectively, and H indicates that the
domain is of HLA-A*11:01 origin, whereas P indicates that
it is of SLA-1*0401 origin.
Constructs were transformed into DH5α cells, cloned,
and sequenced (ABI Prism 3100Avant, Applied Biosys-
tems) (Hansen et al. 2001). Validated constructs of interest
were transformed into an Escherichia coli production cell
line, BL21(DE3), containing the pACYC184 expression
plasmid (Avidity, Denver, USA) containing an isopropyl-
β-d-1-thiogalactopyranoside (IPTG)-inducible BirA gene
to express biotin-ligase. This leads to almost complete in
vivo biotinylation of the desired product (Leisner et al.
2008).
Expression of recombinant proteins
To maintain the pET28-derived plasmids, the media was
supplemented with kanamycin (50 μg/ml) throughout the
expression cultures. When appropriate, the media was
further supplemented with chloroamphenicol (20 μg/ml)
to maintain the BirA containing pACYC184 plasmid. E.
coli BL21(DE3) cells transformed with appropriate plas-
mids were grown for 5 h at 30°C, and a 10-ml sample
adjusted to OD(600)=1 was then transferred to a 2-l fed-
batch fermentor (LabFors®). To induce protein expression,
IPTG (1 mM) was added at OD(600)∼25 and the culture was
continued for an additional 3 h at 42°C (for in vivo
biotinylation of the product, the induction media was
further supplemented with biotin (Sigma #B4501, 125 μg/
ml)). Samples were analyzed by reducing sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
before and after IPTG induction. At the end of the
induction culture, protease inhibitor (PMSF, 80 μg/l) was
added, and cells were lysed in a cell disrupter (Constant
Cell Disruptor Systems set at 2,300 bar) and the released
inclusion bodies were isolated by centrifugation (Sorval
RC6, 20 min, 17,000×g). The inclusion bodies were
washed twice in PBS, 0.5% NP-40 (Sigma), and 0.1%
deoxycholic acid (Sigma) and extracted into urea–Tris
buffer (8 M urea, 25 mM Tris, pH 8.0), and any
contaminating DNA was precipitated with streptomycin
sulfate (1% w/v).
MHC class I heavy chain purification
The dissolved MHC-I proteins were purified by Ni2+/IDA
metal chelating affinity column chromatography followed
by Q-Sepharose ion exchange column chromatography,
hydrophobic interaction chromatography, and eventually by
Superdex-200 size exclusion chromatography. Fractions
containing MHC-I heavy chain molecules were identified
by A280 absorbance and SDS-PAGE and pooled. Through-
out purification and storage, the MHC-I heavy chain
proteins were dissolved in 8 M urea to keep them
denatured. Note that the MHC-I heavy chain proteins at
no time were exposed to reducing conditions. This allowed
purification of highly active pre-oxidized moieties as
previously described (Ostergaard et al. 2001). Protein
concentrations were determined by bicinchoninic acid
assay. The degree of biotinylation (usually >95%) was
determined by a gel-shift assay (Leisner et al. 2008). The
pre-oxidized, denatured proteins were stored at −20°C in
Tris-buffered 8 M urea.
Recombinant constructs encoding human and porcine
beta-2 microglobulin
Recombinant human β2m was expressed and purified as
described elsewhere (Ostergaard et al. 2001), (Ferre et al.
2003). Using a previously reported E. coli codon-
optimized gene encoding human β2m as template
(Pedersen et al. 1995), a gene encoding porcine β2m
was generated by multiple rounds of site-directed
mutagenesis (QuikChange® Stratagene, according to the
manufacturer’s instructions) (Online Resource 2). Briefly,
the genes encoding human or pig β2m were N-terminally
fused to a histidine affinity encoding tag (HAT) followed
by a restriction enzyme encoding tag (FXa), inserted into
the pET28 vector and expressed in inclusion bodies in E.
coli. The fusion proteins were extracted into 8 M urea,
purified by immobilized metal affinity chromatography
(IMAC), and refolded by dilution. The fusion tags were
then removed by FXa restriction protease digestion. The
liberated intact and native human or pig β2m were
purified by IMAC and gel filtration chromatography,
analyzed by SDS-PAGE analysis, concentrated, and
stored at −20°C until use (Fig. 1).
Purification and refolding of recombinant porcine β2m
proteins
Porcine β2m was purified in the same way as human β2m
(Ostergaard et al. 2001; Ferre et al. 2003). Briefly, the urea-
dissolved β2m protein was purified by Ni
2+/IDA metal
chelating affinity column chromatography, refolded by
drop-wise dilution into an excess refolding buffer under
stirring (25 mM Tris, 300 mM urea, pH 8.00), and then
concentrated (VivaFlow, 10 kDa). The refolded product was
purified by Ni2+/IDA metal chelating affinity column
chromatography again (this time in aqueous buffer, i.e.,
without urea). Fractions containing HAT-pβ2m were iden-
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tified by SDS-PAGE and pooled. Removal of the HAT tag
was performed by cleavage with factor Xa restriction
protease (FXa) followed by renewed purified by Ni2+/
IDA metal chelating affinity and Superdex200 gel filtration
column chromatography, concentrated by spin ultrafiltration
(10 kDa), mixed 1:1 with glycerol, and stored at −20°C.
SDS-PAGE analysis
Protein samples were mixed 1:1 in SDS sample buffer (4%
SDS, 17.4% glycerol, 0.003% bromophenol blue, 0.125 M
Tris, 8 mM IAA (iodoacetamide)) with or without reducing
agent (2-mercaptoethanol) as indicated, boiled for 3 min,
spun at 20,000×g for 1 min, and loaded onto a 12% or 15%
running gel with a 5% stacking gel. Gels were run at 180 V,
40 mA for 50 min.
Peptide–MHC class I interaction measured by radioassay
and spun column chromatography
A HLA-A*11:01-binding peptide, KVFPYALINK (non-
natural consensus sequence A3CON1 (Sette et al. 1994)),
was radiolabeled with iodine (125I) using a chloramine-T
procedure (Hunter and Greenwood 1962). Dose titrations
of MHC-I heavy chains (HHH or HHP) were diluted into
refolding buffer (Tris–maleate–PBS) and mixed with β2m
(human or porcine) and radiolabeled peptide, and incubat-
ed at 18°C overnight. Then binding of radiolabeled
peptide to MHC-I was determined in duplicate by
Sephadex™ G50 spun column gel chromatography as
previously described (Buus et al. 1995). MHC bound
peptide eluted in the excluded volume, whereas free
peptide was retained on the microcolumn. Both fractions
were counted by gamma spectroscopy, and the fraction
peptide bound was calculated as excluded radioactivity
divided by total radioactivity.
To examine the affinity of the interaction, increasing
concentrations of unlabeled competitor peptide were added.
When conducted under limiting concentrations of MHC-I
molecule, the concentration of competitor peptide needed to
effect 50% inhibition of the interaction, the IC50, is an
approximation of the affinity of the interaction between
MHC-I and the competitor peptide.
Peptide–MHC class I interaction measured
by an enzyme-linked immunosorbent assay
Peptide–MHC-I interaction was also measured in a modi-
fied version of a previously described enzyme-linked
immunosorbent assay (ELISA) (Sylvester-Hvid et al.
2002). Briefly, denatured biotinylated recombinant MHC-I
heavy chains were diluted into a renaturation buffer
containing β2m and graded concentrations of the peptide
to be tested and incubated at 18°C for 48 h allowing
equilibrium to be reached. We have previously demonstrat-
ed that denatured MHC molecules can de novo fold
efficiently, however, only in the presence of appropriate
peptide. The concentration of peptide–MHC complexes
generated was measured in a quantitative sandwich ELISA
(using streptavidin as capture layer and the monoclonal
anti-β2m antibody, BBM1, as detection layer) and plotted
against the concentration of peptide offered (Sylvester-Hvid
et al. 2002). A prefolded, biotinylated FLPSDYFPSV/
HLA-A*02:01 (Kast et al. 1994) complex was used as
standard. Because the effective concentration of MHC (3–
5 nM) used in these assays is below the equilibrium
dissociation constant (KD) of most high-affinity peptide–
MHC interactions, the peptide concentration, ED50, leading
to half-saturation of the MHC is a reasonable approxima-
tion of the affinity of the interaction.
Using peptide libraries to perform an unbiased
analysis of MHC specificity
The experimental strategy of PSCPL has previously been
described (Stryhn et al. 1996). The construction of the
sublibraries and the ELISA-driven quantitative measure-
ments of MHC interaction are as given above.
Briefly, the relative binding (RB) affinity of each PSCPL
sublibrary was determined as RB (PSCPL)=ED50 (X9)/
ED50 (PSCPL) (where ED50 is the concentration needed to
half-saturate a low concentration of MHC-I molecules) and
normalized so that the sum of the RB values of the 20
naturally occurring amino acids equals 20 (since peptides
with a given amino acid in a given position are 20 times
more frequent in the corresponding PSCPL sublibrary than
Fig. 1 SDS-PAGE analysis of peak fractions from size exclusion
chromatography of porcine β2m (11.4 kDa) after removal of histidine
affinity tag (HAT) by FXa protease digestion. Samples were mixed 1:1
in non-reducing SDS sample buffer and loaded onto a 15%
polyacrylamide gel
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in the completely random X9 library). A RB value above 2
was considered as the corresponding position and amino
acid being favored, whereas a RB value below 0.5 was
considered as being unfavorable (these thresholds represent
the 95% confidence intervals). An anchor position (AP)
value was calculated by the equation ∑(RB−1)2. A primary
anchor position is characterized by one or few amino acids
being strongly preferred and many amino acids being
unacceptable. We have arbitrarily defined anchor residues
as having an AP value above 15 (Lamberth et al. 2008).
The peptide–SLA-I*0401 binding activity of each subli-
brary was determined using previously published biochem-
ical binding assay (ELISA) (Sylvester-Hvid et al. 2002)
(with the modifications described above).
Sequence logos
Sequences logos describing the predicted binding motif
for each MHC molecule were calculated as described by
Rapin et al. (2010). In short, the binding affinity for a set
of 1,000,000 random natural 9mer peptides was predicted
using the NetMHCpan method, and the 1% strongest
binding peptides were selected for construction of a
position-specific scoring matrix (PSSM). The PSSM was
constructed as previously described (Nielsen et al. 2004)
including pseudo-count correction for low counts. Next,
sequence logos were generated from the amino acid
frequencies identified in the PSSM construction. For each
position, the frequency of all 20 amino acids is displayed
as a stack of letters. The total height of the stack
represents the sequence conservation (the information
content), while the individual height of the symbols
relates to the relative frequency of that particular symbol
at that position. Letter shown upside-down are underrep-
resented compared to the background (for details see
Rapin et al. (2010)).
MHC distance trees
MHC distance trees were derived from correlations be-
tween predicted binding affinities. For each allelic MHC-I
molecule, the binding affinity was predicted for a set of
200,000 random natural peptides using the NetMHCpan
method. Next, the distance between any two alleles was
defined, as D=1−PCC, where PCC is the Pearson
correlation between the subset of peptides within the
superset of top 10% best binding peptides for each allele.
In this measure, two molecules that share a similar binding
specificity will have a distance close to 0 whereas two
molecules with non-overlapping binding specificities would
have a distance close to 2. Using bootstrap, 100 such
distance trees were generated, and branch bootstrap values
and the consensus tree were calculated.
Results
Generation of chimeric MHC class I molecules
We have previously generated highly active, recombinant
human MHC-I (HLA-I) molecules and accompanying high-
throughput assays and bioinformatics prediction resources.
Here, we transfer the underlying approaches to an important
domesticated livestock animal, the pig, and its MHC
system, the SLAs. MHC-I molecules are composed of a
unique and highly variable distal peptide-binding platform
consisting of the alpha 1 (α1) and alpha 2 (α2) domains of
the MHC-I heavy chain (HC) and a much more conserved
proximal immunoglobulin-like membrane attaching stalk
consisting of the alpha 3 (α 3) domain of the HC non-
covalently associated with the soluble MHC-I light chain
(β2m).
A priori, the establishment of recombinant SLA mole-
cules is complicated by the lack of validated reagents. Any
failure could therefore be caused either by real technical
problems in generating SLA molecules, or merely by a lack
of information about strong peptide binders to the SLA in
question. To reduce this uncertainty, we decided to migrate
from human to pig MHC-I in a step-wise manner and
generate an intermediary chimeric MHC-I molecule com-
posed of a well-known human peptide-binding platform
attached to a SLA stalk, which might allow us to assess
whether we could generate a functional SLA stalk consist-
ing of SLA-1*0401 α3 HC and pig β2m. To this end, we
used the α1α2 domains of the HLA-A*11:01 molecule,
which we expected should be able to bind a known high-
affinity HLA-A*11:01-binding peptide (KVFPYALINK).
This peptide could be 125I radiolabeled and used in a very
robust peptide-binding assay testing whether the human
stalk could be replaced with the corresponding SLA stalk.
Once that had been successfully established, the entire
SLA-1*0401 molecule would be constructed and tested.
We have previously expressed and purified the extracellular
segment spanning positions 1–275 of the human HLA-
A*11:01 in a denatured and pre-oxidized version that rapidly
refold and bind appropriate target peptides (Ostergaard et al.
2001; Ferre et al. 2003). Codon-optimized genes encoding
the corresponding segments of SLA-1*0401 (α1α2) and
SLA-1*0401 (α3) were constructed as described in the
“Materials and methods” section and used to replace the
HLA-A*11:01 gene segment in the above construct gener-
ating a new construct allowing for the expression of SLA-
1*0401. For the generation of HLA-A*11:01/SLA-
1*0401 chimeras, the genes encoding α1 (spanning
positions 1–90), α2 (spanning positions 91–181), and/or
α3 (spanning positions 182–275) domains of HLA-
A*11:01 and SLA-1*0401 were exchanged using Seam-
Less and touch-down cloning strategies. Genes encoding
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the extracellular segments 1–275 of the above natural or
chimeric MHC-I molecules were C-terminally fused to a
biotinylation tag (as indicated for SLA-1*0401 in Online
Resource 1), inserted into pET28, and expressed in
inclusion bodies in E. coli (Fig. 2 shows SDS-PAGE of
lysates of recombinant E. coli before and 3 h after IPTG
induction). The fusion proteins were extracted into 8 M urea
(without any reducing agents), purified by ion exchange,
hydrophobic and gel filtration chromatography (all conducted
in 8M urea, without any reducing agents) (Fig. 3 shows SDS-
PAGE of the purified SLA-1*0401 after gel filtration),
concentrated, and stored in urea at −20°C.
Testing a chimeric molecule consisting of a SLA-1*0401
stalk and a HLA-A*11:01 peptide-binding
platform—comparing human versus porcine β2m
To test the proximal immunoglobulin-like membrane
attaching SLA stalk, we generated recombinant porcine
β2m and a chimeric human/porcine MHC-I heavy chain
molecule where the α1α2 were derived from the human
HLA-A*11:01, and the α3 was derived from the porcine
SLA-1*0401. Since this construct contains the entire
peptide-binding platform of HLA-A*11:01, we reasoned
that the binding of the HLA-A*11:01 restricted peptide,
KVFPYALINK, could be used as a functional readout of
the refolding, activity, and assembly of the entire chimeric
molecule including the porcine SLA stalk. For comparison,
we tested the supportive capacity of human β2m and
folding ability of the entirely human HLA-A*11:01. A total
of four combinations could therefore be tested: porcine or
human β2m in combination with either HHP or HHH
(where the first letter indicates the origin of the α1 domain
(Human HLA-A*11:01 or Porcine SLA-1*0401), the
second letter the origin of the α2 domain, and the third
letter the origin of the α3 domain). A concentration–
titration of heavy chain was added to a fixed excess
concentration (3 μM) of β2m and a fixed trace concentra-
tion (23 nM) of radiolabeled peptide. As shown in Figs. 4
and 5, the four combinations gave almost the same heavy
chain dose titration with a half-saturation occurring around
1–2 nM heavy chain. Porcine β2m supported folding of the
chimeric (HHP) α chain slightly better than it supported
folding of the human (HHH) α chain. Human β2m
Fig. 2 SDS-PAGE analysis of cell lysates of SLA-1*0401 expression
in E. coli before and after induction with IPTG. Samples were mixed
1:1 in a reducing SDS sample buffer and loaded onto a 12%
polyacrylamide gel
Fig. 3 SDS-PAGE analysis of
size exclusion chromatography
peak fractions from SLA-
1*0401 purification. Fraction
numbers are shown above each
lane. Samples were mixed 1:1 in
non-reducing SDS sample buffer
and loaded onto a 12%
polyacrylamide gel. Lanes were
loaded with different volumes,
indicated below each lane, to
avoid overloading. An arrow
indicates the band representing
purified SLA-1*0401-BSP-HAT
heavy chain (36,675 Da)
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supported folding of HHP and HHH equally well. Thus, a
recombinant SLA stalk can fold and support peptide
binding of the peptide-binding platform. These results also
suggest that human β2m can support folding and peptide
binding of porcine MHC-I heavy chain molecules.
Using a positional scanning combinatorial peptide library
approach to perform an unbiased analysis of the specificity
of SLA-1*0401 and human–pig chimeric MHC class
I molecules
Using human β2m to support folding, the recombinant SLA-
1*0401 and human–pig chimeric MHC-I molecule were
tested for peptide binding. We have previously described
how PSCPL can be used to perform an unbiased analysis of
MHC-I molecules (Stryhn et al. 1996). A PSCPL consists of
20 sublibraries for each position where one of each of the 20
natural amino acids have been locked and all other positions
contain random amino acids. Analyzing how much of each
PSCPL sublibrary is needed to support MHC-I folding (see
examples in Fig. 6) and comparing each sublibrary with a
completely random library, the effect of any amino acid in
any position can be examined and expressed as a RB value.
Further, an AP value calculated as the sum of squared
deviations of RB values for each position can be used to
identify the most prominent anchor position (see “Materials
and methods” for calculations). Thus, the specificity of a
nonamer binding MHC-I molecule can be analyzed compre-
hensively with 9×20+1 completely random library=181
sublibraries (Stryhn et al. 1996).
Here, this approach was used to perform a complete
experimental analysis of SLA-1*0401 and a limited
analysis of the chimeric HPP and PHP molecules. A
nonamer PSCPL analysis of SLA-1*0401 can be seen in
Table 1. AP values identified positions 9, 3, and 2 (in that
order of importance) as the anchor positions of SLA-
1*0401. In position 9, the amino acid preferences were
dominated by the large and bulky aromatic tyrosine (Y),
tryptophane (W), and phenylalanine (F), all having RB
values above 4 (Table 1). In the almost equally important
position 3, preferences for negatively charged amino acids
glutamic acid (E) and aspartic acid (D) were observed. In
the lesser important position 2, the most preferred amino
acids were the hydrophobic amino acids valine (V),
isoleucine (I), and leucine (L), followed by the polar amino
acids threonine (T) and serine (S).
Finally, a very limited PSCPL analysis was performed for
the two chimeric human HLA-A*11:01/porcine SLA-1*0401
MHC-I molecules, HPP and PHP (Table 2). For both chimeric
molecules, it could be demonstrated that position 9 is a
strong anchor position. The positively charged amino acids,
arginine (R) and lysine (K), were preferred in position 9 of
the chimeric HPP molecule, whereas the aromatic amino
acid, tyrosine (Y), was exclusively preferred in position 9 of
the chimeric PHP molecule.
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Fig. 5 MHC-I complex formation of the chimeric class I molecule
HHP (HLA-A*11:01 (α1α2), SLA-1*0401 (α3)) with a known HLA-
A*11:01-binding peptide (KVFPYALINK), and human (open squares)
versus porcine β2m (filled circles). The affinity of HHP to porcine and
human β2m was determined as 0.774 nM (95% confidence interval,
0.630 to 0.951) and 1.19 nM (95% confidence interval, 0.958 to 1.47),
respectively
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Fig. 4 HLA-A*11:01 complex formation with a known HLA-
A*11:01-binding peptide (KVFPYALINK) using either human (open
squares) or porcine (filled circles) β2m. The affinity of HLA-A*11:01
to porcine and human β2m was determined as 2.11 nM (95%
confidence interval, 1.96 to 2.27) and 1.07 nM (95% confidence
interval, 0.871 to 1.32), respectively
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Fig. 6 PSCPL position 9 sublibrary analysis of the SLA-1*0401
peptide-binding motif. The amino acids valine, serine, and threonine
are disfavored in position 9, evident by a decrease in affinity
compared to the reference peptide (X9), whereas the large and bulky
amino acids tryptophan and tyrosine are favored as seen by an
increase in affinity compared to the reference peptide
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The positively charged amino acids, arginine (R) and lysine
(K), were preferred in position 9 of the chimeric HPP molecule
similar to the position 9 specificity of the HLA-A*11:01
molecule. In contrast, the aromatic amino acid tyrosine (Y) was
preferred in position 9 of the chimeric PHP molecule similar to
the position 9 specificity of the SLA-1*0401 molecule.
Using NetMHCpan to predict peptides that bind
to SLA-1*0401 or to human–pig chimeric MHC
class I molecules
Our recently described neural network-driven bioinformatics
predictor, NetMHCpan (version 2.0), has been trained on
about 88,000 peptide-binding data points representing more
than 80 different MHC-I molecules (primarily HLA-A and
HLA-B molecules). We have previously shown that
NetMHCpan is an efficient tool to identify peptides that
bind to HLA molecules where no prior data exist (Nielsen et
al. 2007) and demonstrated that NetMHCpan can be
extended to MHC-I molecules of other species1 (Hoof et
al. 2009). We applied NetMHCpan to our peptide repository
of about 10,000 peptides, which over the past decade have
been selected to scan infectious agents (e.g., SARS and
influenza, Sylvester-Hvid et al. 2004; Wang et al. 2010),
improve coverage of MHC-I specificities (e.g., Buus et al.
2003; Christensen et al. 2003), etc. We extracted 29 peptides
as predicted binders to either the SLA-1*0401, the HPP, or
the PHP human/porcine chimeric class I molecules (some of
the peptides were predicted to bind to two or even all three
of these molecules). All these peptide–MHC-I combinations
were tested for binding (Table 3); 13 of 14 peptides bound to
the SLA-1*0401 molecule with an affinity (IC50 value) better
than 500 nM (6 with an affinity less than 50 nM); all 13
peptides tested on the PHP molecule were strong binders
with IC50 values below 50 nM; and 3 of 12 peptides tested
on the HPP molecule bound with an affinity better than
500 nM. Of the 39 peptide–MHC-I combinations tested, 20
(51%) were found to be good binders, 9 (23%) were average
binders, and 10 (26%) did not bind well (Table 3). This is in
stark contrast to the 0.5% frequency of binders among
randomly selected peptides (Yewdell and Bennink 1999).
Next, the NetMHCpan method was used to generate
PSSMs and sequence logos from the corresponding amino
acid frequencies as described by Nielsen et al. (2004). For
each position, the frequencies of all 20 amino acids were
displayed as a stack of letters showing the sequence
conservation/information content (the height of the entire
1 A preliminary report of SLA-1*0401 binding was given in Hoof et
al. (2009).
SLA-1*0401 Amino acid position in peptide
1 2 3 4 5 6 7 8 9
A 1.7 0.8 1.6 1.1 0.8 0.4 1.7 0.7 0.0
C 0.8 0.2 0.4 2.7 1.1 1.0 0.7 1.7 0.0
D 0.4 0.7 7.7 2.1 0.8 0.1 0.5 1.8 0.0
E 1.6 0.0 2.8 0.6 1.0 1.4 0.9 0.9 0.2
F 0.4 0.2 0.8 0.0 1.0 1.1 1.1 1.1 5.8
G 0.5 0.3 0.1 1.5 1.1 1.4 0.0 1.0 0.0
H 0.5 0.2 0.1 0.1 1.3 2.4 0.5 0.7 0.4
I 0.7 3.4 0.3 0.8 0.8 0.9 0.7 0.9 0.3
K 1.1 0.2 0.1 0.4 0.4 1.2 0.4 0.9 0.0
L 0.6 2.1 0.2 0.6 1.0 1.7 1.0 1.2 0.6
M 1.7 1.9 1.0 1.2 1.4 1.4 1.2 1.4 0.7
N 1.4 0.5 0.6 1.4 1.9 0.7 1.0 1.9 0.0
P 0.0 0.0 0.1 1.6 0.5 1.1 1.9 1.2 1.1
Q 1.0 0.9 0.2 1.0 0.5 0.4 0.8 0.7 0.0
R 2.3 0.0 0.1 0.6 2.4 0.9 1.0 0.5 0.2
S 1.8 2.4 1.8 1.1 0.8 1.5 1.6 0.7 0.0
T 1.4 2.5 1.6 0.7 0.9 0.5 2.0 0.7 0.0
V 1.1 3.7 0.3 0.5 0.7 0.8 0.9 0.6 0.8
W 0.3 0.0 0.2 0.6 1.0 0.8 0.6 1.4 5.6
Y 0.6 0.0 0.5 1.3 0.6 0.2 1.6 0.3 4.3
Sum 20 20 20 20 20 20 20 20 20
AP value 7 28 57 8 4 6 5 4 67
Table 1 Binding motif of the
SLA-1*0401 allele determined
by PSCPL strategy
The normalized relative binding
(RB) value indicates whether an
amino acid is favored (RB>2,
bold numbers) or disfavored
(RB<0.5, italic numbers) in a
given peptide position. The
anchor position (AP) value is
given by the equation
∑(RB−1)2 . The important
anchor positions 2, 3, and 9 for
SLA-1*0401 are underlined
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stack) and the relative frequency of amino acids (the height
of the individual amino acids). Figure 7 shows a specificity
tree clustering of the SLA-1*0401 molecule compared to
prevalent representatives of the 12 common HLA super-
types that NetMHCpan originally intended to cover (Lund
et al. 2004). By this token, SLA-1*0401 most closely
resembles that of HLA-A*01:01.
The limited PSCPL analysis of the chimeric MHC-I
molecules revealed strong P9 signals with specificities that
seemed to be determined by the origin of the α1 domain: the
HPP chimera showed an HLA-A*11:01-like P9 specificity,
whereas the PHP chimera showed a SLA-1*0401/HLA-
A*01:01-like specificity. Since the NetMHCpan predictor
successfully captured these chimeric specificities (see above),
we reasoned that the predictor might also be used to perform
in silico dissection of these specificities and used the P9
specificity as an example of such an in silico analysis. The
NetMHCpan predictor considers a pseudo-sequence consist-
ing of 34 polymorphic positions, which contain residues that
are within 4.0 Å of the atoms of bound nonamer peptides
(Nielsen et al. 2007). Of the 34 positions of the pseudo-
sequence, 10 delineates the P9 binding pocket; however, only
3 of these, positions 74, 77, and 97, differ between SLA-
1*0401 and HLA-A*11:01. To explore the effect of these
three residues, we performed in silico experiments where we
examined single substitutions Y74D, G77D, and S97I (the
letter before the position number indicates the SLA-A*0401
single letter residue, whereas the letter after indicates the
HLA-A*11:01 residue) as well as the corresponding triple
substitution (YGS-DDI). As described above, PSSMs were
generated for each of the in silico molecules followed by a
specificity tree clustering (including SLA-A*0401, HLA-
A*01:01, and HLA-A*11:01). Figure 8 shows this tree along
with the sequence logo plots showing the predicted binding
specificity of each in silico MHC-I molecule. Albeit the
Y74D and G77D single substitutions showing some of the
positively charged P9 peptide residue preference of HLA-
A*11:01, they still clustered with HLA-A*01:01. In contrast,
the in silico (YGS-DDI) triple substitution clustered with the
HLA-A*11:01. This suggests that the NetMHCpan method is
capable of defining the residues of the F pocket that
determine the specificity of position 9.
Discussion
We have previously suggested that the specificities of the
entire human MHC-I system should be solved (“the human
Molecule: HPP
Position in peptide
Molecule: PPP
Position in peptide
Molecule: PHP
Position in peptide
Amino
acid
2 9 Amino
acid
2 9 Amino
acid
2 9
A 0.3 0.4 A 0.8 0.0 A 1.0 0.0
C 0.2 0.4 C 0.2 0.0 C 0.0 0.0
D 0.2 0.4 D 0.7 0.0 D 0.0 0.0
E 0.2 0.4 E 0.0 0.2 E 0.0 0.0
F 0.0 0.4 F 0.2 5.8 F 0.1 0.5
G 0.2 0.4 G 0.3 0.0 G 0.4 0.0
H 0.2 0.4 H 0.2 0.4 H 0.2 0.5
I 2.4 0.4 I 3.4 0.3 I 2.7 0.1
K 0.2 2.3 K 0.2 0.0 K 0.1 0.0
L 0.0 0.4 L 2.1 0.6 L 1.8 0.4
M 5.3 0.4 M 1.9 0.7 M 2.1 0.7
N 0.0 0.4 N 0.5 0.0 N 0.2 0.0
P 0.2 0.4 P 0.0 1.1 P 0.0 0.7
Q 0.0 0.4 Q 0.9 0.0 Q 1.1 0.0
R 0.2 9.6 R 0.0 0.2 R 0.2 0.0
S 3.4 0.4 S 2.4 0.0 S 2.8 0.0
T 4.8 0.4 T 2.5 0.0 T 3.6 0.0
V 1.6 0.4 V 3.7 0.8 V 3.3 0.3
W 0.2 0.4 W 0.0 5.6 W 0.1 0.2
Y 0.2 0.4 Y 0.0 4.3 Y 0.2 16.5
Sum 20 20 Sum 20 20 Sum 20 20
AP value 51 81 AP value 28 67 AP value 30 254
Table 2 Comparison of PSCPL
derived binding motifs for the
three MHC-I heavy chains HPP,
PHP, and PPP (hα1pα2pα3,
pα1hα2pα3, and SLA-I*0401)
regarding peptide positions 2
and 9
RB and AP values are defined
as described in Table 1
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MHC”, Buus 1999; Lauemoller et al. 2000). However, due
to the extreme polymorphism of the MHCs, any attempt to
address the specificity of the entire MHC system is a
significant experimental undertaking. During the past
decade, we have established a series of technologies to
support a general solution of human MHC class I and II
specificities. For MHC-I, this includes (1) a highly efficient
E. coli expression system for production of recombinant
human and mouse MHC-I molecules (both heavy chain and
light chain (β2m) molecules) (Pedersen et al. 1995;
Ostergaard et al. 2001), (2) a purification system for
obtaining the highly active pre-oxidized MHC-I heavy
chain species (Ferre et al. 2003), (3) a high-throughput
homogenous peptide–MHC-I binding assay for obtaining
large data sets on peptide–MHC-I interactions (Harndahl et
al. 2009), (4) a positional scanning combinatorial peptide
library approach for a robust and unbiased analysis of the
specificity of any MHC-I molecule (Stryhn et al. 1996), (5)
an immunobioinformatics approach to generate predictors
of the peptide–MHC-I interaction, NetMHCpan, that allows
predictions to be made for any human MHC-I molecules,
HLA-I, even those that have not yet been covered by
existing data set (Hoof et al. 2009; Nielsen et al. 2007), and
finally (6) we have demonstrated that pre-oxidized MHC-I
molecules can be used to generate MHC-I tetramers in a
simple “one-pot, mix-and-read” manner (Leisner et al.
2008). Here, we propose that the next goal should be to
extend the overall approach to MHC-I molecules of other
species of interest. Mouse and rats have been extensively
studied in the past, but much less reagents and information
have accrued for the MHC-I molecules of other species.
Here, we have used an important livestock animal, the pig,
as a model system and demonstrated that it indeed is
possible to transfer the original human approach to other
species.
Before attempting to generate a recombinant version of
the entire porcine SLA-1*0401 molecule, we grafted the
more conserved membrane-proximal “stalk” (the
immunoglobulin-like class I heavy chain α3 and β2m
domains) of porcine SLA-1*0401 onto the peptide-binding
domain of HLA-A*11:01 generating a chimeric human/
porcine MHC-I molecule. This chimeric molecule retained
the peptide-binding specificity of the HLA-A*11:01 mole-
cule, and it clearly demonstrated that the recombinant
porcine stalk was functional and, by inference, also
properly folded. It also suggests that the peptide-binding
specificity of the distal domains do not crucially depend
upon the identity of the proximal stalk. Further, comparing
the ability of human and porcine β2m to support MHC-I
complex formation using either a human or a porcine
MHC-I stalk, we demonstrated that every combination
(porcine β2m/human-α3, porcine β2m/porcine-α3, human
β2m/human-α3, and human β2m/porcine-α3) showed al-
Table 3 Peptide sequences and in vitro determined KD values for the
three different MHC molecules PPP (SLA-1*0401) (top), PHP
(pα1hα2pα3) (middle), and HPP (hα1pα2pα3) (bottom), respectively
Peptide # Sequence Affinity (KD, nM)
PPP
1 HSNASTLLY 452
2 SSMNSFLLY 192
3 YSAEALLPY 202
4 MTFPVSLEY 15
5 MSSAAHLLY 103
6 STFATVLEY 32
7 MTAASYARY 16
8 HTSALSLGY 163
9 ASYQFQLPY 8
10 YANMWSLMY 386
11 STYQPLPLY 38
12 HTAAPWGSY Non-binder
13 ITMVNSLTY 169
14 ATAAATEAY 5
PHP
1 HSNASTLLY 5
2 SSMNSFLLY 2
4 MTFPVSLEY 1
5 MSSAAHLLY 1
6 STFATVLEY 3
9 ASYQFQLPY 1
13 ITMVNSLTY 2
15 STMPLSWMY 1
16 HMMAVTLFY 11
17 KTFEWGVFY 6
18 ATNNLGFMY 1
19 ATATWFQYY 3
20 ITMVNSLTY 2
HPP
2 SSMNSFLLY Non-binder
4 MTFPVSLEY Non-binder
6 STFATVLEY Non-binder
21 FSFGGFTFK Non-binder
22 KVFDKSLLY Non-binder
23 ATFSVPMEK Non-binder
24 RVMPVFAFK 17
25 AVYSSSMVK 127
26 AVARPFFAK 231
27 GSYFSGFYK Non-binder
28 LTFLHTLYK Non-binder
29 MTMRRRLFK Non-binder
The NetMHCpan percentage of success for predicting binders for the
PPP, PHP, and HPP heavy chains were 93%, 100%, and 33%,
respectively
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most the same heavy chain dose titration with identical
half-saturations. These results illustrate the ability for
porcine and human β2m to support complex formation of
SLA molecules and vice versa and suggest evolutionary
that the stalk is quite conserved.
Next, we generated the entire SLA-1*0401 heavy chain and
succeeded in generating complexes using human β2m as the
light chain and PCSPL as peptide donors. The latter solved the
a priori problem of not knowing which peptides would be
needed to support proper folding of SLA-1*0401, and it did so
in an unbiased manner. Furthermore, this approach is highly
efficient since it readily establishes a complete matrix
representing the amino acid preference for each amino acid
and each position of a nonamer peptide. The specificity of
SLA-1*0401 shows two primary anchors: one in positions 9
with a preference for aromatic amino acids and another in
position 3 with a preference for negatively charged amino
acids. In addition, the SLA-1*0401 features a secondary anchor
in position 2 with hydrophobic or polar amino acid preferences.
An alternative approach to solve the problem of identifying
peptides that support folding of MHC-I molecules of so far
unknown specificity is to use our recently developed pan-
specific predictor, NetMHCpan. The successful use of this
predictor to initiate peptide-binding studies was recently
Fig. 7 Specificity tree clustering of the SLA-1*0401 molecule
compared to prevalent representatives of the 12 common HLA
supertypes (Lund et al. 2004). The distance between any two MHC
molecules and the consensus tree is calculated as described in
“Materials and methods”. All branch points in the tree have bootstrap
values of 100%. Sequence logos of the predicted binding specificity
are shown for each molecule. In the logo, acidic amino acids [DE] are
shown in red, basic amino acids [HKR] in blue, hydrophobic amino
acids [ACFILMPVW] in black, and neutral amino acids [GNQSTY]
in green. The axis of the LOGOs indicates in all case positions one
through nine of the motif, and the y-axis the information content (see
Materials and methods)
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demonstrated for HLA-A*3001 (Lamberth et al. 2008).
Although originally developed to cover all HLA-A and
HLA-B molecules, it has also been shown to extend to
MHC-I molecules of other species (Hoof et al. 2009). Here,
we demonstrate that the NetMHCpan predictor is capable of
extracting MHC-I sequence information across species and
correctly relate this to peptide binding even in the absence of
any available data for the specific query MHC-I molecule,
i.e., the SLA-1*0401 as well as the chimeric HPP
(hα1pα2pα3) and PHP (pα1hα2pα3) molecules. It is not
clear why binding of the PHP chimera was more efficiently
predicted than binding of the HPP chimera. One could
speculate that NetMHCpan has not captured the effect of the
different positions of the pseudo-sequence equally well and
not all positions and pockets (and by inference—not all
chimeric molecules) are therefore predicted equally well.
Using the NetMHCpan predictor to cluster SLA-1*0401
and representative molecules of 12 human HLA supertypes
according to predicted peptide-binding specificities, the SLA-
1*0401 specificity closely resembled that of HLA-A*01:01
(IEDB, http://www.immuneepitope.org/MHCalleleId/142,
accessed March 9th 2011). This result was also obvious
from an inspection of the PSCPL analysis of the SLA-
1*0401. The PSCPL analysis of the P9 specificity of the
SLA-1*0401 and the two chimeric molecules suggested
that the P9 specificity primarily was determined by the
α1 domain. This contention was further strengthened by a
NetMHCpan-driven in silico analysis of the residues
delineating the F pocket, which interacts with P9. This
suggests that NetMHCpan can be used to design and
interpret detailed experiments addressing the structure–
function relationship of peptide–MHC-I interaction. In the
case of SLA-1*0401, NetMHCpan suggests that Y74,
G77, and S97 play a prominent role in defining the P9 F
pocket. Whereas the NetMHCpan readily captured the P9
anchor residue of SLA-1*0401, it did not capture the P3
anchor (at least not in the 2.4 version). We surmise that
this shortcoming is due to insufficient examples of the use
of P3 anchors within the currently available peptide–
MHC-I binding data. Inspecting the pseudo-sequence of
SLA-1*0401 and HLA-A*01:01 vs. HLA-A*11:01 sug-
gests that the presence of an arginine in position 156 might
Fig. 8 Comparison of specific in silico mutations of the SLA-1*0401
molecule and comparison with the two HLA molecules: HLA-
A*11:01 and HLA-A*01:01. The distance between any two MHC
molecules and the consensus tree is calculated as described in
“Materials and methods”. All branch points in the tree have bootstrap
values of 100%. The SLA-1*0401 mutations are indicated as Y74D,
G77D, and S97I, where the letter before the position number indicates
the SLA-1*0401 single letter residue and the letter after indicates the
HLA-A*11:01 residue. YGS-DDI is the corresponding triple substi-
tution. Sequence logos are calculated and visualized as described in
Fig. 7. The axis of the LOGOs indicates in all case positions one
through nine of the motif, and the y-axis the information content (see
Materials and methods)
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explain the preference for negatively charged amino acid
residues in P3. Future NetMHCpan-guided experiments
could pointedly address this question, and the resulting
data could complement existing data and be used to update
and improve the NetMHCpan predictor.
All in all the two complementary approaches, PSCPL
and NetMHCpan, agreed on the specificity of the SLA-
1*0401 molecule, as well as of the two chimeric MHC-I
molecules. Thus, the specificity of SLA-1*0401 appear to
be well established. This specificity has successfully been
used to search for foot-and-mouth disease virus (FMDV)-
specific CTL epitopes in FMDV-vaccinated, SLA-1*0401-
positive pigs, and the recombinant SLA-1*0401 molecules
have been used to generate corresponding tetramers and
stain pig CTLs (Patch et al. 2011). In conclusion, we here
present a set of methods that can be used to generate
functional recombinant MHC-I molecules, map their
specificities and identify MHC-I-restricted epitopes, and
eventually generate peptide–MHC-I tetramers for validation
of CTL responses. This suite of methods is not only
applicable to humans, but potentially to any species of
interest.
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Identification of peptides from foot-and-mouth disease virus
structural proteins bound by class I swine leukocyte antigen (SLA)
alleles, SLA-1*0401 and SLA-2*0401
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Summary Characterization of the peptide-binding specificity of swine leukocyte antigen (SLA) class I
and II molecules is critical to the understanding of adaptive immune responses of swine
toward infectious pathogens. Here, we describe the complete binding motif of the SLA-
2*0401 molecule based on a positional scanning combinatorial peptide library approach.
By combining this binding motif with data achieved by applying the NetMHCpan peptide
prediction algorithm to both SLA-1*0401 and SLA-2*0401, we identified high-affinity
binding peptides. A total of 727 different 9mer and 726 different 10mer peptides within the
structural proteins of foot-and-mouth disease virus (FMDV), strain A24 were analyzed as
candidate T-cell epitopes. Peptides predicted by the NetMHCpan were tested in ELISA for
binding to the SLA-1*0401 and SLA-2*0401 major histocompatibility complex class I
proteins. Four of the 10 predicted FMDV peptides bound to SLA-2*0401, whereas five of
the nine predicted FMDV peptides bound to SLA-1*0401. These methods provide the
characterization of T-cell epitopes in response to pathogens in more detail. The development
of such approaches to analyze vaccine performance will contribute to a more accelerated
improvement of livestock vaccines by virtue of identifying and focusing analysis on bona
fide T-cell epitopes.
Keywords binding motif, prediction, SLA, T-cell epitope
Introduction
The major histocompatibility complex class I (MHC I)
molecules are highly polymorphic proteins that bind 8 to
11 amino acid (AA) peptides derived from the intracellular
protein metabolism. In humans, such MHC class I molecules
are referred to as human leukocyte antigens (HLA) and in
swine are termed swine leukocyte antigens (SLA). These
integral membrane proteins are found on all nucleated cells
in vertebrates and play a crucial role in the cell-mediated
immune response against viruses, other intracellular patho-
gens and transformed cells (cancer). When an endogenous
peptide engages in a productive interaction with a MHC
class I heavy chain and the non-polymorphic MHC
I-stabilizing subunit molecule, beta-2-microglobulin (b2m),
they generate a heterotrimeric peptide/MHC/b2m (pMHC)
complex that is displayed at the cell surface. When surface-
exposed MHC complexes incorporate foreign peptides,
derived from a virus for instance, these complexes serve as
targets for the T-cell receptor (TCR) on CD8+, MHC I-
restricted, peptide-specific, cytotoxic T lymphocytes (CTLs).
In this way, endogenous peptides are constantly presented
on the cell surface, signaling the cell’s current state of
integrity to the immune system of the host. If the peptide
presented is of foreign origin, T cells may become activated
and kill the infected or transformed cell (Doherty &
Zinkernagel 1975; Zinkernagel & Doherty 1975; Bevan
1995; Harty et al. 2000).
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The effect of polymorphism of the MHC I molecule is
reflected in the different peptide-binding motifs that different
class I molecules have, with peptide-binding anchor
positions (APs) typically in positions 1, 2, 3 and 9 (Sette
& Sidney 1999; Lamberth et al. 2008). More than 5400
different HLA-I alleles have been registered according to
the IMGT/HLA database (http://www.ebi.ac.uk/imgt/hla/
stats.html), and this number is growing rapidly as more
efficient HLA typing techniques are employed worldwide.
The same has been seen for SLA typing in recent years, with
highly specific primer-based typing systems being used with
success for both class I and class II genes in inbred as well as
outbred pigs (Ho et al. 2006, 2010a,b; Yeom et al. 2010).
As such, there is an equivalent need for biochemical data.
However, characterizing the peptide-binding motif for each
of these alleles is not feasible. Rather, application of the
NetMHCpan peptide-binding predictor algorithm (Nielsen
et al. 2007; Hoof et al. 2009) developed from the extensive
human database available provides a method for quantita-
tive predictions of peptide binding to any MHC protein.
Thus, potential peptides that will bind can be reduced from
hundreds (or even thousands) to a more dexterous number
that can be tested.
Previously, we reported that the bioinformatics tools
originally developed to cover all HLA-I molecules, despite
the evolutionary distance, can be applied to SLA-I molecules
(Hoof et al. 2009; Pedersen et al. 2011). Here, we have used
the NetMHCpan predictor to predict peptides likely to be
bound by the SLA-1*0401 and SLA-2*0401 molecules
using a NetMHCpan rank score threshold of 2.00%. In this
way, we were able to limit the number of possible peptides
derived from the structural proteins of foot-and-mouth
disease virus (FMDV), strain A24, from more than 700 to
<16. Furthermore, by comparing the sequences of these
peptides with the AA binding preferences exhibited by the
SLA molecule in question, we were able to further reduce
the number of peptides to be tested. The final peptide
candidates were then analyzed in vitro for the ability to
induce the formation of pMHC complexes with a high
enough affinity to allow proper folding using the recombi-
nant SLA-1*0401 and SLA-2*0401 class I heavy chains.
Through the production of recombinant SLA molecules,
mapping of their peptide-binding motifs using universal
peptide libraries, that is, the positional scanning combina-
torial peptide libraries (PSCPL) (Stryhn et al. 1996;
Lamberth et al. 2008), and the screening of AA sequences
from FMDV structural proteins for possible peptide/MHC
matches using NetMHCpan (Hoof et al. 2009), we were able
to identify several in vitro binding peptides and characterize
the SLA-2*0401 binding motif. Such data add to the
knowledge of the binding characteristics for SLA molecules
in general and could eventually lead to further insight into
specific viral-derived peptides that induce porcine CTLs
during infection. The result of taking these approaches is a
rapid and accurate capacity to identify T-cell epitopes and
the subsequent ability to measure specific T-cell immunity
following vaccination or infection (Patch et al. 2011).
Materials and methods
Recombinant construct encoding the SLA-2*0401
protein
SLA-2*0401 recombinant protein was produced using a
previously described standard expression system (Pedersen
et al. 2011). Briefly, a transmembrane, truncated fragment
encompassing residues 1–276 of the SLA-2*0401 alpha
chain (Genscript, Appendix S1) followed by an FXa-BSP-
HAT tag (FXa = factor Xa cleavage site comprising the
AA sequence IEGR = I (isoleucine), E (glutamine acid),
G (glycine), R (arginine), BSP = biotinylation signal peptide,
HAT = histidine affinity tag for purification purposes) was
inserted into a pET28a expression vector (Novagen). The
construct was transformed into DH5a cells and sequenced
(ABI Prism 3100Avant; Applied Biosystems) (Hansen et al.
2001). The validated construct of interest was transformed
into an Escherichia coli (E. coli) production cell line, BL21
(DE3), containing the pACYC184 expression plasmid (Avid-
ity) with an IPTG (Isopropyl-beta-D-thiogalactoside)-induc-
ible BirA gene to express biotin-ligase. This leads to almost
complete in vivo biotinylation of the desired product
(Schmidt et al. 2009).
Expression and purification of recombinant SLA-2*0401
and human beta-2 microglobulin
SLA-2*0401 heavy chain proteins were produced as previ-
ously described (Pedersen et al. 2011). E. coli BL21(DE3) cells
containing the SLA proteins were lyzed in a cell disrupter
(Constant Cell Disruptor Systems set at 2300 bar), and the
released inclusion bodies were isolated by centrifugation
(Sorval RC6, 20 min, 17 000 g). The inclusion bodies were
washed twice in PBS, 0.5%NP-40 (Sigma), 0.1%deoxycholic
acid (DOC; Sigma) and extracted into urea–Tris buffer (8 M
urea, 25 mMTris, pH8.0). SLA-2*0401heavy chain proteins
extracted in 8 M ureawere purified as previously described for
the SLA-1*0401 molecule (Pedersen et al. 2011). In brief,
this was carried out by successive immobilized metal adsorp-
tion, hydrophobic interaction, and Superdex-200 size exclu-
sion chromatography. Throughout purification and storage,
the MHC I heavy chain proteins were dissolved in 8 M urea to
keep them denatured. The pre-oxidized, denatured proteins
were stored at20 °C inTris-buffered 8 Murea. Recombinant
human b2m was expressed and purified as described else-
where (Ostergaard et al.2001; Ferre et al.2003). Complexing
the porcine alpha chains with human b2m and peptide
allowed the application of the ELISA for class I MHC folding
using mouse anti-human b2m, as described below and
previously (Pedersen et al. 2011). Reagents for porcine b2m
are not available.
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Peptides and peptide libraries
All peptides were purchased from Schafer-N. Briefly, they
were synthesized by standard 9-fluorenylmethyloxycarbonyl
(Fmoc) chemistry, purified by reverse-phase high-perfor-
mance liquid chromatography (to at least >80% purity,
frequently 95–99% purity), validated by mass spectrometry
and quantitated by weight.
PSCPL peptides were used to determine the SLA-2*0401-
binding motif. The experimental strategy of PSCPL has
previously been described for both HLA (Stryhn et al. 1996)
and SLA (Pedersen et al. 2011) proteins. Briefly, pools of
random peptides with a single fixed AA in a fixed peptide
position for every AA in every peptide position were used to
determine the MHC-binding pocket motif of the MHC I
protein. PSCPL peptides were used in a quantitative ELISA
as described for the SLA-1*0401 molecule (Pedersen et al.
2011). The relative binding (RB) affinity of each PSCPL
sublibrary was determined as RB (PSCPL) = ED50(X9)/
ED50(PSCPL) and normalized, so that the sum of the RB
values of the 20 naturally occurring AA equaled 20 (ED50
being the concentration needed to half-saturate a low
concentration of MHC class I molecules). Anchor position
values were calculated by the equation ∑(RB  1)2.
PSCPL peptides were synthesized using standard solid-
phase Fmoc chemistry on 2-chlorotrityl chloride resins.
Briefly, an equimolar mixture of 19 of the common Fmoc
AAs (excluding cysteine) was prepared for each synthesis
and used for coupling in eight positions, whereas a single
type of Fmoc AA (including cysteine) was used in one
position. This position was changed in each synthesis
starting with the N-terminus and ending with the C-
terminus. In one synthesis, the AA pool was used in all nine
positions. The library therefore consisted of
20 9 9 + 1 = 181 individual peptide libraries:
• 20 PSCPL sublibraries describing position 1: AX8, CX8,
DX8, … YX8
• 20 PSCPL sublibraries describing position 2: XAX7, XCX7,
XDX7, … XYX7
• etc.
• 20 PSCPL sublibraries describing position 9: X8A, X8C,
X8D, … X8Y
• a completely random peptide library: X9
X denotes the random incorporation of AA from the mixture,
whereas the single-letter AA abbreviation is used to denote
the identity of the fixed AA. Following synthesis, the peptides
were cleaved from the resin in trifluoroacetic acid/1,2-
ethanedithiol/triisopropylsilane/water 95:2:1:3 v/v/v/v,
precipitated in cold diethyl ether and extracted with water
before desaltingonC18-columns, freeze dryingandweighing.
ELISA for affinity of peptide binding
Peptides were tested for their ability to form complexes with
the SLA-1*0401 and SLA-2*0401 proteins using a previ-
ously described immunosorbent assay (Sylvester-Hvid et al.
2002). Complexes of heavy chain with human b2m and
peptide were formed in 96-well plates (Thermo Scientific).
All peptides were dissolved in 150 ll standard folding buffer
[PBS, 0.1% pluriol (Lutrol F-68, BASF), pH 7.0] using
sonication for 5 min. A fivefold dilution series of peptide in
12 consecutive points was performed in standard folding
buffer. Following a 48-h incubation (18 °C), samples were
transferred to streptavidine-coated plates (Nunc, DK-4000)
and incubated for 3 h at 4 °C. Plates were washed in wash
buffer (PBS, 0.05% Tween-20) and probed with a mouse
anti-hb2m mAb (Brodsky et al. 1979), BBM1 (70 nM), for
1 h at room temperature. All wells were washed in wash
buffer and detection antibody [HRP-conjugated goat-anti-
mouse IgG (1.13 nM); Sigma] was added followed by a 1-h
incubation at room temperature. Plates were washed and
substrate (TMB; Kirkegaard & Perry Laboratories) was
added to all wells. Reactions were stopped using H2SO4
(0.3 M) and plates read at 450 nm using a ELx808
Microplate reader (Biotek). Data were analyzed using EXCEL
and PRISM software.
A pre-folded, biotinylated FLPSDYFPSV/HLA-A*02:01
(Kast et al. 1994) complex was used as a standard to
convert OD450 values to the amount of complex formed
using the second-order polynomial (Y = a + bX + cX2),
thereby enabling a direct conversion of the actual peptide
concentration offered to the actual concentration of cor-
rectly formed pMHC complex. Because the effective concen-
tration of MHC (2–5 nM) used in these assays is below the
equilibrium dissociation constant (KD) of most high-affinity
peptide–MHC interactions, the peptide concentration, ED50,
leading to half-saturation of the MHC is a reasonable
approximation of the affinity of the interaction.
Results
Analysis of the peptide-binding specificity of
SLA-2*0401 with the PSCPL
The porcine MHC class I heavy chain, SLA-2*0401, was
tested for binding PSCPL using human b2m to support
folding, as previously described (Stryhn et al. 1996; Peder-
sen et al. 2011). Similar to the SLA-1*0401 molecule
(Pedersen et al. 2011), no differences were seen for the SLA-
2*0401 allele when comparing human b2m and porcine
b2m in supporting MHC peptide binding and complex
folding (data not shown). Each peptide sublibrary was
titrated to determine the EC50 (KD) for SLA-2*0401. The
peptide-binding preferences for the SLA-2*0401 heavy
chain protein are shown in Table 1. Amino acids in each
peptide position were assigned a RB value as described in
Materials and Methods. Amino acid residues with RB values
above 2 (shown in boldface, Table 1) indicate support of
peptide binding, whereas AAs having RB values below 0.5
(shown in italics, Table 1) are considered disfavored. A
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primary AP is characterized by AAs being strongly pre-
ferred, and many AAs were unaccepted by the class I
molecule in question. Anchor position values of 15 or more
indicate primary anchors (underlined values, Table 1)
(Lamberth et al. 2008). Such anchors are of critical impor-
tance for peptide binding.
The PSCPL analysis of SLA-2*0401 identifies positions
2 and 9 as APs, as is commonly seen for many class I
molecules (Sette & Sidney 1999; Lamberth et al. 2008). The
motif in Table 1 shows that the AAs asparagine (N) and
tryptophan (W) are favored for peptide binding in positions 2
and 9 respectively. The preference of AAs with larger side
chains such as tryptophan (W), tyrosine (Y) and phenylal-
anine (F) in position 9 was revealed by RB values of 11.2,
4.1 and 3.0 respectively (Table 1). Such RB values indicate
that this anchor must align with a large and deep F pocket.
The B pocket responsible for binding the AA in position 2 of
the peptide is most stable binding hydrophilic side chains,
resulting in a preference for the AAs serine (S) and
asparagine (N) with RB values of 3.3 and 8.9 respectively.
These preferences are illustrated in Fig. 1, where logos
displaying single-letter AA codes were generated to com-
pare the in vitro SLA-binding motifs for the PSCPL with
those of in silico NetMHCpan-based peptide preference
predictions. NetMHCpan is a mathematical algorithm
developed for MHC peptide-binding predictions in several
different species of interest (Nielsen et al. 2007; Hoof et al.
2009). For SLA-1*0401, the data show that the PSCPL-
based matrix detected preferences only for aspartic acid (D)
and glutamic acid (E) in position 3 of the peptide.
Furthermore, the NetMHCpan-based logo had tyrosine (Y)
preferred in position 9 with phenylalanine (F) second most
preferred, whereas the PSCPL data indicate a preference of
phenylalanine (F) over tyrosine (Y) (Fig. 1). The PSCPL
showed the same preference for the SLA-2*0401 molecule
regarding tyrosine (Y) and phenylalanine (F) in position 9
(Fig. 1). Additionally, a shared preference for serine (S) was
seen between the two SLA-2*0401 logos in position 2, as
well as a unique preference for asparagine (N) within the
PSCPL matrix only. These differences between the NetMHC-
pan-based logo and the PSCPL-based logo likely reflect the
limited amount of peptide-binding data available for the
NetMHCpan algorithm-based predictions with regard to
MHC molecules that share specificity with these two SLA
molecules (Hoof et al. 2009). Increasing the data available
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Figure 1 Sequence logo representations of the SLA-1*0401- and SLA-2*0401-binding motifs. The logos were calculated from the top 1% highest
scoring peptides selected from a pool of 200 000 natural 9mer peptides using either the positional scanning combinatorial peptide library matrix or
NetMHCpan as predictors. In the sequence logo, each peptide position is represented by a stack of letters indicating its significance for binding
(information content) and the height of each letter (amino acid) is proportional to its relative frequency (Schneider & Stephens 1990). Acidic residues
are displayed in red, basic in blue, neutral in green, and hydrophobic in black. Underrepresented amino acids are displayed upside down. SLA, swine
leukocyte antigen.
Table 1 SLA-2*0401-binding motif
SLA-2*0401
Amino acid position in peptide
1 2 3 4 5 6 7 8 9
A 0.3 0.4 1.3 1.9 0.8 0.6 2.6 0.8 0.0
C 0.4 0.1 0.6 0.9 0.2 0.4 0.5 1.0 0.0
D 0.5 0.3 0.7 0.4 1.5 2.2 1.3 1.5 0.1
E 0.7 0.1 1.1 0.8 0.8 0.1 3.7 2.7 0.0
F 2.0 0.2 0.3 0.9 1.3 1.5 0.4 0.8 3.0
G 0.1 0.9 0.4 0.2 1.0 0.2 0.4 1.6 0.1
H 1.0 0.1 0.1 0.5 0.9 2.3 0.4 0.7 0.3
I 1.2 0.7 0.6 0.5 1.2 0.8 1.7 0.6 0.3
K 0.5 0.2 0.1 1.1 0.4 0.3 0.2 0.6 0.1
L 0.5 0.3 0.9 0.8 0.8 1.0 0.7 0.7 0.1
M 2.2 0.3 1.4 0.8 1.1 1.5 1.2 1.0 0.3
N 0.8 8.9 1.6 0.7 1.8 0.3 0.8 0.7 0.1
P 0.1 0.5 0.7 3.3 1.4 1.6 0.6 0.8 0.0
Q 1.4 0.2 0.8 1.5 3.3 2.5 2.8 1.0 0.0
R 2.2 0.2 1.4 1.4 0.5 1.2 0.4 1.1 0.1
S 1.6 3.3 1.0 0.8 0.9 0.6 0.8 0.9 0.1
T 0.9 1.8 1.1 0.8 0.5 1.2 0.4 0.7 0.1
V 1.1 0.8 0.8 0.4 0.7 0.2 0.3 0.8 0.0
W 0.9 0.2 2.1 1.0 0.5 0.9 0.3 1.0 11.2
Y 1.9 0.5 3.1 1.3 0.6 0.6 0.4 1.1 4.1
Sum 20 20 20 20 20 20 20 20 20
AP value 9 77 10 9 8 10 19 5 132
Normalized relative binding (RB) values indicate whether an amino acid
is favored (RB  2.0, bold numbers) or disfavored (RB  0.5, italic
numbers) for binding of each position in the peptide. Anchor position
(AP) values are given by the equation ∑(RB  1)2. Important AP values
are underlined.
SLA, swine leukocyte antigen.
Published 2012. This article is a U.S. Government work and is in the public domain in the USA., doi: 10.1111/j.1365-2052.2012.02400.x
Pedersen et al.4
for swine MHC class I proteins will improve the NetMHCpan
algorithm prediction profile.
Identification of peptides derived from FMDV bound by
SLA-1*0401 and SLA-2*0401 alleles
The P1 region of FMDV, which codes for the viral capsid or
structural proteins, was screened for 9mer and 10mer
peptides that would potentially bind SLA-1-*0401 and
SLA-2*0401 using the NetMHCpan version 2.3 (Nielsen
et al. 2007). Nine such peptides were identified for the
SLA-1*0401 allele (four 9mers and five 10mers), and 10
peptides (five 9mers and five 10mers) were identified for
SLA-2*0401 (Table 2). Selection of peptides was based on
the NetMHCpan algorithm predictions and further analyzed
for the AA preference in positions 2, 3 and 9 of the
individual peptides based on the PSCPL-binding motifs
(Table 1 and Pedersen et al. 2011). Some peptides were
selected because of their NetMHCpan rank despite not
satisfying one of the primary anchors according to the
PSCPL motif. Others were left out despite expressing an
anchor–residue match and a proper NetMHCpan rank
because of in-house peptide limitations. Within a pool of
726 possible peptide combinations from the P1 region, eight
of the nine peptides selected for either SLA-1*0401 or SLA-
2*0401 were within the top 10 highest ranking peptides for
predicted binding (Appendix S2). All chosen peptides had a
NetMHCpan rank score of <2% (Erup et al. 2011), meaning
that <2% of random natural peptides had a predicted
binding affinity stronger than the selected peptides.
These peptides, predicted to be bound, were tested for
actual binding by SLA-1 and SLA-2 in an in vitro ELISA
binding assay. Five of the nine FMDV-derived peptides
predicted to be bound by the SLA-1*0401 molecule tested
positive in the assay. These peptides include four 9mers
(TVYNGTSKY, MTAHITVPY, SSVGVTHGY and YLS-
GIAQYY) and one 10mer (NMTAHITVPY). Additionally,
we observed that four of the 10 peptides predicted to be
bound by SLA-2*0401 produced correctly folded peptide–
MHC complexes. These included three 9mers (MTAHITVPY,
SSVGVTHGY and YLSGIAQYY) and one 10mer (NTYLS-
GIAQY). The respective binding affinity (KD) values for all
bound peptides ranged between 0.8 and 433 nM. Peptides
with KD values below 500 nM are considered strong (50–
500 nM) or very strong (0.1–50 nM) binders (Table 2).
Two additional peptides, from the VP35 region of the
Sudan Ebola virus and from the conserved hypothetical
protein of the Vibrio cholera bacteria respectively, also were
tested for binding by the SLA-2*0401 protein for compar-
ison (Table 2). These peptides previously have been shown
to be bound by SLA-1*0401 with high affinity (Pedersen
et al. 2011). As for SLA-1*0401, both peptides were found
to be strongly bound by the SLA-2*0401 molecule with KD
values of 1 and 2 nM respectively (Table 2).
Discussion
Previously, we defined the peptide motifs that are bound by
the class IMHCprotein of swine, SLA-1*0401 (Pedersen et al.
2011). We now expand this analysis to an additional SLA
protein, SLA-2*0401, and describe a method for the analysis
of a virus proteome to identify the peptides that will be bound
by porcine MHC I proteins. Peptides from the P1 region of the
FMDV genome, which encodes the structural proteins of the
virus, were identified using this method for the gene products
of two class I alleles, SLA-1*0401 and SLA-2*0401. These
two class I proteins are commonly expressed alleles in
commercial pig breeds as well as in different porcine cell lines
Table 2 Peptide candidates for SLA-1*0401 and SLA-2*0401 affinity analysis
Peptide sequence
FMDV peptides tested for SLA-1*0401 FMDV peptides tested for SLA-2*0401
NetMHCpan
predicted%
rank score KD (nM)
Actual binding
status
NetMHCpan
predicted%
rank score KD (nM)
Actual binding
status
TVYNGTSKY 0.17 87 Intermediate 0.05 NB Non-binder
MTAHITVPY 0.01 0.8 Strong 0.05 7 Strong
SSVGVTHGY 0.10 433 Intermediate 0.40 14 Strong
AAKHMSNTY 1.00 ND ND 0.40 NB Non-binder
YLSGIAQYY 1.50 17 Strong 0.25 42 Strong
LAAKHMSNTY 0.20 NB Non-binder 0.12 NB Non-binder
NMTAHITVPY 2.0 67 Strong 0.80 NB Non-binder
NTYLSGIAQY 0.20 NB Non-binder 0.12 22 Strong
ATVYNGTSKY 0.15 NB Non-binder 0.80 NB Non-binder
QSSVGVTHGY 0.80 NB Non-binder 1.50 NB Non-binder
Peptide sequence
SLA-2*0401 Ebola/Cholera peptides
NetMHCpan predicted% rank score KD (nM) Actual binding status
ASYQFQLPY 0.01 2 Strong
ATAAATEAY 1.00 1 Strong
ND, not determined; NB, non-binding peptide having a KD > 5000 nM; FMDV, foot-and-mouth disease virus; SLA, swine leukocyte antigen.
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used for experimental research (Smith et al. 2005; Ho et al.
2006, 2009). Hence, the determination of binding motifs for
such proteins is of great value as a tool in the analysis of
porcine immune responses and vaccine development.
A comparison of in silico predictions with in vitro analysis
of peptide binding, expressed as the formation of correctly
folded porcine MHC class I, supports previously published
data describing the capacity of the NetMHCpan predictor to
identify successful peptide/MHC binding beyond humans
(Hoof et al. 2009; Pedersen et al. 2011). All 12 different
peptides tested for the SLA-2*0401 molecule were predicted
by the NetMHCpan to be bound, and six formed complexes
with the SLA class I alpha chain and b2m in vitro (Table 2).
These data show the NetMHCpan predicted actual peptide
binding at a rate of 50%, based on the limited data available
to date. Of the nine peptides selected for SLA-1*0401-
binding tests, all were predicted to be bound and five formed
complexes with the heavy chain during the in vitro analysis.
For the SLA-1*0401 molecule, 55.6% of the predictions
were confirmed. These results were obtained using a
prediction algorithm based on human MHC proteins. As
such, they illuminate the value of using the extensive
human database to apply to swine MHC peptide predictions
to identify potential immune epitopes.
Of the 10 peptides from the sequence of the FMDV
structural protein region identified by the algorithm, four of
the six that failed to be bound by SLA-2*0401 have random
binding scores. Contrarily, none of the four peptides thatwere
bound by SLA-2*0401 have random binding scores calcu-
lated fromthePSCPLmatrix values and theapproximation for
longer peptide-binding prediction described by Lundegaard
et al. (2008) (data not shown). This indicates that improve-
ment could be achieved by adding quantitative SLA peptide-
binding data derived using the PSCPL matrix for the
NetMHCpan neural network to refine the algorithm and
generatemore accurate predictions (Nielsen et al. 2007; Hoof
et al. 2009). In addition, one peptide (YLSGIAQYY) was
predicted not to be bound by SLA-2*0401 but in fact was
strongly bound. Considering several peptides predicted to be
bound failed to do so in vitro illustrates the need for more data
to enhance the NetMHCpan for species other than humans.
Differences in peptide motifs expressed by the two SLA
alleles, SLA-1*0401 and SLA-2*0401, are illustrated by
peptides bound by one allele but not by the other. The 10mer
peptide, NTYLSGIAQY, was bound by SLA-2*0401 with an
affinity (KD) value of 22 nM but was not bound by the SLA-
1*0401 alpha chain (Table 2). This supports the higher
preference for the AA tyrosine (Y) in position 3 (RB = 3.1) by
the SLA-2*0401 molecule and that the residue is disfavored
in the same position for SLA-1*0401 (RB = 0.5) peptide
binding. SLA-1*0401 is unique from most other alleles in
that this alpha chain has a peptide-binding anchor in
position 3 as well as in the more commonly observed APs 2
and 9 (Pedersen et al. 2011). Thus, the side chain of the AA
in position 3 factors into peptide binding, and so the
NTYLSGIAQY peptide does not bind despite the positions 2
and 9 anchors being satisfied (T: RB = 2.5 and Y: RB = 4.3
respectively). The opposite effect is seen for the 10mer
peptide NMTAHITVPY. This peptide is readily bound by SLA-
1*0401 with a KD value of 67 nM but is not bound by SLA-
2*0401. Methionine (M) is disfavored in position 2 in the
SLA-2*0401 protein, whereas it is favored by the SLA-
1*0401 peptide-binding motif (RB = 0.3 and 1.9 respec-
tively). Furthermore, threonine (T) in position 3 is less
favored for SLA-2*0401 than for SLA-1*0401.
As with the differences in binding preferences, similarities
also are seen for the two SLA alpha chains analyzed when
analyzing these viral peptides. Some of the identified binding
peptides are shared, and this sharing can be explained by
the identical preferences for tyrosine (Y) in the important
position 9 anchor and for methionine (M) in position 1.
There is also the shared preference for serine (S) and
threonine (T) in the position 2 anchor (Table 1; Pedersen
et al. 2011). In addition, our data show that both SLA
proteins can bind 9mer peptides as well as 10mer peptides
with similar affinities. This observation may indicate that
peptide epitopes longer than nine AAs may be common for
these MHC proteins. Such peptides would lead to different
recognition patterns expressed by TCRs than the more often
reported 9mers. The reason for this lies in the conformation
of the peptide–MHC complex, which would differ in the way
the peptide bulges away from the groove. This is caused by
the bound peptide now having one or even two additional
AAs in the center available for TCR recognition, depending
on which peptide AA interacts with the respective anchors
within the MHC groove (Fig. 2).
9’mer:
1
2 9
10
10’mer:
3 10
2 10
Figure 2 Illustration of commonly known 9mer peptide-binding vs.
three different proposed 10mer peptide-binding scenarios and the
effect on the exposure of the central amino acids. Black bars illustrate
important interactions between the peptide and the anchor position
residues in the B- and F-pockets of the major histocompatibility
complex (MHC) class I-binding groove. Numbers indicate the peptide
position of the primary MHC-interacting amino acids within the
peptide.
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To date, most analysis has focused on 9mer peptides as
candidates for strong class I complex folding. Longer
peptides, specifically the 10mers, were included in this study
to expand the pool of possible peptides for analysis and,
hence, possible T-cell epitope candidates. For human class I
(Chen et al. 1994; Urban et al. 1994; Tynan et al. 2005),
binding of peptides other than 9mers has been readily shown
with resulting diverse peptide conformations within the HLA
class I-binding groove. Longer peptides not only provide a
larger pool of combinations of potential peptide sequences
and binding configurations (Fig. 2), but also contribute to
greater diversity in the center region of the peptide available
for TCR recognition as a result of the peptide bulging away
from the binding cleft. Hence, depending on the individual
binding pattern of the peptide, binding of a 10mer peptide
could include additional AAs between the anchors of the
bound peptide available for TCR interactions. Such a change
in conformation could have the potential to expand pMHC-
mediated activation of virus-specific CTLs.
The ability of MHC molecules to bind the same peptide in
different combinations, depending on the identity of the
peptide anchor residues, would appear to have distinct
advantages to the immune system. Based on the PSCPL RB
values of the respective pockets expressed by the SLA-
1*0401 and SLA-2*0401 molecules, and in combination
with the respective 10 AA peptides bound, the model
predicts that the two 10mer peptides bind by a position
2/position 10 (P2/P10) or P1/P10 anchor manner
(NMTAHITVPY) for SLA-1*0401 and a P3/P10 anchor
manner (NTYLSGIAQY) for SLA-2*0401 (Table 1; Pedersen
et al. 2011). These binding patterns are only speculations
and rely on a comparison of the AA in peptide positions 1–3
with the MHC preferences expressed for the individual AA
in P1–3, combined with the comparison of the AA in
peptide positions 9 and 10 with the preferences expressed
for the individual AA in P9. Future mapping of MHC class I-
binding motifs using an X10-based peptide library as
compared to exclusively X9 will further illuminate which
AA positions of the 10mer peptides account for binding
interactions between the peptide residues and the anchors
of the MHC class I protein groove.
In conclusion, we determined the binding motif of an
additional swine MHC class I molecule, SLA-2*0401. Fur-
ther, the NetMHCpan prediction algorithm based on human
MHC proteins identified peptides from a viral proteome of
interest. Based on in silico predictions and in vitro verifica-
tions, we identified four FMDV peptides bound by SLA-
2*0401: MTAHITVPY, SSVGVTHGY, YLSGIAQYY and
NTYLSGIAQY; and five FMDV peptides bound by SLA-
1*0401: TVYNGTSKY, MTAHITVPY, SSVGVTHGY, YLS-
GIAQYY and NMTAHITVPY. Three of these peptides were
observed to be commonly shared between the two heavy
chain molecules (MTAHITVPY, SSVGVTHGY and YLS-
GIAQYY), whereas one peptide (NTYLSGIAQY) was bound
only by the SLA-2*0401 protein and two peptides (TVYNGT-
SKY and NMTAHITVPY) were bound only by the SLA-
1*0401 protein. All these peptides are candidate T-cell
epitopes by virtue of being strongly bound by two of the most
highly expressed porcine class I MHC proteins.
Analysis of antigen-specific, MHC I-restricted T cells using
MHC tetramersmadewith the peptides identified here showed
that at least one of these, MTAHITVPY bound by SLA-1
*0401, reacts with FMDV-specific T cells (Patch et al. 2011).
The reason for including Ebola and V. cholera peptides in this
study was an ambition of adding the SLA-2*0401 molecule
to the experimental setup of such tetramer staining analyses.
FMDV-specific porcine CTLs should not recognize either
Ebola- or V. cholera-derived peptides bound and presented by
the SLA-2*0401 molecule, and hence, these peptides should
make for good negative controls. Subsequent studies indicate
that other peptides represented in the data presented here are
T-cell epitopes, and confirmation of these preliminary results
is underway, now also including the SLA-2*0401 molecule.
Minimally, these data, together with our previous reports
(Patch et al. 2011; Pedersen et al. 2011), show that the
approach of using the NetMHCpan prediction algorithm,
developed for human MHC molecules, can be effective in
predicting MHC peptide interactions in other species.
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Abstract 
The  affinity  and  stability  of  peptides 
bound  by  major  histocompatibility  complex  (MHC) 
class I molecules are important factors in presentation 
of viral epitopes  to cytotoxic T  lymphocytes  (CTLs) of 
the adaptive  immune  system.  In  swine,  such peptide 
presentations  by  swine  leukocyte  antigens  (SLA)  are 
crucial  for  immunity during most  viral  infections  and 
diseases.   
The identification of peptide candidates, derived from 
viral  genomes  of  interest,  for  SLA  binding  and 
presentation continues to be an exhaustive task seeing 
hundreds and sometimes even thousands of different 
peptide  sequences  available  within  a  single  viral 
proteome. 
In  this  study, we  expand  the  analysis 
of  SLA  binding  preferences  by  determining  the 
complete  nonamer  SLA‐3*0401  PSCPL  (positional 
scanning combinatorial peptide library) binding matrix 
and suggest a method to facilitate the task of specific 
peptide  selection.  This  was  done  by  combining  the 
ability of such a matrix, to predict peptide candidates 
for MHC binding, with  that of  the  in  silico prediction 
algorithm  NetMHCpan.  Analyses  of  such  peptide 
binding predictions were performed for two additional 
SLA molecules, the SLA‐1*0401 and SLA‐2*0401, along 
with  the  identification  of  several  virally  derived 
peptide epitope candidates. In addition, a comparison 
of  the  affinity  and  stability  of  peptide‐SLA  (pSLA) 
complexes  was  performed  and  a  significant 
observation  of  peptides  being  bound  by  low  affinity 
also  produce  pSLA  complexes  of  low  stability  was 
made. Furthermore, it was found that peptides bound 
with high affinity produce pSLA complexes of various 
stabilities  ranging  from  0  –  200  hours  in  half‐life 
periods.  
In  conclusion,  the  combination  of 
NetMHCpan  and  SLA  PSCPL matrix  prediction  led  to 
identification of more peptides with high affinity and 
stability than each prediction method alone. Applying 
these methods  thus  constitute a highly cost‐effective 
guide  for epitope discovery studies and MHC binding 
analysis, not only  in  the  case of porcine  immunology 
but for any species of interest. 
 
Key words: MHC, binding predictions, peptide affinity, 
complex stability 
 
Introduction 
MHC class  I molecules can be seen as 
tell‐tales  of  the  immune  system  displaying  to  the 
surroundings  endogenously  derived  peptides  from 
processed  self‐  as  well  as  non‐self  proteins. 
Recognition of  such peptide MHC  complexes  (pMHC) 
by specific CTLs can lead to the activation of cytotoxic 
T cells. Cells  infected by an  intracellular pathogen will 
display non‐self peptides on  their  cell  surface hereby 
signaling a state of alert to circulating CTLs  leading to 
subsequent elimination of the infected cells. 
Peptide ‐ MHC‐I affinity is the primary 
criteria  for  presentation  of  peptides  by MHC  class  I 
molecules.  Once  bound,  the  stability  of  the  pMHC 
influence  the  timeframe  in  which  peptides  are 
displayed at the cell surface of antigen presenting cells 
(APCs), and hence the stability of individual pMHC has 
a proposed additional  impact on  the  immunogenicity 
of the peptides, with stably bound peptides being the 
more immunogenic (Busch and Pamer 1998, Harndahl 
et al. 2012, van der Burg et al. 1996).  
Knowledge  about  the  MHC‐I  binding 
specificity  is  thus  paramount  in  epitope  discovery  to 
limit  the  pool  of  peptides  available  for  analysis.  The 
peptide  binding  specificities  of  the  human  leukocyte 
antigen (HLA) molecule have been thoroughly studied 
and several high performance prediction servers, such 
as NetMHCpan,  exist  to  predict  peptide‐HLA  binding 
(Lundegaard et al. 2011, Nielsen et al. 2007, Nielsen et 
al.  2008,  Zhang  et  al.  2009). However,  knowledge of 
the peptide  binding motifs of MHC‐I molecules  from 
other species such as livestock is limited, complicating 
epitope identification.  
We  recently  reported  the  peptide 
binding  motif  of  the  porcine  MHC‐I  molecules  SLA‐
1*0401  and  SLA‐2*0401,  identified  by  ELISA  based 
positional  scanning  combinatorial  peptide  libraries 
(PSCPL)  (Pedersen et al. 2011, Pedersen et al. 2012). 
Here, we describe  the PSCPL derived peptide binding 
motif  of  the  SLA‐3*0401  molecule  using  a  newly 
developed  methodology  based  on  pMHC‐I  complex 
dissociation  (Rasmussen  et  al.  2012).  Combining  the 
peptide predictions of the  individual binding matrices 
for  SLA‐1*0401,  SLA‐2*0401  and  SLA‐3*0401 with  in 
silico  peptide  binding  predictions  using  NetMHCpan 
(Hoof et al. 2009, Lundegaard et al. 2011) version 2.4, 
we predicted possible peptide binders  from  a  library 
of more than 9000 nonameric peptides to  investigate 
if  combined  predictions  were  more  accurate  than 
using  either  of  the  prediction  tools  alone.  Predicted 
peptides were  screened  for binding  and high  affinity 
binders  were  identified  for  SLA‐1*0401,  SLA‐2*0401 
and SLA‐3*0401. In addition, the stability of pSLA was 
measured  for  peptides  identified  to  be  bound  with 
high  affinity,  showing  that  our  recently  published 
peptide‐HLA  stability  assay  can easily be modified  to 
measure pMHC stability  in other species  (Harndahl et 
al.  2011,  Rasmussen  et  al.  2012).  Comparing  affinity 
and  stability data  identified  several high‐affinity,  and 
highly  stable,  peptide  binders  for  all  three  SLA 
proteins, and a tendency of peptides being bound with 
high  affinity  also  produce  highly  stable  pSLA 
complexes. Despite this it was found that high affinity 
peptides  in  general  produce  pSLA  complexes  of 
various  stabilities  ranging  from 0 – 200 hour half‐life 
periods. Furthermore, these analyses revealed a clear 
correlation between peptides bound with  low affinity 
also produce  low stability pSLA complexes  illustrating 
that  high  affinity  peptide  binding  is  indeed  a 
prerequisite for stable interactions. Such data indicate 
that  the  methodology  presented  here  is  capable  of 
identifying  potential  CD8+  T‐cell  epitopes  as  well  as 
pointing  out  peptides which  are  not  suitable  for  the 
production of stable pSLA complexes. 
All  together  these  methods  provide 
state‐of‐the‐art  tools  for  the  prediction,  analysis  and 
selection of peptides  for MHC  class  I binding, hereby 
paving the way to actual identification of strongly, and 
stably, bound peptides with the potential of being viral 
peptide  epitopes.  These  experiments  introduce  an 
expansion of the field of pMHC analysis now to include 
livestock such as the pig. 
 
Materials and methods 
Recombinant  construct  encoding  the  SLA‐
3*0401 protein  
Recombinant  SLA‐3*0401  protein  was 
produced  as  described  elsewhere  (Pedersen  et  al. 
2011). Briefly, DNA encoding residues 1 to 276 of the 
SLA‐3*0401  alpha  chain  (purchased  from  Genscript) 
was cloned into a pET28a+ vector (Novagen) upstream 
of  a  polytag  consisting  of  a  FXa  cleavage  site,    a 
biotinylation  signal  peptide  (BSP)  and  a  histidine 
affinity tag  (HAT). Correct constructs were verified by 
sequencing (ABI Prism 3100Avant, Applied Biosystems) 
(Hansen  et  al.  2001).  The  validated  construct  of 
interest  was  transformed  into  E.  coli  BL21(DE3), 
containing the pACYC184 expression plasmid  (Avidity, 
Denver, CO) encoding an  IPTG  inducible BirA gene  to 
express biotin‐ligase. This leads to almost complete in 
vivo biotinylation  (85 – 100%) of  the desired product 
(Leisner et al. 2008). 
Expression and purification of recombinant SLA‐
3*0401,  human‐  and  porcine  beta‐2  microglobulin 
(β2m) 
SLA‐3*0401  heavy  chain  proteins  were 
produced  recombinantly  as  previously  described 
(Pedersen  et  al.  2011).  E.  coli  BL21(DE3)  cells 
containing  the  SLA  proteins  were  lyzed  in  a  cell‐
disrupter (Constant Cell Disruptor Systems set at 2300 
bar)  and  the  released  inclusion  bodies were  isolated 
by  centrifugation  (Sorval RC6,  20 min,  17000  g).  The 
inclusion bodies were washed  twice  in PBS, 0.5% NP‐
40  (Sigma),  0.1%  deoxycholic  acid  (DOC,  Sigma)  and 
extracted  into Urea‐Tris buffer  (8M urea, 25mM Tris, 
pH 8.0). 
SLA‐3*0401 heavy chain proteins extracted in 8 
M urea were purified as previously described  for  the 
SLA‐1*0401 molecule  (Pedersen et al. 2011).  In brief, 
this  was  done  by  successive  immobilized  metal 
adsorption,  hydrophobic  interaction‐,  and  eventually 
Superdex‐200  size  exclusion  chromatography. 
Throughout purification and storage the MHC‐I heavy 
chain proteins were dissolved  in 8 M Urea  to ensure 
denaturation. The pre‐oxidized, biotinylated and  fully 
denatured  proteins  were  stored  at  ‐20°C  in  Tris 
buffered 8 M urea. 
Recombinant  human‐  and  porcine    β2m were 
expressed and purified as described elsewhere  (Ferre 
et  al.  2003,  Ostergaard  et  al.  2001,  Pedersen  et  al. 
2011). 
Peptides and peptide libraries 
All  peptides  were  purchased  from  Schafer‐N, 
Denmark  (www.schafer‐n.com).  Briefly,  they  were 
synthesized by standard 9‐fluorenylmethyloxycarbonyl 
(Fmoc)‐chemistry,  purified  by  reversed‐phase  high‐
performance  liquid chromatography (to at  least >80% 
purity,  frequently  95‐99%  purity),  validated  by mass 
spectrometry, and quantified by weight.  
Positional  scanning  combinatorial  peptide 
libraries  (PSCPL)  were  used  to  determine  the  SLA‐
3*0401  binding  motif.  The  experimental  strategy  of 
PSCPL  has  previously  been  described  for  both  HLA 
(Stryhn  et  al.  1996)  and  SLA  (Pedersen  et  al.  2011) 
proteins.  The  individual  PSCPL  peptide  stability 
analysis was performed using 125Iodine‐labeled porcine 
β2m (125I‐ β2m)  in a FlashPlate® based proximity assay 
(Harndahl et al. 2011) explained below.  
ELISA peptide affinity analysis 
Affinity analysis of peptide  interactions with  the SLA‐
1*0401  was  performed  using  a  slightly  modified 
version  of  a  previously  described  immunosorbent 
assay  (Sylvester‐Hvid  et  al.  2002)  most  recently 
described by Pedersen et al. (Pedersen et al. 2012).  
Luminescent oxygen channeling assay (LOCI) for 
peptide affinity analysis  
Affinity analysis of peptide  interactions with  the SLA‐
3*0401  and  SLA‐2*0401  were  performed  using  a 
conformation‐dependent  anti‐SLA  monoclonal 
antibody  based  LOCI  technology  as  previously 
described  for  HLA  (Harndahl  et  al.  2009).  In  brief, 
recombinant,  biotinylated  SLA  heavy  chains  were 
diluted  in  buffer  (0.1%  Lutrol  F  68  (BASF,  Art.  No. 
S30101. Ludwigshafen, Germany)  in PBS, pH 7.2) to a 
concentration  of  2  nM  followed  by  addition  of  15 
times  excess  of  porcine  β2m  and  a  dose  titration  of 
peptide,  and  incubated  at  18°C  for  48  hours.  pSLA 
complexes  were  detected  using  streptavidin  (SA) 
donor  beads  and  an  anti‐SLA  monoclonal  antibody 
(PT85A,  VMRD,  Pullman, Wash.,  USA)  conjugated  to 
acceptor  beads.  Beads  and  pSLA  complexes  were 
incubated  at  18°C  over  night  at  a  final  bead 
concentration of  5 µg/ml,  then  equilibrated  to  room 
temperature 1 hour prior to detection by an EnVision 
multilabel reader (Perkin Elmer, Boston, USA).  
FlashPlate®  scintillation  proximity  assay  (SPA) 
for  SLA‐3*0401  motif  mapping  and  pSLA  stability 
measures 
The  measurement  of  pSLA  stability  was  done  as 
previously  described  for  HLA  (Harndahl  et  al.  2011) 
using peptide and  radiolabeled porcine  β2m  in  a mix 
with recombinant SLA heavy chain 100‐fold diluted  in 
(0.1%  Lutrol  F  68  (BASF,  Art.  No.  S30101. 
Ludwigshafen, Germany) in PBS, pH 7.2) . pSLA folding 
reactions  were  carried  out  in  streptavidin  coated 
scintillation  microplates  (FlashPlate®  PLUS,  Perkin 
Elmer,  Boston,  USA).  Steady‐state  of  the  folding 
reaction was reached by overnight  incubation at 18°C 
at  conditions  of  30  nM  SLA  heavy  chain,  1  nM 
(approximately  25,000  cpm)  of  125I‐β2m  and  10  µM 
peptide.  At  steady‐state  unlabeled  porcine  β2m was 
added to a final concentration of 1 µM to prevent re‐
association  of  any  dissociated  125I‐β2m,  and  the 
temperature was  raised  to 37°C. Dissociation of pSLA 
was  monitored  continuously  on  a  scintillation 
multiplate  counter  (TopCount  NTX,  Perkin  Elmer) 
modified  to  operate  at  37°C.  PSCPL  data  were 
analyzed  as  described  previously  (Rasmussen  et  al. 
2012) and the obtained binding matrix was visualized 
by  the  Seq2Logo  server  (Thomsen  and Nielsen 2012) 
normalizing  the values at each position  to 1, using P‐
weighted  Kullback‐Leibler  logo  types  and  an  even 
amino acid background distribution (0.05 for all amino 
acids).   
   
Results 
 
Mapping  of  the  SLA‐3*0401  peptide  binding matrix 
using PSCPL 
We  have  recently  reported  the 
peptide  binding  specificities  of  the  swine  leukocyte 
antigens, SLA‐1*0401 and SLA‐2*0401 (Pedersen et al. 
2011,  Pedersen  et  al.  2012).  These  peptide  binding 
specificities  were  determined  by  nonameric  PSCPL 
analysis using ELISA. Since then, we have introduced a 
new  method  to  determine  human  MHC‐I  binding 
specificities  (Rasmussen  et  al.  2012),  based  on  a 
pMHC‐I dissociation assay (Harndahl et al. 2011). This 
method  is  based  on  the  dissociation  of  125I‐
radiolabeled  human  β2m  from  in  situ  formed  pHLA 
complexes.  By  125I‐radiolabeling  porcine  β2m,  we 
adopted  this  methodology  to  allow  PSCPL‐based 
determination  of  the  SLA‐3*0401  binding  matrix, 
illustrated in figure 1 and Table 1.  
PSCPL  analysis  of  the  SLA‐3*0401 
molecule  revealed  a  binding  motif  with  a  primary 
anchor in the position 2 (P2) of the peptide displaying 
preferences  for  asparagine  (N)  and  arginine  (R) with 
relative binding (RB) values of 5.6 and 2.3, respectively 
(Figure 1 and Table 1). This suggests a polar, acidic B‐
pocket within the SLA‐3*0401 peptide binding groove. 
Auxiliary anchors were observed  in P1, P3, P7 and P9 
with  anchor  position  (AP)  values  of  9,  11,  11  and  9, 
respectively. For P9 it was found that methionine (M), 
phenylalanine (F) and tyrosine (Y) were preferred with 
RB  values  of  2.4,  2.3  and  2.0,  respectively  (Table  1). 
Isoleucine (I) and aspartic acid (D) were also accepted 
in  P9  having  RB  values  of  1.8  and  1.5,  respectively. 
Furthermore,  it  was  observed  that  arginine  (R), 
glutamine  (Q),  lysine  (K)  and  proline  (P)  were  all 
disfavored  at  P9  (RB  values  of  0.2,  0.3,  0.3  and  0.4, 
respectively). These results  indicate the presence of a 
hydrophobic  F‐pocket  within  the  binding  groove  of 
SLA‐3*0401, although this pocket does not function as 
a  primary  anchor  for  peptide  binding  which  again 
makes  the  binding  motif  for  SLA‐3*0401  rather 
atypical when compared to the dominating P2 and P9 
anchors that are commonly observed for both SLA and 
HLA molecules (Kubo et al. 1994, Lamberth et al. 2008, 
Pedersen  et  al.  2011,  Pedersen  et  al.  2012, 
Rammensee et al. 1999, Rapin et al. 2008, Sette and 
Sidney 1999, Yamada et al. 1999).  Instead, a primary 
anchor was observed only in P2 (AP value of 27), with 
an  auxiliary  anchor  expressing  a  preference  for 
tryptophan  (W),  leucine  (L),  and phenylalanine  (F)  in 
P7  revealing  a  non‐polar  E‐pocket.  Altogether  these 
results  indicate  that  for  SLA‐3*0401  P2  is  the most 
important  peptide  position  in  regard  to  peptide 
binding.  
 
Analysis of peptide‐SLA affinities 
   SLA‐1*0401  peptide  affinity  studies 
were  performed  using  a  previously  described  ELISA 
(Pedersen et al. 2011), whereas affinity measurements 
for SLA‐2*0401 and SLA‐3*0401 were performed by a 
modified version of a previously published LOCI based 
MHC‐I  binding  assay  (Harndahl  et  al.  2009),  using 
acceptor  bead  conjugated  antibody  PT85A  which 
enable  the  capture  of  correctly  folded  pSLA  on  the 
surface  of  donor  beads  leading  to  a  signal  read‐out 
once  excited  by  laser  (Figure  2).  By  using  a 
combination  of  NetMHCpan  (with  a  2  %  rank  score 
threshold) and PSCPL matrix based predictions (with a 
threshold of 25 corresponding to 0.5 % percentile rank 
score  threshold)  a  total  of  157,  72,  and  76  peptides 
were selected to be tested for their ability to be bound 
by  SLA‐1*0401,  SLA‐2*0401,  and  SLA‐3*0401, 
respectively  (Table  2  and  Supporting  Table  1  A  ‐  C). 
Note.  that  the  NetMHCpan‐2.4  prediction  software 
has been trained on a  limited set of SLA binding data 
consisting of 14 SLA‐1*0401 and one SLA‐2*0401  (all 
bound)  peptides.  From  the  157  selected  peptides 
tested on SLA‐1*0401,  it was  found  that 67 peptides 
were bound with high affinity having KD  values of 50 
nM  or  less,  45  peptides  had  intermediate  binding 
affinities  in  the  range  of  50  –  500  nM,  20  peptides 
turned out  to be bound with weak affinities of 500 – 
5000  nM,  and  25  peptides  were  identified  as  non‐
binding peptides with affinities >5000 nM (Table 2). In 
total, it was found that, of the 157 peptides chosen for 
binding  studies, 112  (71.3 %) did bind with KD values 
below 500 nM.  It has previously been described  that 
peptides  with  KD  affinity  values  below  500  nM  are 
likely  to  be  considered  as  immunological  relevant 
(Assarsson et al. 2007). For the SLA‐2*0401 molecule, 
14 peptides  (20%) of  the predicted 72 were  found  to 
have KD values lower than 500 nM, whereas 20 and 32 
peptides respectively were in the range of being either 
weak  or  non‐binding  peptides.  Finally,  76  peptides 
were  tested  for  SLA‐3*0401  binding  identifying  20 
strongly bound peptides, 9 intermediate and 9 weakly 
bound peptides, whereas 38 peptides were  identified 
not to be bound by SLA‐3*0401 (Table 2)  leading to a 
total  of  38  %  of  the  peptides  selected  for  the  SLA‐
3*0401 molecule being bound with affinities stronger 
than  500  nM.  Individual  peptide  sequences,  origin, 
prediction  rank  scores,  and  KD  affinity  values  are 
shown  in Supporting Table 1 A  ‐ C. Examples of LOCI 
dose  titration  curves  for  affinity  analysis  of  two 
individual  peptides,  MTAASYARY  and  KRMMMNLNY, 
bound  by  SLA‐2*0401  and  SLA‐3*0401,  respectively, 
are shown in Supporting Figure 1 and 2.  
 
Combining  PSCPL  matrix‐  and  NetMHCpan  based 
predictions 
To  quantify  the  complementarities  of 
the  PSCPL  matrix  and  NetMHCpan  prediction 
methods,  the  individual  predictions  were  split  into 
subsets predicted by  (a) either  the matrix method or 
the NetMHCpan method,  (b) by both  the matrix  and 
NetMHCpan methods, or  (c) exclusively by one of the 
two.  The  result  of  this  analysis  is  shown  in  Table  3. 
From this comparison, it is seen that the two methods 
are  highly  complementary  when  it  comes  to 
identification  of  SLA  binding  peptides. Depending  on 
the given SLA molecule, only 45–59 % of the peptides 
validated  to be  bound by  SLA  are predicted  by  both 
methods (Table 3, Sensitivity). Also, it is apparent that 
not  one  method  is  consistently  more  accurate  in 
identifying  SLA  peptide  binders  than  the  other.  For 
SLA‐2*0401 we  found  that only 2 of  the 20 peptides 
(10  %),  identified  exclusively  by  the  matrix‐based 
method  turned  out  to  be  bound.  For  the  exclusive 
NetMHCpan predictions 9 of 25  (36%) were  found  to 
bind.  In  contrast  to  this,  the  exclusive matrix‐based 
predictions for the SLA‐3*0401 molecule  identified 47 
% binding peptides (8 of 17), whereas the NetMHCpan 
exclusive  predictions  for  this  SLA  molecule  only 
identified  11  %  binding  peptides  (4  of  35).  The 
predictive  positive  value  (true  positives  divided with 
the  predicted  positive)  for  the  two methods  on  the 
two  SLA  molecules  (SLA‐2*0401  and  SLA‐3*0401)  is 
statistically  significant  (p<0.05  in  both  cases, 
comparison  of  ratia).  That  is,  the  predictive  positive 
value of the NetMHCpan method is significantly higher 
for the SLA‐2*0401 molecule compared to SLA‐3*0401 
and  vice  versa  for  the  PSCPL  matrix  method 
emphasizing  the  complementarities  of  the  two 
methods, and underlining the importance of including 
both  to  ensure  optimal  coverage  of  the  binding 
repertoire of SLA molecules. 
 
pSLA stability analysis 
pMHC  class  stability  has  been 
proposed  to  be  a  better  determinant  of 
immunogenicity  rather  than  binding  affinity  (Busch 
and Pamer 1998, Harndahl et al. 2012, Lazarski et al. 
2005, Mullbacher et al. 1999, Sant et al. 2005, van der 
Burg et al. 1996). In order to investigate the stability of 
pSLA  complexes, we modified an existing  scintillation 
proximity assay  (SPA) based pMHC dissociation assay 
(Harndahl  et  al.  2011)  enabling  us  to measure  pSLA 
stability. Peptides binding with an affinity better than 
500  nM  to  SLA‐1*0401,  SLA‐2*0401  or  SLA‐3*0401 
were  tested  for  their  pSLA  stability.  The  correlation 
between  pSLA  affinity  and  stability  is  shown  for  all 
three  SLA molecules  in  Figure  3 A  –  C.  It was  found 
that  the  pSLA  stability  ranged  from  extremely  stable 
(T½ of 158 hours) to fairly unstable (T½ of 0.18 hours). 
The  correlation between binding affinity and  stability 
was statistically significant for all three SLA molecules 
(Spearmans rank correlations of 0.39  (SLA‐2*0401)  to 
0.78 (SLA‐1*0401), and with p<0.05  in all cases, exact 
permutation  test).  In  general,  it  was  seen  that 
peptides  bound  with  high  affinities  were  also 
generating highly  stable pSLA complexes with T½  ≥ 1 
hour (Figure 3 A – B). It was observed that SLA‐3*0401 
complexes  were more  unstable  than  the  equivalent 
pSLA‐1*0401  and  pSLA‐2*0401,  having  only  six 
peptides with stability T½ periods ranging between 1.1 
and 6.7 hours  (Figure 3 C + Supporting Table 1 C).  In 
comparison,  the  SLA‐1*0401  had  65  peptides  with 
stabilities ranging from T½ of 1 hour to more than 158 
hours, and  several of  those had T½ of more  than 10 
hours  (Figure  3  A  +  Supporting  Table  1  A).  For  SLA‐
2*0401, 18 of  the 20 peptide with measured binding 
affinity stronger than 500 nM were shown to be stably 
bound with T½ of more than 1 hour (Supporting Table 
1 B). This difference between fraction of stable binders 
between  the  SLA‐3*0401  and  the  two  other  SLA 
molecules  is  highly  statistical  significant  (p<0.01, 
comparison of ratia). Note, that analysis here for SLA‐
2*0401  and  SLA‐3*0401  is  limited  to  relative  few 
peptides  identified  with  binding  affinities  stronger 
than  500  nM.  Additional  analyses  including  a  larger 
number  of  peptides  would  be  necessary  to  draw  a 
more  general  conclusion  in  regard  to  those  two 
molecules  and  their  pSLA  complex  stabilities.  Such 
analyses  are  likely  to  confirm  the  pattern  observed 
here  leading  to  the  identification  of  several  more 
highly  stable  pSLA‐2*0401  but  only  a  few  additional 
stable  pSLA‐3*0401  due  to  the  unique  binding 
characteristics of the SLA‐3*0401 molecule expressing 
only  one  dominating  anchor  in  P2  (Table  1)  as 
discussed below. Despite  this,  it was  still  possible  to 
identify peptides that were bound by the SLA‐3*0401 
molecule with high affinity and producing highly stable 
pSLA,  an  example  being  the  peptide  sequence 
RNMSRIFPY,  derived  from  Encephalitozoon  cuniculi 
IEDB  ID:  93734,  (2011).  This  peptide  is  an  almost 
perfect match for the SLA‐3*0401 binding motif (Table 
1)  and was  also  predicted  to  be  bound  by  both  the 
matrix  and  NetMHCpan  prediction  rank  scores 
(Supporting Table 1 C). Furthermore,  in vitro analysis 
verified  this  sequence  as  an  extremely  strong  and 
stable binding peptide with a KD value of 1 nM and a 
stability half‐life of T½ = 6.7 hours (Supporting Table 1 
C).  Such  data  confirm  the  ability  of  the  prediction 
approach,  combining  specific  PSCPL  binding  matrix 
and  in  silico  predictions,  to  identify  potential  T  cell 
epitopes. 
Discussion 
The  mapping  of  the  complete 
nonamer SLA‐3*0401 peptide binding matrix revealed 
a single dominating anchor in P2 of the binding groove 
(Table 1).  Instead of a dominating P9 anchor which  is 
commonly  seen  for  other  SLA  and  HLA  proteins 
(Lamberth et al. 2008, Pedersen et al. 2011, Pedersen 
et al. 2012, Rammensee et al. 1999, Rapin et al. 2008, 
Sette  and  Sidney  1999),  it  was  found  that  this 
molecule displayed a  rather atypical auxiliary peptide 
anchor  for  P7  within  the  E‐pocket  of  the  binding 
groove.  
We  here  present  state‐of‐the‐art  tools  for  peptide 
prediction,  selection,  and  binding  analysis  –  both  in 
terms  of  affinity  and  stability.  These  analyses  were 
based  on  combining  individual  SLA  binding  matrix 
predictions with those of NetMHCpan, and further test 
binding  affinity  and  stability using homogenous, high 
throughput  LOCI  and  SPA  assays,  respectively.  The 
combination of the two individual prediction methods 
resulted  in  an  enhancement  of  the  overall  peptide 
selection  in the range of a 10 to 45 %  increase  in the 
final  number  of  peptides  identified  to  be  bound 
(Supporting Table 1 A  ‐ C). Confirming  the advantage 
gained by combining  the  two prediction  tools  is seen 
for  peptides  TSDGFINGW  and  ITDYIVGYY.  These 
peptides were both  identified  to be bound with high 
affinity  and  to  form  highly  stable  pSLA  but  while 
TSDGFINGW only  came out as a  candidate  ligand  for 
SLA‐1*0401  by  the  matrix‐based  predictions  (matrix 
score  of  195,  NetMHCpan  rank  of  15.00),  the 
ITDYIVGYY  peptide  was  predicted  exclusively  by  the 
NetMHCpan  (matrix  score  of  0, NetMHCpan  rank  of 
0.03),  (Supporting  Table  1  A).  Hence,  combining  the 
two  prediction  tools  resulted  in  inclusion  of  both 
peptides of which one of them would have been  lost, 
were  the  predictions  only  performed  by  one  of  the 
predictors.  Similar  examples  can  be  found  in 
Supporting Table 1 A – C. We observe a general trend 
that  the overlap between  the NetMHCpan and PSCPL 
matrix‐based  predictions  is  highest  for  the  SLA 
molecule where peptide‐binding data form part of the 
training  data  for  the  NetMHCpan  method.  This  is 
consistent  with  earlier  findings  (Rasmussen  et  al. 
2012), and  suggests  that as data  for constructing  the 
pan‐specific  predictor  are  enriched with  SLA  peptide 
binding  measurements,  identified  as  described  here 
using both the PSCPL and pan‐specific predictions, the 
NetMHCpan  method  will  be  able  to  learn  the  SLA 
binding repertoire described by both methods. By way 
of  example  is,  that  the  correlation  between 
predictions  performed  by  the  PSCPL  matrix  and 
NetMHCpan methods,  increase by 33 % when  the 76 
SLA‐3*0401  binding  measurements  obtained  in  this 
study  are  included  in  the  training  data  (data  not 
shown). 
 
Analyzing  the  correlation  between 
pSLA  affinity  and  stability  for  the  three  SLA  proteins 
revealed a general trend of peptides being bound with 
high  affinity, were  also  producing  high  stability  pSLA 
(Figure 3 A – C). Still  it was  found  that  the  individual 
pSLA‐3*0401  turned out  to display significantly  lower 
T½  values  than  those  of  both  the  pSLA‐1*0401  and 
pSLA‐2*0401. Several factors, which could cause such 
a tendency, remain to be addressed  in detail. Factors 
such as the low number of peptides tested, limitations 
in  regard  to  the diversity of peptides  in  the  in‐house 
peptide  library  (comprised  of  some  9000  different 
peptides, where no peptides have  the pattern of N/R 
at  P2  and  D  at  P9,  as  compared  to  “the  whole 
universe” of peptides) or the fact that SLA‐3*0401 has 
a  lack  of  the  otherwise  commonly  expressed  P9 
anchor  in  regard  to  peptide  binding,  could  all  be 
causative  for  the  production  of  low  stability  pSLA‐
3*0401  regardless of  the peptide offered. As  seen  in 
Supporting  Tables  1  A  +  B,  a  trend  for  peptides 
satisfying  both  the  P2  and  P9  anchor  of  SLA‐1*0401 
and  SLA‐2*0401,  as  well  as  the  P3  anchor  of  SLA‐
1*0401, is that they are bound with higher stability, as 
compared to peptides that satisfy only one of the two 
anchors (or only two of the three anchors in regard to 
SLA‐1*0401)  which  tend  to  be  bound  with  lower 
stability.  This observation  is  consistent with previous 
observations  made  for  the  human  class  I  molecule, 
HLA‐A*02:01  (Harndahl  et  al.  2012). Hence,  for  each 
anchor  satisfied  the  stability  of  the  bound  peptide 
seems to increase, which could explain why the “one‐
anchor‐only” molecule,  SLA‐3*0401, produces mostly 
low stable pSLA.  Speculating the biological relevance, 
expression of a single major anchor for P2 could be a 
phenotypic  preference  in  regard  to  SLA‐3*0401 
leading to faster turnover rates in the sense of peptide 
association and dissociation, which again would claim 
pSLA‐3*0401 of lower stabilities as compared to other 
molecules showing slow peptide turnovers but higher 
stabilities.  An  SLA  allele  repertoire  combining  fast‐
unstable and slow‐stable pSLA could be an advantage 
for  the  host  in  the  sense  of  effective  and  diverse 
protection  against  intruding  pathogens  expressing 
both  fast,  and  diverse,  peptide  turnovers  as well  as 
stable peptide presentation.  
 
Having  determined  the  SLA‐3*0401 
binding matrix  and  knowing  how  to  specifically map 
such matrices  can  be  of  great  value when  screening 
for  peptide  candidates.  Not  only  does  it  provide  an 
overview  and  insight of  specific biochemical  features 
within  the  binding  groove,  it  also  contributes  to  the 
overall predictions of possible peptide candidates  for 
binding.  The  prediction  tool  combination  presented 
here  prove  extremely  effective  in  the  initial  steps  of 
identifying CTL peptide epitopes now adding swine to 
the  list  of  species  that  can  be  addressed,  screening 
virtually  any  pathogen  of  interest.  Furthermore, 
improvement  of  the  NetMHCpan  alone,  which  has 
only  been  trained  on  a  very  limited  number  of 
peptides  for  SLA‐1*0401  and  SLA‐2*0401  (15  and  1, 
respectively)  and  none  for  the  SLA‐3*0401  so  far, 
could  also  benefit  the  process  of  selecting  peptide 
candidates  for  pMHC  binding  studies  –  especially 
when  studying  MHC  molecules  for  which  peptide 
binding matrixes have not yet been defined. The data 
achieved  in  this  study,  as  well  as  data  recently 
obtained  for cattle MHC‐I  (BoLA) by  the group at  the 
University  of  Copenhagen, will  further  contribute  to 
the constant improvement of the NetMHCpan by data 
training. 
Finally,  we  here  present  several 
peptides  derived  from  bacteria  and  viruses  such  as 
foot‐and‐mouth disease virus (FMDV) and  Influenza A 
virus which  could  have  a  great  relevance  for  future 
studies in regard to disease in livestock animals, bound 
with  both  high  affinity  and  stability  by  three  of  the 
most  commonly  expressed  SLA molecules worldwide 
(Supporting  Table  1  A  ‐  C).  Such  peptides  can  be 
categorized  as  potential  CTL  epitopes  expressing  the 
ability  to generate stable pSLA,  in  that  they are  likely 
to be targets for circulating CTLs, eventually leading to 
cell activation and elimination of pathogenic intruders. 
Clarifying  details  concerning  the  peptide  binding 
properties  of  swine  MHC  class  I  molecules  could 
contribute  tremendously  to  epitope  discoveries  as 
well  as  to  the  overall  validation  and  analysis  of 
currently  available  or  newly  developed  livestock 
vaccines.  Furthermore,  knowledge  of  SLA  binding 
motifs could  improve current studies and surveillance 
of  porcine  immune  responses  to  agricultural  threats 
such as foot‐and‐mouth disease virus (FMDV), porcine 
reproductive and respiratory syndrome virus  (PRRSV), 
swine influenza virus and others, in what seems to be 
a  continuous  struggle  to  keep  animals  healthy  and 
protected to avoid substantial outbreaks. 
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Figures 
 
Figure  1  Binding motif  of  the  SLA‐3*0401 molecule  determined  by  pMHC  dissociation  driven  PSCPL  analysis  and 
displayed as  logos. Each  logo  represents a  single amino acid. The  larger  the  size of  the amino acid  representative 
letter,  the higher  the affinity  for binding. Positive amino acid  logos  indicate slow pMHC dissociation  rates and high 
binding  affinity.  Negative  amino  acid  logos  indicate  fast  pMHC  dissociation  rates  and  low  binding  affinity.  The 
visualization was performed by the Seq2Logo server (Thomsen and Nielsen 2012) normalizing scores for each peptide 
position to one, using P‐weighted Kullback‐Leibler  logo types with an even amino acid background distribution (0.05 
for all amino acids).   
 
 
Figure 2  Illustration of  the PT85A based LOCI principle  for analysis of SLA‐2*0401 and SLA‐3*0401 peptide affinity. 
Streptavidin (blue) coated donor beads enable the capture of biotinylated pSLA (purple (biotin), green (MHC/β2m), red 
(bound peptide)). Acceptor beads were  coated with  a mouse‐anti‐SLA monoclonal  antibody,  PT85A  (carbon  grey). 
Recognition of the pSLA by PT85A brings the donor and acceptor beads  in close proximity  leading to the transfer of 
singlet oxygen (1O2) from the excited donor bead to the acceptor bead, which results in detectable emission from the 
acceptor bead (orange). 
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Figure 3 A ‐ C pSLA affinity versus stability for predicted peptide candidates with measured KD values below 500 nM. 
A: SLA‐1*0401 (n: 110). B: SLA‐2*0401 (n: 20). C: SLA‐3*0401 (n: 29).  
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Supporting figures 
 
Supporting Figure 1 LOCI based titration curve for affinity analysis of the SLA‐2*0401 binding of peptide MTAASYARY 
(KD 75 nM, T½ of 3.8 hours).  
 
 
Supporting Figure 2 LOCI based titration curve for affinity analysis of the SLA‐3*0401 binding of peptide KRMMMNLNY 
(KD 4 nM, T½ of 1.1 hours). 
 
 
 
 
 
SLA-2
0.001 0.01 0.1 1 10 100 1000 10000
0.0
0.2
0.4
0.6
0.8
1.0
17874/MTAASYARY
Peptide [nM]
Fo
ld
ed
 p
M
HC
 [n
M
]
SLA-3
0.001 0.01 0.1 1 10 100 1000 10000
0.0
0.2
0.4
0.6
13719/KRMMMNLNY
Peptide [nM]
Fo
ld
ed
 p
M
HC
 [n
M
]
Tables 
 
 
Table 1 The complete nonamer SLA‐3*0401 binding matrix as determined by the PSCPL approach. RB values greater 
than 2 are defined as  favored AAs  for peptide binding  (marked  in bold), whereas values below 0.5 are defined as 
destabilizing (marked in italics), (Lauemoller et al. 2001, Stryhn et al. 1996). As previously defined, AP‐values above 15 
are considered as dominating anchors of importance illustrated by underlining (Lamberth et al. 2008). 
 
 
Table 2 Peptide affinity analysis of peptides predicted for SLA binding by the NetMHCpan or PSCPL matrix prediction 
methods. The  total numbers of  identified strong  (KD  ≤ 50 nM),  intermediate  (KD 50  ‐ 500 nM), and weak  (KD 500  ‐ 
5000) as well as non‐binding (KD ≥ 5000 nM) peptides are indicated for each SLA molecule.  
 
SLA-3*0401 Amino acid position in peptide
1 2 3 4 5 6 7 8 9
A 0,8 0,7 0,6 0,8 0,9 1,0 0,7 0,9 0,9
C 0,4 0,6 0,5 0,7 0,5 0,5 0,7 0,9 0,5
D 0,9 0,4 0,3 0,5 0,4 0,7 0,5 0,8 1,5
E 0,4 0,4 0,4 0,6 0,4 0,9 0,5 1,2 0,9
F 0,6 0,5 3,0 1,7 1,6 0,8 2,2 1,5 2,3
G 0,9 0,6 0,4 0,3 0,7 0,6 0,5 0,5 0,6
H 0,8 0,5 0,8 1,3 1,1 1,0 0,8 0,8 0,6
I 0,7 0,7 0,8 0,5 1,1 1,0 0,6 1,9 1,8
K 2,2 0,7 0,6 1,8 0,7 1,5 0,4 0,7 0,3
L 1,7 0,5 1,1 1,4 0,9 1,1 2,1 1,4 0,9
M 1,6 0,5 1,4 1,3 1,1 1,2 1,9 0,7 2,4
N 0,6 5,6 1,2 0,9 1,7 1,1 0,6 0,5 0,7
P 0,3 0,4 0,5 0,7 0,9 0,9 0,7 1,4 0,4
Q 0,5 0,7 0,5 1,1 0,8 1,1 0,7 0,9 0,3
R 3,1 2,3 2,8 1,8 2,4 1,5 0,7 0,7 0,2
S 0,8 1,3 0,6 0,8 0,7 1,2 0,6 0,6 0,7
T 1,1 1,3 0,7 0,8 0,6 1,1 0,6 1,0 0,5
V 1,0 1,1 1,1 0,7 0,8 0,9 0,8 1,2 1,1
W 0,6 0,5 1,2 1,0 1,0 0,8 3,4 0,9 1,2
Y 0,9 0,6 1,6 1,2 1,6 1,0 0,8 1,5 2,0
Sum 20 20 20 20 20 20 20 20 20
AP‐value 9 27 11 4 5 1 11 3 9
Molecule ≤ 50 50 ‐ 500  500 ‐ 5000  ≥ 5000 
SLA‐1*0401 67 45 20 25
SLA‐2*0401 6 14 20 32
SLA‐3*0401 20 9 9 38
Peptide affinity (KD, nM)
 Table 3 Comparing abilities of the PSCPL matrix‐ and NetMHCpan based prediction methods to  identify true binding 
peptides  for  SLA‐1*0401,  SLA‐2*0401 and  SLA‐3*0401. The  sensitivity of each prediction  scenario  is given as  (true 
positives)/(actual  positives),  i.e.  the  share of  all  peptides  actually  identified  to be bound  (from  the  pool  of  PSCPL 
matrix or NetMHCpan predicted candidates), that were also found to be so within the pool of peptides predicted by 
the respective method exclusively.  
 
 
 
 
 
 
 
 
 
 
 
PSCPL matrix or 
NetMHCpan 
prediction
Peptides predicted by
either PSCPL matrix or 
NetMHCpan
Sensitivity 
SLA‐1*0401 157 112 (71.3 %) 1.00
SLA‐2*0401 72 20 (27.8 %) 1.00
SLA‐3*0401 76 29 (38.2 %) 1.00
Combined 
prediction
Peptides predicted by
PSCPL matrix and 
NetMHCpan
Sensitivity 
SLA‐1*0401 61 53 (86.9 %) 0.473
SLA‐2*0401 27 9 (33.3 %) 0.450
SLA‐3*0401 24 17 (70.8 %) 0.586
NetMHCpan 
prediction
Peptides predicted by
NetMHCpan exclusively Sensitivity 
SLA‐1*0401 76 44 (57.9 %) 0.393
SLA‐2*0401 25 9 (36.0 %) 0.450
SLA‐3*0401 35 4 (11.4 %) 0.138
PSCPL matrix
prediction
Peptides predicted by
PSCPL matrix exclusively
Sensitivity 
SLA‐1*0401 20 15 (75.0 %) 0.134
SLA‐2*0401 20 2 (10.0 %) 0.100
SLA‐3*0401 17 8 (47.1 %) 0.276
Peptides bound
Peptides bound
Peptides bound
Peptides bound
Supporting Tables
Supporting Table 1 A
SLA‐1*0401 peptide binding analysis
Prediction Affinity/Rank
Peptide amino acid sequence Origin/Uniprot ID/Position PSCPL matrix NetMHCpan Affinity (KD, nM) Stability (T1/2, h)
Predicted by PSCPL
matrix
Predicted by
NetMHCpan
AVEDFLAFF Andes virus/Q9E005/1037 679 2.00 (WB) 2 22,69 Yes Yes
STAPTGSWF NA 186 0.40 (SB) 2 7,30 Yes Yes
GTDSGFAAY SARS-like coronavirus/Q3I5J2/187 65 0.08 (SB) 2 158,75 Yes Yes
MADSFKSDY NA 170 1.00 (WB) 2 14,71 Yes Yes
VLDKWNTNY Variola virus/Q89167/164 81 0.80 (WB) 3 25,12 Yes Yes
TIDKSSPLY Vaccinia virus/Q85324/95 172 0.25 (SB) 3 16,68 Yes Yes
MIDSDEWVY Entamoeba histolytica/Q512E5/461 84 0.80 (WB) 3 49,13 Yes Yes
TSDGFINGW Yersinia pestis/A6BRR8/79 195 15,00 3 5,34 Yes No
ITDITSPLW Marburg virus/P35262/2017 185 0.80 (WB) 3 65,22 Yes Yes
TQDLFLPFY SARS-CoV/Q202H8/55 89 3,00 3 4,21 Yes No
ITDYIVGYY Escherichia coli/B3C476/239 0 0.03 (SB) 4 13,09 No Yes
SVDGFRASY NA 353 0.40 (SB) 4 35,71 Yes Yes
KLDAWLLPF Salmonella typhi/Q8Z2M9/132 230 1.00 (WB) 4 16,26 Yes Yes
NTDAFSREY
Variola virus/Q0N575/184 171 0.40 (SB) 4 6,03 Yes Yes
KLDPTNTLW Machupo virus/Q8AZ68/370 240 3,00 4 32,59 Yes No
GVEPGHAFY Mycobacterium tuberculosis/A4KFR1/150 175 0.40 (SB) 4 5,74 Yes Yes
MTAHITVPY
Foot-and-mouth disease
virus strain A24 P1
protein 1 0.01 (SB) 4 7,23 No Yes
SVEVKLPDY Dengue virus type4/Q2YHF0/449 93 2.00 (WB) 5 53,56 Yes Yes
VTDPGGLYY 67 0.01 (SB) 5 12,33 Yes Yes
HSDDALFIY Sangassou virus/Q1L0R2/123 112 0.17 (SB) 5 8,98 Yes Yes
RADSMMLGY Pseudomonas mallei/Q62FQ6/356 131 0.10 (SB) 5 30,50 Yes Yes
EVAGAGSGF Mycobacterium tuberculosis/Q6MWX9/706 146 15,00 6 3,01 Yes No
NIDNMCHLY Vaccinia virus/Q49PZ6/18 184 1.00 (WB) 6 12,14 Yes Yes
FTFWTFANY NA 7 0.05 (SB) 7 38,25 No Yes
LIDGRTSFY Lassa virus/Q6Y630/140 213 0.30 (SB) 7 5,88 Yes Yes
YTDKIAMSY
Francisella tularensis
subsp. 
Tularensis/A7JE81/332 5 0.03 (SB) 7 10,34 No Yes
ATDFKFAMY NA 0 0.08 (SB) 8 104,90 No Yes
RVERIKSEY Yellow fevervirus/Q9W9I1/281 85 1.50 (WB) 8 29,52 Yes Yes
SSDLRSWTF 174 2.00 (WB) 8 2,07 Yes Yes
TMDVNHPIY Variola virus/Q0NIE/511 342 0.80 (WB) 8 6,80 Yes Yes
VSDGPPTGY Variola virus/Q89222/298 144 0.50 (WB) 8 87,80 Yes Yes
ATEDPSSGY Ebola virus/P60170/205 128 0.30 (SB) 10 4,15 Yes Yes
VVDALRNIY Tula virus/Q9YQR5/1005 120 0.80 (WB) 10 15,11 Yes Yes
GTDSNGMLW Mycobacterium tuberculosis/Q6MWX8/1587 226 2.00 (WB) 10 12,52 Yes Yes
ASAAHLAAY Shigella sonnei/Q3YTU7/42 80 0.03 (SB) 11 2,46 Yes Yes
MTAASYARY NA 4 0.01 (SB) 11 0,85 No Yes
IVDCLTEMY NA 145 0.40 (SB) 12 13,14 Yes Yes
MIEPRTLQY NA 93 0.17 (SB) 12 3,98 Yes Yes
SVAMCRTPF Yellow fevervirus/Q1X881/2440 174 3,00 12 4,14 Yes No
IVDINVKDY Influenza A virus/genbankAY702454/107 75 3,00 12 3,89 Yes No
QTDNDIWFW Escherichia coli/B3BVD0/932 71 15,00 13 36,67 Yes No
ITDITKYLY Bacillus anthracis/B0ARG1/50 96 0.05 (SB) 14 4,78 Yes Yes
YVYFYDLSY Variola virus/Q0NLZ1/504 0 0.01 (SB) 14 0,21 No Yes
ATAAATEAY Ebola virus/Q05127/154 8 0.01 (SB) 15 6,97 No Yes
KSNRIPFLY Giardia lamblia/A8BAY0/318 5 0.80 (WB) 15 0,15 No Yes
LTDDMIAAY SARS-CoV/Q202H8/847 156 0.05 (SB) 16 11,41 Yes Yes
LSDDAVVCY SARS-like coronavirus/P0C6W6/5125 98 0.50 (WB) 16 10,38 Yes Yes
RIARFHRPY Brucella suis/Q8FVB3/115 92 0.80 (WB) 16 1,68 Yes Yes
RVSTGLYRY Mycobacterium tuberculosis/A4KJM5/1479 68 0.30 (SB) 17 3,86 Yes Yes
EIAQHGAWY Escherichia coli/B3BCL5/74 160 2.00 (WB) 18 1,14 Yes Yes
LTDSDSPTY Mycobacterium tuberculosis/A4KDY3/1298 87 0.80 (WB) 18 4,06 Yes Yes
QTDNQLAVF West Nile virus strainPTRoxo/A8KCE3/2252 135 1.50 (WB) 18 27,51 Yes Yes
QTDPLWQKY Vibrio vulnificus/Q8D5T5/90 76 0.40 (SB) 20 ND Yes Yes
LLDGLLAWY Mycobacterium tuberculosis/A4KM19/247 252 1.00 (WB) 22 4,38 Yes Yes
SLA‐1*0401 peptide binding analysis
Prediction Affinity/Rank
Peptide amino acid sequence Origin/Uniprot ID/Position PSCPL matrix NetMHCpan Affinity (KD, nM) Stability (T1/2, h)
Predicted by PSCPL
matrix
Predicted by
NetMHCpan
VVYRGTTTY SARS-like coronavirus/P0C6W6/5508 4 0.08 (SB) 28 1,25 No Yes
FTDNNELEF Bacillus anthracisTsiankovskii-I/B3J7Q9/95 149 0.50 (WB) 31 0,49 Yes Yes
CSDETTLYY Francisella tularensis
subsp. Tularensis/A7JDX6/88 5 0.03 (SB) 32 1,48 No Yes
RVFPGDHFY Mycobacterium tuberculosis/A4KKI8/230 3 0.05 (SB) 32 4,07 No Yes
VSDGGPNLY
Influenza A virus
(A/duck/Guangdong/173/04(H5
N1))/genbank AY737302/591 190 0.08 (SB) 37 1,72 Yes Yes
SSDISFIKY Vaccinia virus/Q80HY4/66 63 0.40 (SB) 40 0,77 Yes Yes
ASYAGAGAY Artificially designedsequence 0 0.03 (SB) 40 0,36 No Yes
EVDQTKIQY Yellow fevervirus/Q9WN82/22 103 4,00 41 2,70 Yes No
CTDDNALAY SARS-like coronavirus/P0C6T7/4138 74 0.03 (SB) 43 4,59 Yes Yes
ATVKGMQSY NA 2 0.05 (SB) 50 0,36 No Yes
FTIRDVLAY Yersinia enterocolitica/A1JNP9/275 0 0.03 (SB) 52 0,36 No Yes
ASYQFQLPY Vibrio cholerae/A6Y7B0/208 4 0.01 (SB) 53 0,61 No Yes
RTDAWSYPV Escherichia coli/B3BD85/110 112 0.80 (WB) 55 1,28 Yes Yes
RSNDTELNY Marburg virus/P35262/1181 68 0.17 (SB) 57 0,24 Yes Yes
MTSGSSSGF Mycobacterium tuberculosis/Q6MWX9/2924 125 0.40 (SB) 57 0,62 Yes Yes
RLASYGLYY Variola virus/Q9PXS2/560 9 0.05 (SB) 71 0,38 No Yes
RTWAYHGSY Dengue virus type4/Q2YHF0/2788 0 0.08 (SB) 72 0,62 No Yes
SSDDIPPRW Variola virus/Q9PXS3/58 326 5,00 72 4,16 Yes No
KSDGTGTIY SARS-like coronavirus/P0C6T7/4173 296 0.40 (SB) 78 0,59 Yes Yes
RSADGSPPY Mycobacterium tuberculosis/A4KJ56/29 296 0.08 (SB) 82 0,50 Yes Yes
RTWNYHGSY West Nile virus strainPTRoxo/A8KCE3/2831 0 0.08 (SB) 91 0,43 No Yes
QTEENLLDF NA 141 3,00 92 1,03 Yes No
ALTDLGLIY Lassa virus/Q9IMI9/201 63 0.15 (SB) 93 2,08 Yes Yes
KSDLQPPNY NA 104 1.00 (WB) 100 0,97 Yes Yes
KMFHGGLRY Mycobacterium tuberculosis/A4KLJ6/79 1 0.08 (SB) 105 0,18 No Yes
VVAANRSAF Mycobacterium tuberculosis/A4KJA4/104 78 3,00 109 0,23 Yes No
AVEGGLYPV NA 76 15,00 109 0,39 Yes No
ETESVNSNY Giardia lamblia/A8BQ55/260 79 2.00 (WB) 110 0,48 Yes Yes
RTLASGLIY Yersinia pestis/A6BRM7/395 4 0.05 (SB) 117 0,24 No Yes
FLYPSWSLY Cryptosporidium parvum IowaII/Q5CTZ8/176 3 0.05 (SB) 122 0,34 No Yes
YAQMWTLMY Dengue virus type3/P27915/3248 0 0.08 (SB) 140 0,56 No Yes
FTYAPAGMY Listeria monocytogenes/A3FVB4/508 0 0.01 (SB) 151 0,69 No Yes
ATTFARFLY Salmonella typhi/Q8Z4W4/505 0 0.10 (SB) 155 0,26 No Yes
KTAVVVTRY Yersinia enterocolitica/A1JJ64/43 5 0.05 (SB) 165 0,72 No Yes
ASYAAAAAY Artificially designedsequence 3 0.03 (SB) 174 0,31 No Yes
ATAWRTGGY Pseudomonas mallei/Q62HR4/293 0 0.05 (SB) 174 0,51 No Yes
DTEDNVPPW NA 114 32,00 196 0,79 Yes No
YTASVVAAY NA 7 0.01 (SB) 213 0,40 No Yes
KVFFGPIYY Variola virus/Q0N679/1007 0 0.05 (SB) 234 1,07 No Yes
AVSFRNLAY NA 0 0.05 (SB) 236 0,38 No Yes
MSWESTAEY Bacillus anthracisTsiankovskii-I/B3J8I0/10 1 0.01 (SB) 261 0,54 No Yes
YTSDYFISY NA 8 0.01 (SB) 265 0,40 No Yes
MSAIVSCRY Salmonella typhi/Q8Z5E5/93 8 0.10 (SB) 268 0,36 No Yes
KTFEWGVFY Entamoeba histolytica/Q50Y27/4 8 0.01 (SB) 272 0,60 No Yes
YTYPCIPEY NA 8 0.01 (SB) 279 0,80 No Yes
FTAMQALDY Salmonella typhi/Q8Z404/38 3 0.08 (SB) 290 1,16 No Yes
RTWFHGSLY Cryptosporidium parvum IowaII/Q5CQR9/77 0 0.01 (SB) 310 0,40 No Yes
ESDMEVFDY NA 241 2.00 (WB) 312 0,36 Yes Yes
EISGSSARY Yellow fevervirus/Q9YRV3/1420 63 1.50 (WB) 324 ND Yes Yes
GSDGGLDDY NA 100 2.00 (WB) 359 0,43 Yes Yes
QTWHGDAPY Vibrio parahaemolyticus/A6B1M3/64 0 0.08 (SB) 365 0,34 No Yes
QTNLYNLLY Salmonella typhi/Q8Z632/273 2 0.03 (SB) 380 3,05 No Yes
ISAYTHWYY
Francisella tularensis
subsp. 
Tularensis/A7JES6/146 6 0.05 (SB) 384 1,53 No Yes
AMYDPQTYY Rickettsia sibirica/Q7P8Y1/1874 2 0.05 (SB) 417 0,29 No Yes
SLA‐1*0401 peptide binding analysis
Prediction Affinity/Rank
Peptide amino acid sequence Origin/Uniprot ID/Position PSCPL matrix NetMHCpan Affinity (KD, nM) Stability (T1/2, h)
Predicted by PSCPL
matrix
Predicted by
NetMHCpan
HSNASTLLY NA 2 0.03 (SB) 507 ND No Yes
KSTDSESDW NA 156 6,00 521 ND Yes No
YIFFASFYY NA 0 0.08 (SB) 541 ND No Yes
RTWHYCGSY NA 0 0.08 (SB) 546 ND No Yes
HMMAVTLFY NA 2 0.03 (SB) 734 ND No Yes
YTFEPHYFY NA 6 0.01 (SB) 823 ND No Yes
DSDDWLNKY NA 102 5,00 1001 ND Yes No
ESSDDELPY NA 82 1.50 (WB) 1117 ND Yes Yes
VSYAAAAAY NA 2 0.03 (SB) 1200 ND No Yes
GTTEVNGLY NA 0 0.08 (SB) 1293 ND No Yes
ITMVNSLTY NA 8 0.01 (SB) 1375 ND No Yes
WVAGVQLLY NA 4 0.08 (SB) 1950 ND No Yes
YANMWSLMY NA 3 0.05 (SB) 2385 ND No Yes
VSALRLFNY NA 92 0.40 (SB) 2429 ND Yes Yes
QTYMYTGQY NA 0 0.05 (SB) 3098 ND No Yes
ITTFFTFAY NA 0 0.03 (SB) 3134 ND No Yes
MTRGLLGSY NA 0 0.15 (SB) 3248 ND No Yes
CTLNKSHLY NA 1 0.08 (SB) 3831 ND No Yes
VTIGNAYIY NA 5 0.10 (SB) 4233 ND No Yes
LTFLDCLYY NA 1 0.05 (SB) 20000 ND No Yes
MTRVLPFTY NA 1 0.15 (SB) 20000 ND No Yes
MTRGILGSY NA 0 0.12 (SB) 20000 ND No Yes
YSYIFLSSY NA 4 0.03 (SB) 20000 ND No Yes
VTRGAVLMY NA 1 0.10 (SB) 20000 ND No Yes
STFTFPGIY NA 0 0.05 (SB) 20000 ND No Yes
ATIMPHNLY NA 9 0.08 (SB) 20000 ND No Yes
MTRVTNNVY NA 0 0.25 (SB) 20000 ND No Yes
ITFQSILGY NA 4 0.03 (SB) 20000 ND No Yes
FSIPVTFSY NA 0 0.05 (SB) 20000 ND No Yes
ITAGYNRYY NA 2 0.10 (SB) 20000 ND No Yes
MTAAQIRRY NA 7 0.15 (SB) 20000 ND No Yes
SAYERGLRY NA 3 0.05 (SB) 20000 ND No Yes
GSQYVSLAY NA 1 0.08 (SB) 20000 ND No Yes
ASFAAQLFY NA 5 0.03 (SB) 20000 ND No Yes
GTEYRLTLY NA 191 0.25 (SB) 20000 ND Yes Yes
ESENISEPY NA 83 2.00 (WB) 20000 ND Yes Yes
TTSDFFVNY NA 105 0.08 (SB) 20000 ND Yes Yes
NQDLNGNWY NA 93 15,00 20000 ND Yes No
MSDIFHALV NA 98 0.80 (WB) 20000 ND Yes Yes
QSAANMYIY NA 69 0.17 (SB) 20000 ND Yes Yes
LTMDREMLY NA 66 0.01 (SB) 20000 ND Yes Yes
TSSARSSEW NA 189 3,00 20000 ND Yes No
NMAPEKVDF NA 76 32,00 20000 ND Yes No
LTAHYCFLY NA 1 0.01 (SB) 20000 ND No Yes
Supporting Table 1 B
SLA‐2*0401 peptide binding analysis
Prediction Affinity/Rank
Peptide amino acid sequence Origin/Uniprot ID/Position PSCPL matrix NetMHCpan Affinity (KD, nM) Stability (T1/2, h)
Predicted by PSCPL
matrix
Predicted by
NetMHCpan
ASYQFQLPY Vibrio cholerae/A6Y7B0/208 30 0.01 (SB) 18 51,00 Yes Yes
MNYAAAAAY NA 456 0.03 (SB) 22 131,70 Yes Yes
YTIGIGAFY NA 1 0.03 (SB) 25 10,80 No Yes
SSLPSYAAY
SARS-like 
coronavirus/P0C6T7/3924 60 0.15 (SB) 30 1,70 Yes Yes
IIYYQLAGY Variola virus/Q0N4Z8/220 174 0.40 (SB) 38 1,30 Yes Yes
ITLKVFAGY Salmonella typhi/Q83T18/304 36 0.12 (SB) 44 22,00 Yes Yes
MVASQLARY
Yersinia 
enterocolitica/A1JQV7/564 66 0.08 (SB) 56 3,90 Yes Yes
MTRGLLGSY
West Nile virus strain
PTRoxo/A8KCE3/1531 1 0.03 (SB) 72 1,00 No Yes
MTAASYARY NA 55 0.01 (SB) 75 3,80 Yes Yes
QQYHRFGLY Variola virus/Q89107/120 0 0.01 (SB) 116 0,50 No Yes
YTASVVAAY NA 4 0.01 (SB) 170 1,50 No Yes
VSYAAAAAY NA 89 0.03 (SB) 186 7,80 Yes Yes
VSIPVTNTW
Brucella 
melitensis/Q9L772/174 37 2.00 (WB) 194 5,60 Yes Yes
ESLLHQASW Ebola virus/A3RCD1/57 89 4.00 195 93,00 Yes No
FTFWTFANY NA 7 0.01 (SB) 212 2,00 No Yes
HTSALSLGY
Vibrio 
vulnificus/Q8DEM6/164 7 0.05 (SB) 219 2,90 No Yes
YTSDYFISY NA 7 0.03 (SB) 298 1,60 No Yes
MVFQNYALY
Listeria 
monocytogenes/A3FZ93/80 5 0.01 (SB) 321 6,20 No Yes
RSVWIPGRW
Pseudomonas 
mallei/Q62BF8/186 59 4.0 375 0,20 Yes No
FTIRDVLAY
Yersinia 
enterocolitica/A1JNP9/275 2 0.03 (SB) 431 1,30 No Yes
RVYNNTARY NA 101 0.08 (SB) 525 ND Yes Yes
ESPSSDEDY NA 47 32.00 718 ND Yes No
YSSPHLLRY NA 51 0.03 (SB) 729 ND Yes Yes
KSWPAAIDW NA 138 8.00 790 ND Yes No
SLRPNDIVY NA 44 1.50 (WB) 1143 ND Yes Yes
ISRQIHWCW NA 77 6.00 1464 ND Yes No
SLA‐2*0401 peptide binding analysis
Prediction Affinity/Rank
Peptide amino acid sequence Origin/Uniprot ID/Position PSCPL matrix NetMHCpan Affinity (KD, nM) Stability (T1/2, h)
Predicted by PSCPL
matrix
Predicted by
NetMHCpan
QTYMYTGQY NA 9 0.01 (SB) 1713 ND No Yes
RYQAQQVEW NA 108 8.00 1740 ND Yes No
YANMWSLMY NA 1 0.01 (SB) 1829 ND No Yes
LTEAQDQFY NA 119 3.00 2120 ND Yes No
YTITYHDDW NA 46 5.00 2158 ND Yes No
YTNPQFNVY NA 225 0.03 (SB) 2846 ND Yes Yes
ITMVNSLTY NA 3 0.03 (SB) 3147 ND No Yes
DTRAIDQFF NA 39 5.00 3652 ND Yes No
YSRMLYIEF NA 48 1.00 (WB) 3654 ND Yes Yes
VTEPGTAQY NA 102 1.50 (WB) 4093 ND Yes Yes
MLYPRVWPY NA 1 0.03 (SB) 4427 ND No Yes
YTGPDHQEW NA 1277 8.00 5198 ND Yes No
MMAWRMMRY NA 4 0.01 (SB) 5323 ND No Yes
HTAEIQQFF NA 35 0.80 (WB) 6677 ND Yes Yes
STFATVLEY NA 1 0.01 (SB) 7274 ND No Yes
ATAVNQECW NA 56 15.00 7405 ND Yes No
SSMNSDAAY NA 83 0.40 (SB) 9871 ND Yes Yes
FAHDDRYLY NA 0 0.05 (SB) 20000 ND No Yes
FQMDYSLEY NA 1 0.03 (SB) 20000 ND No Yes
HQYPANLFY NA 1 0.01 (SB) 20000 ND No Yes
YAYNSSLLY NA 2 0.01 (SB) 20000 ND No Yes
FSSQLGLFY NA 4 0.05 (SB) 20000 ND No Yes
MTRVTNNVY NA 1 0.05 (SB) 20000 ND No Yes
HMMAVTLFY NA 1 0.01 (SB) 20000 ND No Yes
MANIFRGSY NA 2 0.05 (SB) 20000 ND No Yes
YAQMWSLMY NA 0 0.03 (SB) 20000 ND No Yes
ISVQPLWEW NA 54 6.00 20000 ND Yes No
MTAAQIRRY NA 45 0.30 (SB) 20000 ND Yes Yes
FSVPLDEGF NA 586 5.00 20000 ND Yes No
HSNLNDATY NA 132 0.40 (SB) 20000 ND Yes Yes
STEPPMLNY NA 44 1.00 (WB) 20000 ND Yes Yes
FGMPNPEGY NA 622 2.00 (WB) 20000 ND Yes Yes
YSYIFLSSY NA 39 0.01 (SB) 20000 ND Yes Yes
KSLDNYQEW NA 45 6.00 20000 ND Yes No
RVYPNPEVY NA 590 0.80 (WB) 20000 ND Yes Yes
SSVSSFERF NA 50 3.00 20000 ND Yes No
VSRLEHQMW NA 257 5.00 20000 ND Yes No
SAYYLDIGF NA 39 1.50 (WB) 20000 ND Yes Yes
QTWHGDAPY NA 48 0.25 (SB) 20000 ND Yes Yes
SSNPVMSRF NA 73 0.80 (WB) 20000 ND Yes Yes
SSNAKNSEW NA 43 5.00 20000 ND Yes No
KSAAIDGEY NA 50 1.50 (WB) 20000 ND Yes Yes
MYADDTAGW NA 44 5.00 20000 ND Yes No
Supporting Table 1 C
SLA‐3*0401 peptide binding analysis
Prediction Affinity/Rank
Peptide amino acid sequence Origin/Uniprot ID/Position PSCPL matrix NetMHCpan Affinity (KD, nM) Stability (T1/2, h)
Predicted by PSCPL
matrix
Predicted by
NetMHCpan
RNMSRIFPY
Encephalitozoon 
cuniculi/Q8SSE7/755 287 0.10 (SB) 1 6,70 Yes Yes
RVFNNYMPY SARS-CoV/Q19QX2/2140 85 0.01 (SB) 1 5,00 Yes Yes
KRMMMNLNY
Rift valley fever
virus/A2SZV2/1030 23 1.50 (WB) 4 1,10 No Yes
RRMATTFTF Variola virus/Q0NBG5/290 31 0.80 (WB) 4 1,10 Yes Yes
RRARYWLTY Giardia lamblia/A8BPJ1/256 43 0.50 (WB) 4 1,70 Yes Yes
RAYRNALSM
Yellow fever
virus/Q89318/36 34 0.03 (SB) 8 0,60 Yes Yes
RARKRGITM
Mycobacterium 
tuberculosis/A4KI89/219 27 0.50 (WB) 11 0,30 Yes Yes
KNNFWFWEY
Entamoeba 
histolytica/Q50ND6/107 169 0.80 (WB) 12 0,90 Yes Yes
RRSRRSLTV
West Nile virus strain
PTRoxo/A8KCE3/211 54 32,00 17 0,40 Yes No
RIRAANLPI
Mycobacterium 
tuberculosis/A4KJM5/1391 28 3,00 17 0,20 Yes No
KSFFSRLNW
Influenza A virus
(A/Northern 
Ireland/44233/2003(H3N2))/g
enbank AY738729/55 21
0.30 (SB)
24 0,20 No Yes
SARRRHLVF
Mycobacterium 
tuberculosis/A4KH94/44 40 0.40 (SB) 25 0,30 Yes Yes
KRIRLKHIF
Cryptosporidium parvum Iowa
II/Q5CXD6/25 40 6,00 27 1,40 Yes No
YRFRFRSVY Variola virus/Q9PXS7/740 38 1.00 (WB) 33 0,40 Yes Yes
YSRPWNWTF Giardia lamblia/A8BGW5/121 24 0.30 (SB) 35 0,50 No Yes
RRFFPYYVY NA 65 0.80 (WB) 39 0,30 Yes Yes
RRRQWASCM
Salmonella 
typhimurium/P26474/262 27 15,00 40 0,40 Yes No
TSFASSWIY
Rickettsia 
rickettsii/B0BWV4/130 44 0.40 (SB) 42 0,30 Yes Yes
RVRRLNWAA
Pseudomonas 
mallei/Q62BN5/105 50 32,00 43 0,30 Yes No
RRLHRLLLM NA 187 1.50 (WB) 44 0,70 Yes Yes
RMFKRVFNM Yersinia pestis/A6BP81/183 43 0.03 (SB) 52 0,40 Yes Yes
LNIMNKLNI Variola virus/Q89231/129 46 32,00 89 0,20 Yes No
SLA‐3*0401 peptide binding analysis
Prediction Affinity/Rank
Peptide amino acid sequence Origin/Uniprot ID/Position PSCPL matrix NetMHCpan Affinity (KD, nM) Stability (T1/2, h)
Predicted by PSCPL
matrix
Predicted by
NetMHCpan
MARWITWAM
Shigella 
flexneri/Q7UCA1/179 29 1.50 (WB) 122 0,20 Yes Yes
KTLKGGWFF
Vibrio 
vulnificus/Q8DF54/110 31 0.25 (SB) 134 0,20 Yes Yes
KSYEHQTPF
SARS-like 
coronavirus/P0C6T7/247 7 0.01 (SB) 137 0,30 No Yes
KARARLLSM Salmonella typhi/Q935J1/915 30 0.25 (SB) 302 0,20 Yes Yes
RRFKYLLNV Machupo virus/Q6XQI0/691 75 9,00 373 0,30 Yes No
RRFNRTKPM NA 75 6,00 554 ND Yes No
SRWSRKMLM NA 37 50,00 912 ND Yes No
LNWFEIWIV NA 60 50,00 1318 ND Yes No
RIYSHIAPY NA 6 0.01 (SB) 1506 ND No Yes
RNNDPTLPY NA 75 1.50 (WB) 1659 ND Yes Yes
GMFANRWII NA 34 2.00 (WB) 2514 ND Yes Yes
RWFVRNPFF NA 22 0.17 (SB) 3034 ND No Yes
RVFKETLFL NA 27 0.80 (WB) 3758 ND Yes Yes
VTFWGFWLF NA 23 0.25 (SB) 4911 ND No Yes
RTFDRFFEE NA 31 32,00 20000 ND Yes No
RRVRRRVLV NA 66 32,00 20000 ND Yes No
RLFFIDWEY NA 55 0.25 (SB) 20000 ND Yes Yes
YTFFFTQYF NA 27 0.20 (SB) 20000 ND Yes Yes
RSFRIHILF NA 55 0.01 (SB) 20000 ND Yes Yes
RYFTVAFLF NA 23 0.20 (SB) 20000 ND No Yes
TVFYNIPPM NA 19 0.30 (SB) 20000 ND No Yes
RRRRRRAAL NA 82 7,00 20000 ND Yes No
LSNFMLWQF NA 44 4,00 20000 ND Yes No
RLRRRRHPL NA 31 3,00 20000 ND Yes No
RVFYFAIFY NA 38 0.05 (SB) 20000 ND Yes Yes
TTRHRKPTY NA 30 10,00 20000 ND Yes No
SMFDSWGPF NA 1 0.01 (SB) 20000 ND No Yes
SQYHRFPIY NA 6 0.01 (SB) 20000 ND No Yes
YMIGYTAYY NA 0 0.03 (SB) 20000 ND No Yes
RVYPNPEVY NA 7 0.03 (SB) 20000 ND No Yes
AMYDPQTYY NA 1 0.05 (SB) 20000 ND No Yes
FLYPSWSLY NA 0 0.05 (SB) 20000 ND No Yes
RQHPGLFPF NA 7 0.01 (SB) 20000 ND No Yes
VMFRNASEY NA 6 0.03 (SB) 20000 ND No Yes
HQYPANLFY NA 4 0.01 (SB) 20000 ND No Yes
YSYIFLSSY NA 1 0.03 (SB) 20000 ND No Yes
ASYAAAAAY NA 2 0.05 (SB) 20000 ND No Yes
VSYAAAAAY NA 2 0.05 (SB) 20000 ND No Yes
YAYNSSLLY NA 5 0.01 (SB) 20000 ND No Yes
RTLDTLALY NA 3 0.03 (SB) 20000 ND No Yes
FQMDYSLEY NA 3 0.03 (SB) 20000 ND No Yes
YTYATRGIY NA 3 0.05 (SB) 20000 ND No Yes
RLYPFGSYY NA 3 0.01 (SB) 20000 ND No Yes
HMMAVTLFY NA 3 0.01 (SB) 20000 ND No Yes
GMFSWNLAY NA 4 0.01 (SB) 20000 ND No Yes
SSMNSFLLY NA 5 0.01 (SB) 20000 ND No Yes
RMFLAMITY NA 10 0.01 (SB) 20000 ND No Yes
MQYLNPPPY NA 7 0.01 (SB) 20000 ND No Yes
KMFHGGLRY NA 6 0.01 (SB) 20000 ND No Yes
RLASYGLYY NA 4 0.03 (SB) 20000 ND No Yes
ITMVNSLTY NA 8 0.01 (SB) 20000 ND No Yes
MMHASTSPF NA 1 0.01 (SB) 20000 ND No Yes
Supporting Table 1 A ‐ C SLA‐1, ‐2, and ‐3*0401 peptide prediction, affinity and stability analysis as well as successful predictions. Stability analysis (T½) was 
performed for peptides with a KD of 500 nM or less. Affinity (KD) is given in nano molar (nM).  Stability (T½) periods are given in hours (h). NetMHCpan rank
thresholds are 0.500 for strong binders (SB) and 2.00 for weak binders (WB). Peptides with NetMHCpan rank values above 2.00 were considered as predicted 
non‐binders. PSCPL matrix scores were calculated as the multiplication of all RB values for each of the nine amino acids in the peptide. A matrix score threshold 
of >25 was set for peptides considered as PSCPL matrix predicted binders. Peptides with KD affinities of >500 nM are shaded (grey).  
ND: Not Determined. NA: Not Assigned.
MHC molecule / total 
peptides tested  PSCPL Binding Matrix 
Affinity Measures 
(KD) 
Stability Measures 
(T½) 
SLA‐1*0401 / 157 peptides  Determined by ELISA (Pedersen 
et al. 2011)  
Determined by 
ELISA  Determined by SPA 
SLA‐2*0401 / 72 peptides  Determined by ELISA (Pedersen 
et al. 2012)  
Determined by 
LOCI  Determined by SPA 
SLA‐3*0401 / 76 peptides  Determined by SPA  Determined by 
LOCI  Determined by SPA 
Supporting Table 2   Methods used to determine the respective SLA heavy chain binding matrices as well as peptide 
affinities and stabilities. Enzyme‐Linked Immunosorbent Assay (ELISA). Scintillation Proximity Assay (SPA). Luminiscent 
Oxygen Channeling Assay (LOCI). 
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6. Paper IV 
 
Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by 
vaccination 
 
Patch JR, Pedersen LE, Toka FN, Moraes M, Grubman MJ, Nielsen M, Jungersen G, Buus 
S, Golde W.T. 
 
Clin Vaccine Immunol. 2011 Feb:18(2):280-8 
 
The work presented in this manuscript addresses the potential induction of FMDV-
specific CD8+ CTLs as a result of vaccination against FMDV. We hypothesize that using a 
recombinant human adenovirus vector based vaccine, delivering FMDV antigens in a T 
cell-directed manner, would enhance cytolytic activity and effectively increase pSLA 
peptide concentration for stimulation of a CTL response.  
The results confirm the hypothesis and show the induction of FMDV-specific CTLs 
capable of killing MHC-matched target cells. These data were further confirmed by 
specific SLA tetramer staining of activated PBMCs. 
In this manuscript we present the first demonstration of FMDV-specific CTL killing and 
confirmation by MHC tetramer staining in response to vaccination against FMDV. 
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Foot-and-mouth disease (FMD) continues to be a significant threat to the health and economic value of
livestock species. This acute infection is caused by the highly contagious FMD virus (FMDV), which infects
cloven-hoofed animals, including large and small ruminants and swine. Current vaccine strategies are all
directed toward the induction of neutralizing antibody responses. However, the role of cytotoxic T lymphocytes
(CTLs) has not received a great deal of attention, in part because of the technical difficulties associated with
establishing a reliable assay of cell killing for this highly cytopathic virus. Here, we have used recombinant
human adenovirus vectors as a means of delivering FMDV antigens in a T cell-directed vaccine in pigs. We
tested the hypothesis that impaired processing of the FMDV capsid would enhance cytolytic activity, presum-
ably by targeting all proteins for degradation and effectively increasing the class I major histocompatibility
complex (MHC)/FMDV peptide concentration for stimulation of a CTL response. We compared such a T
cell-targeting vaccine with the parental vaccine, previously shown to effectively induce a neutralizing antibody
response. Our results show induction of FMDV-specific CD8 CTL killing of MHC-matched target cells in an
antigen-specific manner. Further, we confirm these results by MHC tetramer staining. This work presents the
first demonstration of FMDV-specific CTL killing and confirmation by MHC tetramer staining in response to
vaccination against FMDV.
Foot-and-mouth disease (FMD) is a highly infectious viral
disease that affects cloven-hoofed animals and remains an im-
portant threat to livestock throughout much of the world (re-
viewed in reference 18). Many species of wild animals are
susceptible to infection, but agricultural concerns are particu-
larly focused on swine, cattle, sheep, and goats. This acute
disease is characterized by fever and viremia that last 1 to 2
days, the formation of vesicular lesions in the mouth and on
the feet and teats, lethargy, lameness, and loss of meat and
milk production. Clinical signs of disease resolve within 7 to
10 days; however, an asymptomatic persistent infection (car-
rier state) can develop, particularly in previously vaccinated
cattle (14, 17). The etiological cause of disease is FMD virus
(FMDV), which has a single-stranded, positive-sense RNA
genome of 8 kb. FMDV is a member of the Picornaviridae
family, genus Aphthovirus. Following entry of the virus into the
cell and uncoating, the released viral genome serves as an
mRNA for the translation of viral proteins. Initially synthe-
sized as a single polypeptide, the protein is subsequently
cleaved by viral proteases, including leader (Lpro) and 3Cpro,
into mature structural and nonstructural proteins (53).
FMDV is highly cytopathic, and several viral proteins are
known to play a role in disrupting the host immune response
(reviewed in reference 19). Lpro cleaves the host translation
initiation factor eIF4G, which plays a critical role in cap-de-
pendent mRNA translation (12). An internal ribosomal entry
site (IRES) in the 5 untranslated region of the FMDV ge-
nome allows synthesis of viral proteins to continue while ef-
fectively shutting down host protein synthesis (2, 27). Lpro also
promotes the degradation of NF-B, a regulator of beta inter-
feron (IFN-) transcription (10). The combined actions of Lpro
allow FMDV to block synthesis of the antiviral proteins IFN-
and -, to which FMDV is sensitive (7, 9). In addition to the
role of 3Cpro in cleaving the viral polyprotein into mature
protein products, it has been shown to induce the cleavage of
eIF4A and eIF4G (3). This protease has also been implicated
in the cleavage of histone H3 (15, 54), thus further inhibiting
host transcription and translation. In addition, both the pre-
cursor protein 2BC and the coexpressed mature products, 2B
and 2C, are involved in disruption of the cellular secretory
pathway (33, 34). Combined with the loss of host protein syn-
thesis, this disruption of the secretory pathway appears to be
responsible for inhibition of new MHC class I translation and
surface expression in FMDV-infected cells (51).
The immunopathology of this acute infection includes a
transient lymphopenia (1, 13). Viral infection was shown to
lead to inhibition of the type I IFN response of multiple pop-
ulations of dendritic cells (36, 37). In vitro, natural killer (NK)
cells have been shown to lyse FMDV-infected cells (56). How-
ever, analysis of cells from FMDV-infected animals shows a
loss of NK cell function during the acute phase of infection
(55) (reviewed in reference 16).
The development of neutralizing antibodies plays a central
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§ Supplemental material for this article may be found at http://cvi
.asm.org/.
 Published ahead of print on 22 December 2010.
280
role in FMDV immunity and often correlates with protection
of vaccinated animals against live virus challenge (32). Cur-
rently available vaccines consist of killed virus in adjuvant and
are effective at providing protection but do not allow for the
“differentiation of infected from vaccinated animals” (DIVA)
(48). A leading candidate for a next-generation FMDV vaccine
is a replication-defective human adenovirus 5 (Ad5) viral vec-
tor delivering FMDV capsid precursor (P1) and 3Cpro, an
“empty capsid” vaccine. This platform has DIVA capability
and is very compatible with diagnostic tests in use at present.
The parent polypeptide is processed by the 3Cpro into the
protein components of the capsid (reviewed in references 20
and 48). This vaccine strategy is effective in swine (30, 31, 35)
and cattle (39). However, like the killed-virus vaccine and
natural infection, neutralizing antibodies raised against the
vaccine strain do not provide cross-serotype protection. This
limits the value of vaccination during an FMDV outbreak or in
disease eradication (48), as virus strain matching is required
for vaccine efficacy.
CD8 cytotoxic T lymphocytes (CTLs) play an important
role in adaptive immunity and are capable of directly killing
virus-infected cells in an antigen-specific manner through the
release of perforin and granzymes as well as through Fas-Fas
ligand interactions (reviewed in references 5 and 58). Unlike
antibodies which recognize complex antigens, CTLs recognize
antigens that have been processed and cleaved into 8- to 12-
amino-acid peptides by the proteasome and then loaded into
MHC class I molecules in the lumen of the endoplasmic retic-
ulum (reviewed in reference 46). These peptide/MHC com-
plexes are then transported to the surface of the infected cell,
where they are displayed to T cell surveillance. CTL recogni-
tion occurs when an appropriate T cell receptor (TCR), in
association with the CD8 molecule, stably binds to the peptide/
MHC complex, resulting in stimulatory signaling cascades
within the CTL (58). The ability of CTLs to recognize epitopes
that remain hidden to neutralizing antibodies makes them at-
tractive candidates for enhancing FMDV immunity.
In contrast to the focus on neutralizing antibodies, the role
of CTLs in FMDV immunity has gone largely unexplored. The
ability of the virus to inhibit MHC synthesis and transport and
the speed with which the virus is cleared presumably result in
limited antigen exposure for MHC class I-restricted T cells. In
addition to the virus-induced lymphopenia, data from in vitro
studies would predict that FMDV-specific CTLs are not elic-
ited by natural FMDV infection if MHC class I expression is
blocked in vivo as has been described in vitro (51). This would
make FMDV-infected cells invisible to class I-restricted CTLs.
Given the cytopathic nature of the virus, this hypothesis has
gone largely untested, as FMDV-infected cells are rapidly
lysed in vitro and cannot be used as target cells in assays for
antigen-specific cell lysis.
We have overcome these limitations with two alternative
approaches. First, we employed recombinant Ad5 FMDV vac-
cine technology as a method for delivering FMDV antigens to
both stimulating and target cells for the in vitro CTL killing
assay. Here, we describe our development of an assay using
swine leukocyte antigen (SLA) homozygous pigs and the
MHC-matched PK (15) cells as target cells. Second, in order to
maximize the CTL response, we used a vaccine construct con-
taining a mutation in 3Cpro that inhibits its ability to process P1
into mature capsids. This approach tests the hypothesis that
one result of reduced processing of the primary polypeptide
precursor would be an increase in the pool of FMDV proteins
available for loading of FMDV-derived peptides into MHC
class I molecules. This is then predicted to enhance stimulation
of CTLs specific for FMDV peptides.
Further, to confirm that CTL killing was antigen specific and
MHC restricted, we developed class I MHC tetramers using
the NetMHCpan prediction algorithm developed for human
class I MHC (38) and extended to other species, including
swine (reference 25 and this report). Here we report that the T
cell-targeting vaccine elicited a greater overall CTL killing
response than the parental vaccine and correlated with the
induction of FMDV-specific CTLs by MHC tetramer staining.
MATERIALS AND METHODS
Cell lines. Porcine kidney [PK(15)] cells (ATCC CCL-33) and PK(15)-EGFP
cells (described below) were maintained in minimal essential medium (MEM)
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS)
(Thermo Fisher Scientific, Waltham, MA) and 3.4 mM L-glutamine, 3 mM
dextrose, 1 mM sodium pyruvate, 5% sodium bicarbonate, nonessential and
essential amino acids, 2-mercaptoethanol, and antibiotics (MEM-10). Baby ham-
ster kidney (BHK-21) cells (ATCC CCL-10) were maintained in basal medium
Eagle (BME) (Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 10%
tryptose phosphate broth, 2 mM L-glutamine, and antibiotics (BME-10). Human
293 cells (ATCC CRL-1573) were maintained in MEM supplemented with 10%
FBS, 2 mM L-glutamine, and antibiotics. Peripheral blood mononuclear cells
(PBMCs) were maintained in Roswell Park Memorial Institute (RPMI)-1640
medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 3.4 mM
L-glutamine, 3 mM dextrose, 1 mM sodium pyruvate, 5% sodium bicarbonate,
nonessential and essential amino acids, 2-mercaptoethanol, and antibiotics.
IBRS2 (swine kidney) cells were maintained in MEM supplemented with 10%
FBS, 2 mM L-glutamine, and antibiotics.
Animals. Yucatan 4b.0/4b.0 (24) pigs were obtained from Sinclair Research,
Inc., Columbia, MO. Animals were held for at least 1 week before being entered
into a study. All animal procedures were reviewed and approved by the Plum
Island Institutional Animal Care and Use Committee.
Antibodies. A mouse monoclonal antibody (MAb) against porcine CD6, clone
MIL8, was purchased from AbD Serotec (Raleigh, NC). Mouse MAbs against
porcine CD8 (R-phycoerythrin [RPE], clone 76-2-11) and CD4 (fluorescein
isothiocyanate [FITC], clone 74-12-4) were purchased from BD Biosciences (San
Jose, CA). Monoclonal anti-FMDV-VP1 (clone 6HC4.1.3 [45]) and anti-VP2
(VP0) (clone F1412SA [57]) were used in combination to probe for Western
blotting. In addition, a mixture of rabbit polyclonal antibodies raised against the
FMDV capsid proteins (VP1, VP2, and VP3) were used for Western blotting
(43). Anti-tubulin- MAb was used for control staining of the Western blot
(clone DM1A from Thermo Scientific, Fremont, CA).
Viruses. The production of viruses Ad5A24 (Ad5-FMDV-B), Ad5VSV-G
(Ad5-VSV-G) (35), and Ad5-Blue (Ad5-Empty) (35) have been previously de-
scribed. A mutation in the active site of the 3Cpro gene (21) was subcloned into
pAd5-A24, replacing the parental, wild-type 3Cpro, and was termed pAd5A24-
3C-mut. Production of this new adenovirus, Ad5A24-3C-mut (Ad5-FMDV-T),
was otherwise identical to that of the parental virus. All adenoviruses were grown
in 293 cells. FMDV, strain A24 Cruzeiro, was propagated in BHK-21 cells.
Western blotting. IBRS2 cells were seeded in a 96-well microplate at 20,000
cells/well in 50 l supplemented, phenol red-free MEM and incubated for 24 h
at 37°C. Following attachment, cells were infected with adenovirus constructs at
a multiplicity of infection (MOI) of 20, or with FMDV A24 at an MOI of 10, and
then incubated for 24 h or 5 h, respectively. Whole-cell lysates were prepared,
and protein expression was evaluated by separation by SDS-PAGE followed by
Western blotting.
Vaccination. Six Yucatan 4b.0/4b.0 pigs were divided into two groups of three
pigs each and vaccinated with either Ad5-FMDV-B or Ad5-FMDV-T. PBS was
administered to one additional pig as a negative control. For both vaccination
and boosting, animals were given a total of 5  109 PFU of the appropriate
adenovirus. Virus was delivered intradermally in a total of 2 ml to four sites on
the neck (0.5 ml/site) using the DERMA-VAC NF needle-free system (Merial,
Duluth, GA). Pigs were boosted 12 weeks postvaccination and again 11 or 13
months postvaccination.
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Isolation of PBMCs. Porcine blood was collected in Vacutainer tubes contain-
ing heparin. Typically, 20 ml of blood was diluted with 14 ml of phosphate-
buffered saline (PBS), followed by the addition of a 12-ml underlay of Lym-
phoprep (Axis-Shield, Oslo, Norway), and then centrifuged at 1,000  g for 20
min at room temperature. The band of peripheral blood mononuclear cells
(PBMCs) was harvested and washed three times with PBS, followed by suspen-
sion in RPMI.
Stimulator/target cell preparation. PK(15) cells were chosen because they are
MHC haplotype 4b.0/4.b0 (23), matching the MHC locus of the Yucatan swine
under study. To prepare stimulator cells, PK(15) cells were seeded into 24-well
plates and allowed to attach overnight. Cell medium was removed and cells were
infected with adenovirus at an MOI of 10 in 0.2 ml of RPMI 1640 (nonsupple-
mented) for 1 h at 37°C with occasional rocking. For target cells, we developed
PK(15)-EGFP cells. pEGFP-C1 (Clontec, Mountain View, CA) was linearized
by digestion with PciI (New England BioLabs, Ipswich, MA) and transfected into
PK(15) cells using the ProFection mammalian transfection system (Promega,
Madison, WI). Stably transfected cells were selected by growth in the presence of
Geneticin (500 g/ml) (Invitrogen, Carlsbad, CA) and cloned by two rounds of
limiting dilution. For the assay, 2  106 cells were infected with the appropriate
virus at an MOI of 10 for 1 h in a low volume of MEM. Target cells were then
given MEM-10 and incubated overnight at 37°C.
CD6 purification. PBMCs isolated from vaccinated pigs were suspended at a
concentration of 107 cells/ml, and 1 ml was added to each well of infected PK(15)
cells (typically 10 to 16 replicate wells), followed by the addition of 1 ml/well of
RPMI 1640 (supplemented). Plates were incubated at 37°C for 3 to 5 days.
Stimulated PBMCs were recovered from wells and reisolated on Lymphoprep in
order to remove dead cells. To positively select CD6 cells, purified PBMCs
were labeled with mouse anti-porcine CD6 MAb (1 l/106 cells) followed by
MACS goat anti-mouse IgG microbeads and separated on LS columns using a
MidiMACS magnetic separator (Miltenyi Biotec, Gladbach, Germany), accord-
ing to the manufacturer’s instructions, resulting in approximately 95% CD6
cells (data not shown).
Cytotoxic T lymphocyte killing assay. In vitro expanded, CD6-enriched cells
were suspended in supplemented RPMI 1640 at a concentration of 107 cells/ml,
plated (100 l/well) in a low-binding 96-well plate (Thermo Fisher Scientific,
Waltham, MA), and diluted 2-fold to obtain final effector-to-target-cell (E:T)
ratios of 50:1, 25:1, 12:1, and 6:1. Trypsinized PK(15)-EGFP target cells were
suspended at 105 cells/ml and added to the effector cells (100 l/well). In order
to discriminate dead target cells from live cells, 5 l of 7-amino-actinomycin D
(7-AAD) (BD Biosciences, San Jose, CA) was added to each well. The plate was
centrifuged at 233  g for 1 min and then incubated at 37°C for 4 h. Following
incubation, cells were resuspended and data were acquired by a FACSCalibur
flow cytometer with a high-throughput sampler (HTS) (BD Biosciences, San
Jose, CA). Data were analyzed using CellQuest Pro software (BD Biosciences,
San Jose, CA) by gating on PK(15)-EGFP cells and determining the percentage
of 7-AAD-positive (lysed) cells. Background lysis was determined by 7-AAD
staining of target cells in the absence of effectors, and this percentage was
subtracted from all groups.
Serum neutralization assay. Endpoint titers of serum neutralization of FMDV
A24 were determined according to the procedure described by Pacheco and
coworkers (40). Briefly, 4-fold serum dilutions were incubated at 37°C with 100
50% tissue culture infective doses (TCID50) of FMDV serotype A24 for 1 h in a
microtiter plate, after which BHK-21 cells were added (104 cells/well). Following
incubation for 3 days, wells were scored for cytopathic effect and endpoint titers
were calculated, which represent the reciprocal of the log dilution of serum able
to neutralize 100 TCID50 of virus.
Tetramer construction and staining. Peptides and recombinant SLA-1*0401
and human 2-microglobulin (2m) were produced and complexed into tetram-
ers as described previously (28) with minor modifications. Briefly, recombinant
2m and peptides were added to 10-fold and 40-fold excesses, respectively, of
SLA-1*0401 in a reaction buffer containing a cocktail of protease inhibitors [0.68
mM EDTA, 4.8 M pepstatin A, 94.4 M 1-10 phenanthroline, 0.1 mM N-
ethylmaleimide, 8.9 M tosyl-L-lysine chloromethyl ketone (TLCK), 9.3 M
tosyl-L-phenylalanine chloromethyl ketone (TPCK), 66.8 M phenylmethylsul-
fonyl fluoride (PMSF)] followed by the addition of streptavidin-allophycocyanin
(SA-APC). For tetramer staining, 2  105 to 5  105 cells were washed with cold
FACS buffer (PBS, 0.3% bovine serum albumin, 0.1% sodium azide) and resus-
pended in solution containing tetramer previously mixed 1:1 with 2 FACS
buffer. Cells were incubated at room temperature with rocking for 20 min and
then washed three times in cold FACS buffer. Cells were resuspended in FACS
buffer containing fluorescent MAbs against porcine CD8 and CD4 and then
incubated at room temperature for 20 min. After being washed three times in
FACS buffer, cells were fixed in PBS containing 1% formaldehyde and stored at
4°C until being analyzed by flow cytometry.
RESULTS
Mutation of FMDV 3C protease results in reduced capsid
processing and production of anti-FMDV antibodies. Previous
work by Moraes and coworkers demonstrated that vaccination
of swine with Ad5A24 (Ad5-FMDV-B) resulted in the gener-
ation of a protective anti-FMDV antibody response (35). Mu-
tation of the 3C protease resulting in an amino acid change
(C163S) is known to inhibit processing of P1 into mature cap-
sid proteins (21). A second adenovirus construct with the same
P1 polyprotein derived from FMDV strain A24 and the mutated
3C protease was made, which we designate Ad5-FMDV-T. This
construct was predicted to provide enhanced stimulation of a
CTL response based on previous work that demonstrated a
lack of antibody response to a similar construct made for
FMDV strain A12 (31).
To demonstrate the reduced activity of 3C in this new con-
struct, IBRS2 cells were infected with Ad5-FMDV-B, Ad5-
FMDV-T, Ad5-Empty, or FMDV strain A24. Cell lysates were
analyzed by SDS-PAGE followed by Western blotting. We
detected the presence of P1 cleavage products VP0, VP3, and
VP1 in the lysates of cells infected with either FMDV or
Ad5-FMDV-B, with little or no P1 precursor (Fig. 1). In con-
trast, cells infected with Ad5-FMDV-T showed a significant
decrease in the presence of VP0, VP3, and VP1, with signifi-
cantly more unprocessed P1 (Fig. 1), suggesting a reduction of
3Cpro activity and consequent accumulation of P1.
Sera from pigs vaccinated and boosted with Ad5-FMDV-B
and Ad5-FMDV-T were tested for FMDV neutralizing anti-
bodies as described in Materials and Methods. All three pigs
vaccinated with Ad5-FMDV-B generated neutralizing antibod-
ies following priming, with elevated titers following two rounds
of boosting (Fig. 2). In contrast, of the three pigs vaccinated
with Ad5-FMDV-T, only p945 generated detectable neutraliz-
ing antibodies following priming. Both p945 and p947 had
serum neutralizing antibodies following boost, with the titer for
p947 remaining relatively low. Neutralizing antibodies were
FIG. 1. Reduced capsid processing of Ad5-FMDV-T. IBRS2 cells
were infected with the indicated virus as described in Materials and
Methods. Following infection, cell lysates were made and proteins
were separated by SDS-PAGE and visualized by Western blotting
using either MAbs against VP2 (visualized as the VP0 precursor) and
VP1 (left) or a mix of rabbit polyclonal antibodies against FMDV
capsid proteins (right).
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never detected in serum from p925 or from the PBS negative
control, p863. These data suggest that Ad5-FMDV-T is less
effective than Ad5-FMDV-B at eliciting neutralizing antibod-
ies, presumably due to less efficient processing of P1 by 3Cpro.
Establishment of an FMDV CTL assay. The animals vacci-
nated with either Ad5-FMDV-T, Ad5-FMDV-B, or PBS were
boosted 12 weeks postvaccination and analyzed. PBMCs were
collected 24 days postboost and stimulated for 5 days in the
presence of PK(15) cells infected with Ad5-FMDV-T and then
tested for cytolytic activity against target cells that were either
mock infected or infected with Ad5-FMDV-T. Consistent with
our hypothesis, we observed the greatest antigen-specific cytolysis
by cells derived from pigs vaccinated with Ad5-FMDV-T (Fig. 3).
Due to low effector cell numbers, we were unable to evaluate
the response against mock-infected cells for p864 and p925,
and thus we omitted data from these two animals from Fig. 3.
In spite of the observed elevation of antigen-specific cytolysis,
with the exception of p945 we observed poor titration of target
cell killing across several effector-to-target-cell (E:T) ratios
(data not shown). A similar lack of titration of cytolysis by bulk
PBMCs was previously observed by Denyer and coworkers,
who demonstrated that purification of CD6 cells by positive
selection prior to incubating with target cells resulted in titra-
tion of cytolytic activity across E:T ratios (11).
Based on this information, we enriched for CD6 cells fol-
lowing antigen stimulation in all further experiments, as de-
scribed in Materials and Methods. PBMCs isolated from pigs
vaccinated with Ad5-FMDV-T and enriched for CD6 expres-
sion exhibited enhanced cytolysis of Ad5-FMDV-T-infected
target cells that titrated across E:T ratios, compared to mock
or Ad5-Empty-infected cells (Fig. 4). The level of killing de-
tected by this refined assay was slightly reduced, likely due to
the elimination of NK cells from the responding population.
The animal vaccinated with PBS showed no specific killing (see
Fig. S1 in the supplemental material). In subsequent figures,
we show the data for the 50:1 E:T ratio only, with the cytolysis
of Ad5-Empty-infected cells subtracted from each group,
though all four E:T ratios were always run. Finally, with this
new assay, we tested the kinetics of the expansion culture over
the course of 5 days and found that the highest level of killing,
FIG. 2. Reduced neutralizing antibodies in Ad5-FMDV-T-vacci-
nated animals. Serum samples from pigs vaccinated with PBS, Ad5-
FMDV-B, or Ad5-FMDV-T were collected before and following prim-
ing and boosting (solid bars, prevaccination; open bars, preboost;
striped bars, pre-second boost; shaded bars, final). Serum neutralizing
titers (SNT) were determined as described in Materials and Methods.
Final serum was collected 26 days or more postboost.
FIG. 3. Elevated CTL activity in Ad5-FMDV-T-vaccinated ani-
mals. PBMCs were isolated from vaccinated animals, stimulated in the
presence of Ad5-FMDV-T-infected PK(15) cells for 5 days, and then
assayed for cytolytic activity against Ad5-FMDV-T-infected or mock-
infected target cells, as described in Materials and Methods. The mean
and standard deviation of results for duplicate wells of an E:T ratio of
50:1 are shown.
FIG. 4. Titration of CD6 CTL activity. PBMCs isolated from pigs
vaccinated with Ad5-FMDV-T (}, p925; f, p945; ●, p947) were stim-
ulated with Ad5-FMDV-T-infected cells for 3 days and then enriched
for CD6 surface expression. Effector and target cells were mixed at E:T
ratios of 50:1, 25:1, 12:1, and 6:1. Cytolysis of target cells was measured
by flow cytometry with target cells mock infected or infected with
Ad5-Empty or Ad5-FMDV-T. All error bars represent the standard
deviation of results for duplicate wells.
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with minimum background, was detected on day 3 (data not
shown), so all expansion cultures were done for 3 days.
Specificity of CTL cytolytic activity for FMDV P1. The de-
velopment of this CTL assay was achieved with these vacci-
nated and boosted animals such that by 9 months following the
first boost, antigen-specific cytolysis was difficult to detect, sug-
gesting a waning of CTL immunity. Therefore, all pigs were
boosted a second time with the vaccinating virus construct
(p864 to p866 with Ad5-FMDV-B and p925, p945, and p947
with Ad5-FMDV-T) and activation of CTL killing was tracked
using the assay.
In order to test the ability of the different adenovirus constructs
to stimulate CTLs, PBMCs isolated from pigs 4 days after boost-
ing with Ad5-FMDV-B were stimulated with cells infected with
either Ad5-FMDV-B or Ad5-FMDV-T. Following enrichment
for CD6 cells, the effector cells were mixed with target cells
infected with either Ad5-FMDV-B, Ad5-FMDV-T, Ad5-Empty,
or Ad5-VSV-G or mock infected. Ad5-VSV-G contains the gene
for glycoprotein G of vesicular stomatitis virus, strain New Jersey
(VSV-NJ), and served as a negative-control antigen. CD6
cells stimulated with Ad5-FMDV-B, compared to those stim-
ulated with Ad5-FMDV-T, appeared to show less overall tar-
get cell killing, but there was no statistical difference between
these groups (Fig. 5). Specificity for FMDV P1 was shown by
little or no cytolysis of target cells infected with Ad5-VSV-G or
mock infected (Fig. 5), eliminating the possibility that expres-
sion of any adenovirus-delivered transgene may contribute to
cell lysis independent of antigen specificity.
Vaccine targeting T cells induces an enhanced CTL re-
sponse. Following the second boost of animals, PBMCs were
obtained on days 4, 8, 14, and 28 and CTL killing activity for
each pig was assayed. Antigen-specific cytolysis remained low
throughout the experiment in animals vaccinated with the
Ad5-FMDV-B construct. In Fig. 6, a small rise in antigen-
specific killing on day 4 after the second boost is apparent. Low
CTL lysis was observed when analyzing cells taken the day of
the boost or 8 and 14 days following the boost. These data
suggest that Ad5-FMDV-B is a poor inducer of CTLs. Data
from all time points are shown relative to Ad5-Empty, except
for data for day 14, which are shown relative to Ad5-VSV-G
because small numbers of effector cells isolated necessitated
omitting mock and Ad5-Empty target groups.
PBMCs from pigs boosted with Ad5-FMDV-T and stimu-
lated ex vivo with Ad5-FMDV-T-infected cells were tested for
lysis of target cells infected with Ad5-FMDV-T, Ad5-Empty,
or mock infected. In contrast to cells from the Ad5-FMDV-B-
vaccinated animals, here we observed increased levels of anti-
gen-specific cytolysis 4 days following the boost that waned to
preboost levels by day 14 or 28 (Fig. 6). In all three animals, a
high level of specific killing of PK(15) cells infected with the
Ad5-FMDV-T construct was observed. Pig 925 had little killing
activity 8 days after vaccine boost but good activity (equivalent
to the day 4 result) when assayed 14 days after boost. This may
indicate a technical problem with that day’s sample from that
animal (day 8, p925). As shown above, this animal (p925)
showed no detectable neutralizing antibody either (Fig. 2).
With that exception, the Ad5-FMDV-T-vaccinated animals
had higher levels of target cell killing than the Ad5-FMDV-B-
vaccinated animals through 14 days following the boost.
Animals vaccinated and boosted with Ad5-FMDV-T showed
elevated mean killing of Ad5-FMDV-T-infected target cells
compared to that of those vaccinated and boosted with Ad5-
FMDV-B when cells isolated 4 days after the respective final
boost were analyzed. This enhanced killing was statistically
significant (P  0.05; Fig. 7). As described above, the animal
that was given PBS as a negative control never showed antigen-
specific killing of target cells (see Fig. S1 in the supplemental
material).
CTL cytolytic activity correlates with staining by an FMDV
peptide-SLA-1 tetramer. In order to further characterize the
effector cells, we developed pMHC tetramers for the SLA-1
molecule expressed by these animals, SLA-1*0401. The MHC
class I peptide binding prediction algorithm NetMHCpan has
previously been demonstrated to accurately capture the bind-
ing specificity of SLA class I molecules (25). Using this pre-
diction method, we identified a peptide (MTAHITVPY) de-
rived from the P1 capsid precursor of FMDV strain A24 that
binds SLA-1*0401 at a low Kd (dissociation constant) (L. E.
Pedersen, M. N. Harndahl, K. Lamberth, W. T. Golde, O.
Lund, M. Nielsen, and S. Buus, unpublished data). As a neg-
ative control, a second SLA-1 tetramer was used that con-
tained a peptide (ATAAATEAY) derived from the Ebola
virus VP35 protein, which also binds to SLA-1*0401. For the
experiments associated with the second boost (Fig. 6), a por-
tion of the PBMCs isolated for evaluation of CTL killing were
set aside for SLA-1 tetramer staining.
Cells were stained with antibodies specific for CD4 and CD8
and with the tetramers. Analysis by flow cytometry was carried
out by gating on the CD4	/CD8 cell population and deter-
mining the percentage of tetramer-positive (tetramer) cells
(see Fig. S2 in the supplemental material). For pigs vaccinated
with Ad5-FMDV-B, little tetramer staining was detected from
samples taken 4 days following the second boost (Fig. 8) or
thereafter (data not shown). This result correlated with low
levels of cytolytic activity from the same samples (Fig. 6). In
contrast, pigs vaccinated with Ad5-FMDV-T had a 2- to 3-fold
FIG. 5. Differential antigen stimulation. PBMCs from Ad5-FMDV-
B-vaccinated pigs were isolated 4 days postboost and stimulated for 3 days
with PK(15) cells infected with either Ad5-FMDV-T or Ad5-FMDV-B.
Following CD6 purification, effector cells were assayed for cytolysis of
target cells infected with Ad5-FMDV-T (solid bars), Ad5-FMDV-B
(open bars), or Ad5-VSV-G (shaded bars) or mock-infected (striped bars)
cells. Data are shown relative to Ad5-Empty. The mean and standard
deviation of results for triplicate wells are indicated.
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increase, compared to preboost levels, in tetramer staining
of the CD8 population isolated 4 days following the second
boost (Fig. 8). Increased tetramer staining was correlated
with peak cytolysis (compare Fig. 6 and Fig. 8) and was no
longer detectable by 8 days after the boost. These data show
that FMDV peptide MTAHITVPY is presented by SLA-
1*0401 molecules in vivo and serve as confirmation of the
presence of anti-FMDV, MHC-restricted CTLs.
A number of other peptides from the viral capsid precursor
protein, P1, were also shown to bind the SLA-1 MHC class I
protein. In addition, more peptides were identified that bind
SLA-2 of these Yucatan pigs (SLA-2*040201) (L. E. Pedersen,
M. Harndahl, M. Nielsen, J. R. Patch, G. Jungersen, S. Buus, and
W. T. Golde, unpublished data). We also prepared tetramers
from these combinations and tested them on CD8 T cells from
the vaccinated pigs in this study. All of these tetramers were
negative for staining cells taken 4 days after boost and all other
time points tested. Only the SLA-1*0401/MTAHITVPY tet-
ramer stained cells from the Ad5-FMDV-T vaccinated animals.
DISCUSSION
In the present study, we tested the ability of two nonrepli-
cating adenovirus vectors to generate a CTL cytolytic response
FIG. 7. CD6 CTL activity generated by Ad5-FMDV-T vaccina-
tion. Mean CTL cytolysis activity on day 4 following final boost of pigs
vaccinated with Ad5-FMDV-B or Ad5-FMDV-T was determined after
subtracting percentage of lysis of the highest negative-control target
cell group from that of Ad5-FMDV-T target cells for each individual
pig. Error bars represent the standard deviations (n 
 3), and the
asterisk indicates statistical significance (P 0.05) as determined by an
unpaired, one-tailed Student’s t test with unequal variances.
FIG. 6. CD6 CTL activity generated following second boost. PBMCs from Ad5-FMDV-B (p864, p865, and p866)- or Ad5-FMDV-T (p925,
p945 and p947)-vaccinated pigs were isolated before and following boosting and treated as described in the legend to Fig. 5, except that only data
from Ad5-FMDV-T secondary antigen stimulation are shown. Target cells: }, Ad5-FMDV-T; f, mock. Additionally, pigs 864, 865, and 866 were
tested on target cells: Œ, Ad5-FMDV-B; ●, Ad5-VSV-G. Data from all time points are shown relative to Ad5-Empty. Error bars represent the
standard deviation of results for duplicate wells.
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in swine to FMDV epitopes. The ability of this vaccine plat-
form to induce the production of neutralizing antibodies to
empty FMDV capsids in both swine (30, 31, 35, 43) and cattle
(39) is well established. However, its ability to stimulate an
antigen-specific CTL response has not been addressed. We
hypothesized that the parental adenovirus-based empty capsid
vaccine would provide relatively poor stimulation of CTLs
because of the efficiency of capsid processing and formation.
We reasoned that inhibited processing of FMDV P1 would
enhance CTL activation, presumably as a result of enhanced
degradation of P1 and subsequent loading of peptides onto
class I MHC molecules. Swine were vaccinated with a T cell-
directed adenovirus-based vaccine for FMDV (Ad5-FMDV-
T), which contained a mutant 3Cpro that processes P1 poorly.
The decreased processing of P1 by Ad5-FMDV-T was evident
in Western blot analysis, as well as in the titers of virus-neu-
tralizing antibodies in serum.
Whole PBMCs isolated from vaccinated animals demon-
strated cytolytic activity against appropriate target cells. How-
ever, enriching for CD6 cells before mixing the effector and
target cells improved the analysis of CTL activity. These results
are in agreement with those of Denyer and coworkers, who
demonstrated improved titration of antigen-specific, MHC-
restricted cytolysis by enriching for the CD6 population of
swine T cells (11). The CD6 cell population has been char-
acterized as consisting of MHC-restricted CTLs and helper T
cells, including CD4/CD8	, CD4	/CD8, and CD4/CD8
populations (8, 11, 41, 42, 49). Thus, an additional advantage
of positively selecting for CD6 cells is the elimination of
non-MHC-restricted cytolytic cells such as NK cells and  T
cells, which do not express CD6 (44).
The MHC restriction of this CTL response was strongly
supported by SLA-1 tetramer staining of cells derived from
these animals. When peripheral blood cells derived from pigs
vaccinated with Ad5-FMDV-T were analyzed, an increase in
tetramer/CD4	/CD8 cells was detected. The increase in
tetramer-positive cells correlated with the peak of cytolytic
activity, consistent with MHC-restricted cytolytic activity. We
also noted that for pigs vaccinated with Ad5-FMDV-T, the
relative tetramer staining of samples taken 4 days after the
second boost correlates with the relative level of CTL killing
activity. However, given the small number of animals in the
group, this correlation is not statistically significant.
The enhanced cytolysis and tetramer staining of cells derived
from pigs vaccinated with Ad5-FMDV-T relative to those vac-
cinated with Ad5-FMDV-B are supportive of our hypothesis
that decreased capsid processing enhances CTL activity. How-
ever, it is possible that the precursor and mature capsid pro-
teins are cleaved differently by the proteasome, resulting in a
lack of MTAHITVPY peptides displayed in MHC molecules
of the Ad5-FMDV-B-infected cells. This could explain why few
tetramer-positive cells were detected in animals vaccinated with
Ad5-FMDV-B. At minimum, this peptide from the C-terminal
half of the VP2 region of P1 is not near the cleavage site at the
FIG. 8. Tetramer staining of CD4	/CD8 CTLs. For time points shown in Fig. 6, PBMCs were stained with antibodies against CD4 and CD8
and costained with SLA-1*0401 tetramers bound to either an FMDV (red) or Ebola virus (blue) peptide. Histograms of tetramer-positive CTLs
from Ad5-FMDV-B (A)- or Ad5-FMDV-T (B)-vaccinated animals are shown. Numbers indicate percent FMDV tetramer-positive cells from the
CD8, CD4	 gate and were calculated by subtracting the percentage of cells stained with the negative-control tetramer.
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junction of VP2 and VP3. Differential tetramer staining can-
not, therefore, be attributed to a loss of this peptide due to
precursor cleavage by 3Cpro.
Although CTLs play a central role in the adaptive immune
response to intracellular antigens, their role in FMDV immu-
nity has received little attention, in part because of the tech-
nical difficulties in establishing appropriate assays with which
to measure their activity. In addition to the requirement for
genetic matching of MHC class I alleles between effector and
target cells, the cytopathic nature of FMDV has hampered
development of a cytolytic assay. As a consequence, investiga-
tors have measured other biological properties of CD8 cells,
such as proliferation (6, 26, 47, 50) or IFN- secretion (22), as
proxies for CTL killing activity. The present report describes
an alternative strategy for directly assessing CTL killing in
response to FMDV antigens and relies on recombinant expres-
sion of FMDV proteins. In an earlier report, Li and coworkers
described vaccination of swine with an attenuated pseudora-
bies virus containing a gene for the FMDV P1 capsid precursor
that was effective at generating CTL killing activity (29). How-
ever, these investigators did not address MHC restriction,
characterization of the cells responsible for killing, or antigen
specificity of the reported CTL activity. In contrast, we now
present data describing the first description of using MHC
tetramers to identify antigen-specific CTLs in swine in general
and the first time that anti-FMDV CTL killing in any livestock
species has been correlated with tetramer staining.
Whether CTLs can play a significant role in FMDV protec-
tion and vaccination strategies remains to be determined. Pre-
vious work in swine found that a complete lack of capsid
processing resulted in a failure to generate neutralizing anti-
bodies, and challenged animals developed clinical signs com-
parable to those of unvaccinated animals (30, 31). However,
the dose of vaccine used was more than a log lower than the
dose used here. Reports using higher doses of a P1-based
vaccine in swine resulted in partial protection in the absence of
FMDV-specific antibodies (50). Similar results were obtained
in cattle by the same investigators (52).
In vitro, FMDV inhibition of MHC class I surface expression
begins in as little as 30 min postinfection (51). Thus, even
under ideal conditions where anti-FMDV CTLs are primed
and expanded, control of infection by CTLs depends on host
cells infected by wild-type virus in vivo processing and display-
ing FMDV peptides leading to the CTL response before inhi-
bition of new MHC class I protein expression is blocked by
viral proteases. Although neutralizing antibodies are likely to
remain the principal focus of FMDV vaccination, CTLs may be
able to contribute to cross-serotype and subtype immunity be-
cause potential T cell epitopes are not limited to the structural
proteins, where most of the immune-driven diversity is located
(4). Whereas antibody epitopes are large and three dimen-
sional, the T cell epitopes are linear and extremely small (8 to
12 amino acids) and have the potential to be highly conserved
over the different serotypes of FMDV. Further work directed
toward refining the induction and measuring of the CTL re-
sponse, as well as evaluating protection from challenge, is
needed to determine if induction of CTL immunity can yield
protection across serotypes in diverse breeds of pigs and other
species of interest, especially cattle.
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7. SLA Tetramers 
 
The identification of peptides strongly bound by SLA molecules, and producing stable pSLA 
complexes, was performed in regard to (i) achieving knowledge about the individual SLA 
binding profiles, and (ii) producing stable pSLA complex based tetramers for staining of porcine 
PBMCs. 
 
7.1. FMDV TETRAMER STAINING 
pSLA tetramer studies were performed at PIADC as part of this PhD project using FMDV derived 
peptides, followed by staining of PBMCs isolated from six animals previously vaccinated and 
boosted against FMDV. These studies resulted in the identification of an FMDV T cell epitope 
(Figure 13). General results and findings of the overall study are fully discussed in Paper IV, and 
presents the first demonstration of FMDV-specific CTL killing of infected porcine kidney (PK15) 
cells with confirmation by SLA allele matched tetramer staining.  
My primary focus will be on the tetramer part of the studies presented in Paper IV, in that it 
constitutes a general section of the overall PhD project. Hence, the killing analysis and results 
are only briefly discussed.  
 
To date the role of CTLs in FMDV immunity has gone largely unexplored partly due to the role 
of neutralizing Abs been proven dominating in the establishment of protection against the virus 
as described above. Furthermore, the ability of the virus to inhibit MHC synthesis and transport 
to the surface has previously been described in vitro (Sanz-Parra et al. 1998). The inhibited MHC 
synthesis and transport combined with the virus-induced lymphopenia, predict FMDV-specific 
CTLs to play a minor role in clearing natural FMDV infection, if the MHC class I expression is as 
well obstructed in vivo. Further complicating the analysis of specific CTLs and their role during 
FMDV infection is that FMDV infected cells are rapidly lysed in vitro, and hence cannot be used 
as targets in assays for antigen-specific cell lysis.  
We developed an assay using available strains of pigs homozygous for SLA-1*0401, -2*0401, 
and -3*0401. Further, the porcine fibroblast cell line, PK15, cells are a genetic match to the SLA 
class I genes expressed in these pigs and thus are appropriate targets for the in vitro killing 
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assay. Using the replication defective Ad5 virus vector expressing FMDV P1 protein, we were 
able to infect PK15 target cells without lysis and thus test CTLs from vaccinated, MHC matched 
pigs for killing of the infected PK15 cells. A vaccine construct containing a mutation in the 
protease 3Cpro (Ad5-FMDV-T) enabled us to test a hypothesis that an increase in the 
intracellular pool of FMDV proteins available for degradation and loading of FMDV-derived 
peptides into SLA class I molecules would enhance stimulation of FMDV peptide specific CTLs. 
To confirm that the observed CTL induced killing was antigen specific, and MHC restricted, 
FMDV pSLA complex based tetramers were produced and used to stain PBMCs isolated from 
the vaccinated animals at identical time points post vaccine boost as for the PBMCs used to kill 
infected PK15 targets. A comparison of animals vaccinated using the Ad5-FMDV-T vaccine with 
animals vaccinated with a 3Cpro intact vaccine (Ad5-FMDV-B) was performed, to verify the 
hypothesis of enhanced CTL stimulation due to inactive 3Cpro (Figure 13 A versus B, Day 4).  
 
 
Figure 13. Tetramer staining of CD8
+
CD4
-
 PBMCs using two tetramers produced with either an FMDV (red) or Ebola 
(blue) virus-derived peptide. Histograms of tetramer stained CD8
+
CD4
-
 PBMCs from Ad5-FMDV-B (A) or Ad5-
FMDV-T (B) –vaccinated animals are shown. Numbers indicate the individual percentage FMDV tetramer positive 
cells within the CD8
+
CD4
-
 population of PBMCs after subtracting the percentage of cells stained with the negative-
control Ebola-tetramer. The figure shows responses for three Ad5-FMDV-B vaccinated pigs (p864, 865, 866) and 
three Ad5-FMDV-T vaccinated pigs (p925, 945, 947). The figure is taken from Paper IV of this thesis. 
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As illustrated in Figure 13, animals vaccinated with the Ad5-FMDV-T construct stained clearly 
positive with tetramer at day 4 post vaccine boost (Figure 13B), whereas the Ad5-FMDV-B 
vaccinated animals showed no staining for samples taken at the same time point (Figure 13A). 
Similar staining was seen for the Ad5-FMDV-B vaccinated group of animals pre-boost and on 
day 8 (not shown). These data confirm the hypothesis stated above and classifies the Ad5-
FMDV-T construct as a CTL inducing vaccination approach against FMDV, and identify the FMDV 
derived peptide of the positive tetramer (MTAHITVPY) as a CTL epitope capable of being 
recognized by a significant number of activated CTLs within the CD8+CD4- population (ranging 
from 5.63 – 20.42 % between different animals). An increase in tetramer staining in the scale of 
2- to 3-fold was seen for Ad5-FMDV-T vaccinated animals on day 4 post boost as compared to 
pre-boost levels (Figure 13B) and correlated with peak cytolysis of adenovirus infected PK15 
target cells observed at day 4 post boost (Figure 6, Paper IV). In a previous study performed in 
cattle, it was found that bovine leukocyte antigen (BoLA) class II tetramers (DRB3*1201-P16-7) 
positively stained between 10 and 15.5 % of bovine CD4+ T cells derived from cattle previously 
immunized once (Norimine et al. 2006). Instead of boosting their animals with antigen, 
Norimine et al. used in vitro stimulation of positively selected CD4+ lymphocytes for one week 
with peptide P16-7 to achieve proliferation of the peptide specific cell population. We observed 
a decrease in cytolysis and absence of positive tetramer staining at day 8 post boost (Figure 13B 
and Paper IV, Figure 6), which might be an indication of the dose and duration of the Ad5 
antigen expression not being efficient enough to create a durable response for longer periods 
without further boosting. A certain level of pre-boost staining was observed for p945 and p947 
(Figure 13B) which was likely due to previous vaccination of the animals followed by a primary 
boost 12 weeks post vaccination. The tetramer staining presented in Figure 13 was performed 
following a second boost at 11 (FMDV-T) and 13 (FMDV-B) months post vaccination. Altogether 
these data serve as confirmation of the presence of anti-FMDV, SLA-restricted CTLs and 
illustrate the ability of the methods, developed in this project to fit the porcine model, in the 
identification of CTL epitopes and monitoring of immune responses induced by vaccination.  
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7.2. INFLUENZA TETRAMER STAINING 
Approaching the end of the PhD project, having established in-house SLA molecules with 
several identified high affinity peptide binders derived from Influenza along with the tools 
available to specifically monitor activated porcine CTLs, I got the opportunity to get fresh blood 
samples from 20 animals which were part of another project. These animals had been 
immunized five times against swine influenza A with three week intervals. Unfortunately, once I 
got knowledge about their existence they had just received their fifth and final immunization 
and faced elimination. Hence I only had one chance to try and identify any influenza epitopes. 
The animals had received chemically (C3H4O2) inactivated TCID50/ml doses between 2.32 x 10
5 
and 2.32 x 107 of various swine influenza A strains divided into different groups of pigs and 
delivered intramuscularly in the ratio of 1:1 in Freunds Incomplete adjuvant (Table 2). Blood 
samples were collected from all 20 pigs and each of them was SLA allele typed using the PCR-
SSP typing method and custom SLA class I designed high resolution primers. Of the 20 animals 
typed, 16 turned out to express the allele of interest (SLA-1*0401) for which we had previously 
identified four influenza peptides, CTELKLSDY, GTEKLTITY, SSSFSFGGF, and YVFVGTSRY, bound 
with high affinities. These influenza peptides were predicted to be bound by NetMHCpan in 
conjunction with the SLA-1*0401 binding matrix criteria, and identified as strongly bound 
peptides by in vitro analysis in the same way as described for the FMDV derived peptides 
presented in Paper II.  
 
 
Table 2. Comparison of influenza peptide sequences within the different strains used for immunizations. Only 
animals with cells found to positively stain with tetramer are shown (pigs 1, 2, 4, 6, 8 and 16) along with pig 17 
which represents the 10 non-responding animals. (+) Peptide sequence present in the viral strain used for 
immunization. (*) Position relative to start codon in virus A/swine/Denmark/12687/2003 (Breum 2012). (†) 
Reassortant swine influenza virus encoding a different N2 gene (Breum 2012). (‡) Reassortant influenza virus strain 
Tetramer peptides and positions Immunization strains 1 - 6
in Influenza viral genome 1 2 3 4 5 6
Peptide
Viral protein
of origin
AA position* 
in virus
Nucleotide 
position* in
virus
A/swine/Den
mark/101310-
1/2011 
(H1N1pdm09)
A/swine/Den
mark/101568-
1/2011 
(H1pdm09†)
A/swine/Den
mark/19126/
1993 (H1N1)
A/swine/Den
mark/101490-
3/2011 
(H1N1)
A/swine/Den
mark/1037-
2/2011 
(H1N2†)
A/swine/Den
mark/101116-
3/2011 
(H1N2‡)
CTELKLSDY NP 44 - 52 130-156  +  + CTELQLSDY CTELQLSDY CTELQLSDY  +
GTEKLTITY PB2 523 - 531 1567-1593  +  +  +  +  +  +
SSSFSFGGF PB2 320 - 328 958-984  +  +  +  +  +  +
YVFVGTSRY HA 215 - 223 643-669  +  +  YVSVESSKY  YVSVVSSKY  YVSVVSSKY  YVSVGSSKY
Animal ID for pigs immunized by the respective viral strains 1 - 6
1 + 2 4 6 8 15 + 16 17
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with NP gene from H1N1pdm09 virus (Breum 2012). Amino acids in bold (grey), mark substitutions in the peptide 
sequence coded for in the immunization strain as compared to the peptide used for tetramer production. 
 
PBMCs isolated from the 16 animals positive for SLA-1*0401 were initially frozen and later 
analyzed by influenza pSLA-1*0401 complex based tetramer staining using four different 
influenza peptides and two different fluorochrome tetramer labels (allophycocyanin (APC) and 
brilliant violet (BV421)), which enable the identification of tetramer double positive cell 
populations as illustrated in Figure 14A (Pig 4, (GTEKLTITY)). A negative control peptide 
(ASYGAGAGY) was included for comparison. The experimental setup for these immunizations 
was designed for other purposes than tetramer staining, which left us with no non-vaccinated 
or SLA mismatched pigs as negative controls. Hence, I decided to use a human PBMC sample 
stained with tetramers as an additional negative control. Such a control has to be included with 
caution in that it is not a definite negative control. Still, it is capable of proving that the 
tetramers we use are not just staining whatever cells they are offered regardless of their 
species of origin. 
 
Of the 16 correctly SLA matched animals it was found that six pigs (Pig 1, 2, 4, 6, 8, and 16) 
displayed positive signals above background for one or more of the influenza tetramers in the 
staining assay (Table 3). A study examining influenza virus specific CD8+ T cell responses in 
Macaques has recently been performed using macaque MHC class I, Mane-A1*08401, 
tetramers produced with an influenza epitope; RA9 (Jegaskanda et al. 2012). In this study 
animals were infected intranasal and intratracheal at day 0 and day 28, followed by 
administration of a third infection dose 2 to 10 months later using recombinant influenza virus. 
PBMCs were collected from blood and frozen. The results of these experiments showed distinct 
staining of thawed RA9-specific CD8+ T cells by 0.14 % of the CD8+ T cell population compared 
to 0.02 % negative control staining of an influenza naïve Mane-A1*08401-RA9 negative animal, 
corresponding to a 7-fold increase in tetramer staining signal between positive and negative 
samples.  
From our studies, tetramer cell staining examples of double positively stained (SLA matched, 
responding animal 4), no staining (SLA matched, non-responding animal 17) and additional 
negative control staining of human PBMCs with SLA tetramers (SLA mismatched, non-
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responding human) are shown in Figure 14 for one swine influenza A peptide (GTEKLTITY) and 
the negative control peptide (ASYGAGAGY). Here illustrating a 5.4-fold increase in tetramer 
staining signal between positive and negative samples (Figure 14A). A 32.5-fold increase in 
positive tetramer staining was seen for PBMCs derived from pig 4 and stained with the 
influenza tetramer (GTEKLTITY) compared with the same tetramer staining of completely 
mismatched human PBMCs (Figure 14A + C). Comparing the influenza-tetramer data for the six 
pigs with those of the macaque study performed by Jegaskanda et al., it is demonstrated that 
our positive tetramer staining percentages are generally 11 to 46-folds higher, but with similar 
ratios to the negative control samples, and with some variation between different animals and 
peptides. These tetramer staining percentages are generally higher than previously observed 
for fresh ex vivo staining of CD8+ PBMCs responding to vaccination against (or infection with) 
yellow fever (Co et al. 2009) in humans, M. tuberculosis (Wei et al. 2009) in macaque monkeys, 
and hepatitis C (He et al. 1999) in humans, and could be due to a higher degree of auto-
fluorescent cells when studying porcine PBMCs or as a result of a higher level of non-specific, 
false positive tetramer background staining using SLA tetramers. Most of the responses 
reported in humans and macaques were shown to increase in tetramer positive percentage 
scores once stimulated with antigen, hereby reaching numbers around (or above) what is 
reported here for staining of porcine PBMCs. 
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Pig 4 (ASYGAGAGY)
Tetramer BV-A
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C
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a
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r
A
P
C
-A1.2 % 6.5 %
Influenza A peptide
Pig 4 (GTEKLTITY)
A
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Figure 14. Tetramer staining of PBMCs. (A + B): PBMCs from animals previously vaccinated and boosted against 
swine influenza A. (C): Human PBMCs. Individual samples were stained by a negative control peptide (ASYGAGAGY) 
tetramer and a swine influenza A derived peptide (GTEKLTITY) tetramer. Singlet PBMCs were gated in P1 (blue). 
CD8
+
(high)CD4
-
 cells were gated in P2 (orange), and CD8
+
(high)CD4
-
APC
+
BV
+
 double tetramer positive cells were 
gated in P3 (green) for Pig 4 and Pig 17 (A + B). For the human control samples, singlet PBMCs were gated in P1 
(blue), CD8
+
(high) cells were gated in P2 (orange) and CD8
+
(high)BV
+
 tetramer single positive cells were gated in P3 
(green) (C). Percentages of tetramer positive cells within the CD8
+
(high)CD4
-
 population are shown for each sample 
in the figure. Individual staining percentages for all animals and tetramers are given in Table 3. 
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C
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The influenza tetramer studies presented here revealed four influenza derived peptide epitopes 
(CTELKLSDY, GTEKLTITY, SSSFSFGGF, YVFVGTSRY) which were recognized in complex with the 
SLA-1*0401 molecule by porcine CTLs activated by immunization against swine influenza as 
illustrated in Figure 15 for Pig 4. Not all animals were responsive towards every influenza 
tetramer as positive staining was only seen for one of the four tetramers for pigs 1 and 2 (Table 
3) using a threshold of 1 % positive staining of the CD8hi+ PBMC population post negative 
background subtraction, which corresponds to a 2-fold higher staining percentage than 
measured for the negative control tetramer stained cells. Such a 2-fold higher threshold has 
previously been set by others (Ferrari et al. 2004). Furthermore, it was found that 10 of the 16 
animals did not stain positive with any of the tetramers, as illustrated by Pig 17 (Figure 14B + 
15, and Table 3), despite being correctly SLA matched. Such non-responsiveness illustrates how 
SLA bound peptides are not necessarily recognized as epitopes in all animals. Similar 
observations have previously been made for HLA tetramers and yellow fever peptides as well 
(Stryhn 2012). Collectively, the differences in individual peptide responses of animals with 
identical SLA alleles indicate that the SLA-1*0401 tetramers were not just staining any activated 
CTL derived from a correctly matched animal, but only CTLs with the right specificity, and that 
although peptide binding to the SLA molecule may be predicted and verified in advance, this is 
no guarantee for development of a CTL specific immune response to this particular peptide. 
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Figure 15. Percentages of tetramer positive cells within the CD8
+
(high)CD4
-
 population stained by each of the four 
influenza tetramers. Cell populations and individual percentages are shown in Figure 14 and Table 3, respectively. 
All four influenza tetramer peptides tested, along with the negative control tetramer (ASYGAGAGY), are shown 
(black and grey bars, respectively). 
 
An interesting observation was made for Pigs 6, 8 and 16 which had all received viral 
immunization strains that differ in the NP and HA protein regions coding for two of the peptide 
sequences used to produce the tetramers (Table 2). The peptide CTELKLSDY had a single 
substitution in P5 of the peptide (K48Q) compared to the viral strains used for immunization of 
animals 6, 8 and 16, whereas peptide YVFVGTSRY had up to four substitutions (F217S, G219E, 
T220S, R222K) for peptide residues P3, P5, P6, and P8. Still, positive tetramer staining of CTLs 
was seen for all three pigs using these peptides. Such observations could be explained by CTL 
cross-reactivity suggesting that CTL clones can recognize different peptides, some even sharing 
no obvious sequence identity (Frankild et al. 2008). In addition to this, looking at the nature of 
the AAs involved in the substitutions could explain why the CTELKLSDY based tetramers were 
recognized by the porcine CTLs in that lysine (K) features a basic, positively charged -NH3
+ side 
chain and glutamine (Q) features a neutral amide -CONH2 side chain, making both AAs 
hydrophilic and capable of protrude toward the solvent. From a peptide:SLA-1*0401 affinity 
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point of view it is also seen that both K and Q are bound with almost similar RB values of 0.4 
and 0.5, respectively (Paper I, Table 1). For the tetramers produced with the YVFVGTSRY 
peptide, the positive staining could be reasoned by similarities between the different AA 
residues responsible for the substitutions and the respective AA residues within the peptides 
derived from the viral strains. According to the SLA-1*0401 binding matrix it can be seen that 
no major differences exist between the different AA substitutions when it comes to binding 
affinity RB values, slightly favoring the viral strain derived peptide sequences (YVSVESSKY, 
YVSVVSSKY, YVSVGSSKY) for binding compared to the tetramer peptide sequence (Paper I, 
Table 1). Both phenylalanine (F) and serine (S) are being hidden within the D-pocket of the SLA-
1*0401 peptide binding groove responsible for binding residue P3, with neither of them being 
disfavored for binding according to the binding matrix (Paper I, Table 1). Hence, despite their 
overall structural diversity, it could be speculated that such substitution plays a minor role in 
the matter of tetramer staining, in that these residues are not available for recognition by the 
TCR. Furthermore, the only difference seen between threonine (T) and serine in P6 is the 
methyl group of threonine, seeing both AAs as nucleophilic and hydrophilic which makes them 
more or less alike in terms of interacting with the surroundings. For residue P8 the AAs arginine 
(R) and lysine (K) share common features in being positively charged, basic and hydrophilic 
enabling almost similar recognition, whereas the AAs in P5 truly differ in glycine (G) being small 
and hydrophobic and glutamic acid (E) is acidic and hence hydrophilic. Comparing the other P5 
substitution of (G219V) it is noteworthy that both AAs are hydrophobic, with valine (V) being 
somewhat larger in the presentation of a dimethyl group to the solvent. These P5 AA residues 
point away from the groove of the MHC enabling them to interact with the TCR of specific CTLs. 
When that is said, glycine being the smallest existing AA available might enable TCR recognition 
of the YVFVGTSRY-based tetramers, in that it is likely that the glycine P5 residue does not play a 
significant role in this particular TCR:pSLA interaction, or at least is unlikely to interfere with 
such. Nevertheless, further experiments including further negative controls such as non-
vaccinated and SLA mismatched animals, as well as pre-vaccination and pre-boost samples for 
comparison, would be needed for conclusively confirmation of the specific influenza tetramer 
staining data presented in this section.  
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Table 3. Specific staining of porcine CD8
+
(high)CD4
-
 PBMCs using four different influenza peptide-based tetramers. 
Percentages in bold illustrate positive tetramer staining based on a threshold of 1.0 % post background 
subtraction. Italic numbers illustrate no specific binding whereas grey highlights point out positive staining with 
peptides that are not 100 % identical in sequence with those of the respective vaccine constructs used. 
ASYGAGAGY is a designed negative control peptide for defining the relative false-positive background signal. 
Animal ID 17 was included as an example of a non-responding animal. ID Human: Human PBMCs included as an 
additional negative control for comparison.  
 
8. Conclusions and Perspectives 
 
Throughout this PhD project, the fully developed large-scale technology to produce, analyze, 
and validate peptide–MHC interactions, which was pioneered over three decades for mice and 
humans (Ferre et al. 2003, Harndahl et al. 2009, Ostergaard et al. 2001, Pedersen et al. 1995, 
Pig #
Tetramer 
influenza 
peptide 
Peptide present in
immunization strain used
% Tetramer+ cells 
within the
CD8+CD4- 
population
% Tetramer+ cells within
the CD8+CD4- population
(background subtracted)
ASYGAGAGY No 0,80 0,00
CTELKLSDY Yes 1,70 0,90
1 GTEKLTITY Yes 1,90 1,10
SSSFSFGGF Yes 1,70 0,90
YVFVGTSRY Yes 1,60 0,80
ASYGAGAGY No 0,60 0,00
CTELKLSDY Yes 1,70 1,10
2 GTEKLTITY Yes 1,50 0,90
SSSFSFGGF Yes 1,40 0,80
YVFVGTSRY Yes 1,50 0,90
ASYGAGAGY No 1,20 0,00
CTELKLSDY Yes 6,30 5,10
4 GTEKLTITY Yes 6,50 5,30
SSSFSFGGF Yes 3,90 2,70
YVFVGTSRY Yes 5,80 4,60
ASYGAGAGY No 2,60 0,00
CTELKLSDY No 5,80 3,20
6 GTEKLTITY Yes 5,80 3,20
SSSFSFGGF Yes 4,90 2,30
YVFVGTSRY No 5,90 3,30
ASYGAGAGY No 0,90 0,00
CTELKLSDY No 3,00 2,10
8 GTEKLTITY Yes 2,40 1,50
SSSFSFGGF Yes 1,90 1,00
YVFVGTSRY No 2,70 1,80
ASYGAGAGY No 1,10 0,00
CTELKLSDY No 2,80 1,70
16 GTEKLTITY Yes 2,50 1,40
SSSFSFGGF Yes 2,30 1,20
YVFVGTSRY No 2,70 1,60
ASYGAGAGY No 0,30 0,00
CTELKLSDY Yes 0,70 0,40
17 GTEKLTITY Yes 0,50 0,20
SSSFSFGGF Yes 0,60 0,30
YVFVGTSRY No 0,70 0,40
ASYGAGAGY - 0,20 0,00
CTELKLSDY - 0,30 0,10
Human GTEKLTITY - 0,20 0,00
SSSFSFGGF - 0,30 0,10
YVFVGTSRY - 0,30 0,10
  56 
Stryhn et al. 1996), has been applied to analysis of porcine MHC molecules. By doing so, 
instigation of knowledge on potential T cell epitopes in this particular species, has been made 
possible further allowing in silico prediction servers, that identify specific peptides for MHC 
binding, such as the NetMHCpan, also to successfully include swine (Hoof et al. 2009, Larsen et 
al. 2005, Lundegaard et al. 2011, Nielsen et al. 2007, Pedersen et al. 2011, Pedersen et al. 
2012a). Combined with the tetramer technology described in this thesis for specific T cell 
analysis this has enabled fast, accurate “one-pot, mix-and-read” analyses of MHC restricted 
CD8+ T cell reactivity following vaccination. In pigs, in silico prediction of virus derived peptides 
bound by SLA class I molecules has been verified by in vitro analysis of specific peptide binding, 
leading to the identification of strongly bound viral peptides (Pedersen et al. 2011, Pedersen et 
al. 2012a). In addition, the analysis of pSLA stability was included hereby identifying peptides, 
which were not only bound with high affinity but further produce pSLA complexes of high 
stability (Pedersen et al. 2012b). Furthermore, the effects of T cell specific vaccination have 
been investigated by monitoring CD8+ T cell responses post vaccination (Patch et al. 2011). Such 
reverse immunology proposals should be expected to become important in the contribution to, 
as well as support of, the study of livestock immune responses.  
As part of the project, SLA molecules have been produced and their peptide-binding profiles 
analyzed. All SLA alleles were initially identified by PCR-SSP allele specific tissue typing (or 
previously reported in the literature) to be commonly expressed among swine herds. Following 
these approaches, I predicted and identified several peptides which were bound with high 
affinity and generate highly stable pSLA complexes with one or more of the newly produced 
SLA proteins. This was done by using the NetMHCpan prediction tool in concert with individual 
SLA peptide binding matrix predictions, and followed by in vitro peptide affinity and stability 
measures (Hoof et al. 2009, Pedersen et al. 2011, Pedersen et al. 2012b, Pedersen et al. 2012a). 
Having identified such possible peptide epitopes led to SLA based tetramer staining 
experiments in an attempt to positively stain PBMCs from animals previously vaccinated against 
either FMDV (Patch et al. 2011) or swine influenza A. These experiments ultimately led to the 
identification of T cell epitopes as presented in this thesis (Figure 13 and 15).  
Altogether, the assays and experimental approaches presented and discussed here provide new 
tools to (i) identify commonly expressed SLA class I alleles within herds, (ii) analyze the diverse 
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peptide binding profiles of individual SLA proteins, and (iii) identify antigenic peptide ligands 
bound with high affinity and stability by such MHC molecules of interest. These results lead to 
the production of pSLA tetramers, which, when combined with cytokine release and staining 
assays, as well as measuring target cell killing, are capable of (i) providing a tool for the 
enumeration and determination of the relative frequencies of epitope-specific, cytokine-
secreting CTLs in a sample, (ii) evaluating the effector function of such CTLs, i.e. their ability to 
specifically kill infected targets and the identification of specific cytokines and chemokines 
produced, and (iii) identifying viral as well as tumor derived peptide T cell epitopes (Patch et al. 
2011, Romero et al. 1998, Romero et al. 2004).  
 
Some future perspectives and suggested ideas for new projects based on the assays, 
approaches and results presented in this thesis are illuminated in the sub sections 8.1. – 8.3.  
 
8.1. SIMULTANEOUS ANALYSIS OF MULTIPLE SPECIFICITIES 
An interesting approach for future studies would be the establishment of assays capable of 
simultaneously analyzing porcine CTLs with different specificities based on differently labeled 
pMHC complex multimers such as the systemically organized dextramers. Dextramers are 
fluorescently labeled MHC class I oligomers based on dextran backbones, which are capable of 
binding ten times more biotinylated pMHC complexes, and the conjugation of four to five times 
more fluorescein than the conventional tetramers (Batard et al. 2006). They have been shown 
to produce similar or stronger signal than their tetramer counterparts partly due to stronger 
pMHC:TCR avidity, and particularly because of the higher level of fluorescent labeling. Hence, in 
contrast to tetramers, MHC dextramers are not restricted to only the brightest fluorochromes 
for optimal detection. Such features make dextramers interesting alternatives in the 
identification and labeling of minor populations of antigen specific CTLs using higher order 
multicolor flow cytometry, and enabling the use of a broad range of fluorochrome conjugates 
including the ones that are less fluorescent (Batard et al. 2006). Using multicolor staining with 
either dextramers or tetramers would further improve the cell staining assays and approaches 
described in this thesis. Such multicolor staining could enable simultaneous identification and 
enumeration of separate cell populations specific for individual pMHC complexes even after 
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surface-marker gating. This could be done using two different pMHC multimers each with their 
own fluorochrome conjugate. In such ways, single (and dual) specificities of activated CTLs can 
be demonstrated and the cell staining assay itself validated. The scenario of having dual 
specificities expressed simultaneously by a single population of CTLs would be expected to 
require almost identical pMHC complex based tetramers or cross-reactive CTLs. Applying such 
pSLA tetramer or dextramer based multicolor staining assays to swine prove promising for 
future studies of livestock diseases, and could turn out to become valuable tools, eventually 
leading to advanced and high specific validation of the functions of existing vaccines, as well as 
accelerated development of future vaccines.  
 
8.2. SYNTHETIC IMMUNOGENIC PROTEIN (SIP) VACCINES 
By use of the different assays and techniques presented throughout this thesis, it should be 
possible to deliver a new and innovative approach for tailoring synthetic protein vaccines to 
specifically induce an efficient CTL immune response against some of the most important 
infectious diseases currently known to threat the swine production worldwide. Evaluation of 
the different approaches to induce CTL responses with currently available adjuvants would be 
facilitated by tetramer assessment of different vaccine formulations. An approach described 
for, and tested in, mice more than a decade ago (Suhrbier 1997, Thomson et al. 1998) and later 
followed up in regard to enhanced CTL responses using supporting adjuvant (Li et al. 2005), 
make it reasonable to suggest novel vaccines can be designed of a synthetic string of conserved 
sub-dominant, well-defined SLA class I CTL epitopes of viruses such as FMDV, PRRSV and swine 
influenza A virus. Furthermore, it could be suggested that such a vaccine delivered either in a 
CD8 activating adjuvant or in a live non-replicating vector, would be able to induce an efficient 
and sustained CTL response against current viral strains as well as forthcoming virus mutations. 
As described above, the recently developed SLA tetramers could be used to identify important 
peptide epitopes (such as those highly conserved among viral strains) capable of activating 
CTLs, followed by transformation of such identified peptides into a designed string of tandem 
repeated peptides in a synthetic immunogenic protein (SIP) encoded by a carefully designed 
DNA construct. Once the SIP is delivered, degraded and finally presented as peptides by antigen 
presenting cells, the porcine adaptive immune system of vaccinated animals should become 
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activated in a highly specific manner leading to generation of immunologic memory and CTL 
mediated protection against the virus represented by the SIP (Figure 16). Such SIP vaccines 
could turn out to be a novelty with the potential to revolutionize current protein and subunit-
based vaccine approaches and development. 
 
 
Figure 16. From genome to SIP vaccine to protection. 1: Selected genomic regions of the virus of interest is 
screened for peptide candidates with the ability to form complexes with SLA class I molecules using combined in 
silico NetMHCpan and PSCPL matrix predictions followed by in vitro verification. 2: Production of correctly folded 
pSLA tetramers and the identification of T cell epitope peptides capable of being recognized by cytotoxic T cells. 3: 
Design of DNA construct encoding tandem repeats of sequences encoding all identified viral epitopes. 4: 
Recombinant production of the SIP directly from the DNA construct. 5: SIP-based vaccine formulation and adjuvant 
non-vectored/vectored vaccine delivery of SIP proteins/construct. 6: Intracellular degradation of SIPs into peptides 
and SIP peptide load onto SLA class I molecules, followed by cell surface presentation of SIP-pSLA complexes to 
circulating CTLs ultimately leading to adaptive immune activation and protection against the virus of interest. 
 
Investigation of the induction of CTL responses following live non-replicating adenovirus 
vaccine vectored SIP (Ad-SIP) vaccination, or vaccination with the SIP formulated into different 
adjuvants would be highly relevant in the search for optimal adjuvant-based co-delivery and 
immune activation. Such novel adjuvants, with the potential to induce CTL responses, could 
arise from modifications of the cationic adjuvant system (CAF) adjuvant family (Nordly et al. 
2011), immune stimulatory complexes (ISCOMs) (Schiott et al. 2011), Cholera toxin (Olvera-
Gomez et al. 2012) or other new formulations (Heegaard et al. 2011). Succeeding in designing 
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functionally SIP vaccines would tremendously accelerate vaccine development against viral 
infections which require a high quality host CTL response for elimination and establishment of 
protection. 
A potential drawback of the SIP based vaccination approach would be the challenge of getting 
whole SIPs successfully delivered into the cytoplasm of antigen presenting cells, which make 
protein-adjuvant vaccination a substantial task to deal with. This may be overcome by using the 
Ad-SIP construct for the synthesis and delivery of SIPs inside the cells. Still, if the use of 
adenovirus vectors is to be avoided, another solution could be adding “opsonization tags” in 
the construct encoding the SIP, leading to specific glycosylation of the SIP, for example with 
mannose, making it recognizable by mannose-binding lectins at the surface of antigen 
presenting cells. 
Most pork producers are likely to select breeding stock for quality and quantity of meat. Hence, 
vaccine makers will have to customize vaccines to the strains of pigs favored by the producers. 
If vaccines based on the most frequent SLA alleles are successful, however, it is likely that they 
will also introduce selection towards an undesired reduction in SLA diversity. Thus, it will be 
important to include a broad range of SLA specificities in the design of corresponding vaccine 
polyepitopes. 
 
8.3. MULTIMER BASED CANCER TREATMENT 
Using swine as an animal model, it would be possible to validate the effects of human cancer 
vaccines, by monitoring the specificity and status of activation of different cell populations via 
pSLA multimers based on peptides derived from the cancer type of interest. Furthermore, 
pMHC multimers could potentially be used in vivo to label tumor cells for elimination by already 
existing CTLs of the host specific to common viruses such as Epstein-Barr virus (EBV), 
Cytomegalo virus (CMV), and influenza, from which the tetramer peptides should be derived. 
Hereby tetramers would resemble antigen presenting cells bound to the cell surface of tumor 
cells by an anti-tumor specific mAb directly coupled to streptavidin of the tetramer (Figure 17), 
enabling the activation of host CTLs and leading to elimination of the tumor cell.  
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Figure 17. Redirected killing of a tumor cell by an EBV specific CTL. EBV peptides (red) are presented by a pMHC 
tetramer (green/purple), which is attached to the cell surface of a tumor cell (black) via an anti-tumor mAb (pink) 
that recognize tumor antigens (grey). 
 
In vitro studies have shown such Ab-pMHC tetramers to sensitize tumor cells to lysis by specific 
CTLs (Ogg et al. 2000, Robert et al. 2000) making further refinement and development of this 
technique for in vivo utilization an interesting approach for future immunological therapy of 
cancer.  
 
8.4. ANSWERS LEAD TO QUESTIONS 
The approaches, assays and proposals presented in this PhD thesis could ultimately lead to a 
better agriculture in terms of a more productive farming industry and overall greater animal 
health. Still the questions are many, and the greatly accelerated evolution in the field of 
immunology within the past two decades, has now made curiosity-driven research possible at a 
scale not previously imaginable. It is often so in science that most answers tend to bring several 
new questions. Hence, knowing what we do today forces us to strive for more. Could the 
distribution of SLA molecules, such as the commonly expressed SLA-1*0401, be of any interest 
in the susceptibility to, or protection against, certain viruses in swine? Would one commonly 
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occurring class I molecule cover for most of the pSLA complex mediated CTL immune response, 
or would a symphony of several more or less common alleles be a criteria for the induction of 
strong and durable adaptive immune protection? How important are the individual peptide 
anchor requirements and peptide lengths for SLA class I ligand binding, and the corresponding 
level of immunogenicity, and how does pSLA complex stability affect TCR activation? Would 
high peptide turn-overs and a great variety in peptide presentation be beneficial to effective 
protection against disease, or would a low number of a few highly stable pSLA complexes be 
more capable of sufficiently activating CTLs? Would it be possible to specifically monitor 
immune responses in outbred populations, leading to the identification of several conserved 
peptide epitopes from viruses that are constantly mutating to achieve immune evasion? Could 
such epitopes turn out to be potentially valuable vaccine candidates in the design and 
development of highly specific subunit vaccines, and how should such a vaccine be delivered 
for optimal effect? Would it be possible to effectively validate different vaccines and vaccine 
delivery approaches for humans, using the pig as an experimental model, hereby improving our 
understanding of targeting various cancers as well as of the pathogenesis and immune 
elimination of disease in both humans and livestock animals?  
 
Final Thoughts 
To get a full – or at least better – understanding on what is going on in our field of veterinary 
immunology, we need to step back and take yet another look, share and use the technologies 
and approaches available to us in research laboratories around the globe; discard a lot, re-think 
some, use a few, and finally have the courage to go down different alleys embracing whatever 
complexities that we might find. 
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